Modul 4A Anhang 4-G

Dossier zur Nutzenbewertung gemäß § 35a SGB V

Capmatinib (Tabrecta®)

Novartis Pharma GmbH

Modul 4 A – Anhang 4-G

Fortgeschrittenes NSCLC mit einer METex14-Skipping-Mutation nach vorheriger Immuntherapie und/oder Platin-basierter Chemotherapie

Ergänzende Analysen zu den Studien RECAP und GEOMETRY mono-1

Stand: 12.08.2022

Inhaltsverzeichnis

Seite

Abbildungsverzeichnis

Tabellenverzeichnis

Ergänzende Analysen zur Studie RECAP

1 Teilpopulationen

1.1 Pop c vs. ACT

1.1.1 Effectiveness results

1.1.1.1 Overall survival (OS)

Table 1: Overall survival analysis for Pop c vs. ACT, Naive comparison

Parameter	**Capmatinib**	**ACT**
	N = 9	N = 7
Patients with Event - n (%)[a]	4 (44.4)	2 (28.6)
Censored -n (%)[a]	5 (55.6)	5 (71.4)
Median observation time (month)	23.26	13.17
Median time to event with 95% confidence intervals (month)	n.a. (n.a.-n.a.)	n.a. (n.a.-n.a.)
HR (95% CI)[a]	1.65 (0.36-7.60)	
p-value[a]	0.562	

ACT: Appropriate comparative therapy; CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Figure 1: Comparison of overall survival for Pop c vs. ACT, Kaplan-Meier plot, Naive comparison



1.1.1.2 Progression free survival (PFS)

Table 2: Progression free survival analysis for Pop c vs. ACT, Naive comparison

Parameter	**Capmatinib** N = 9	**ACT** N = 7
Patients with Event - n (%)[a]	5 (55.6)	6 (85.7)
Censored -n (%)[a]	4 (44.4)	1 (14.3)
Median observation time (month)	5.42	7.00
Median time to event with 95% confidence intervals (month)	22.24 (1.25-n.a.)	7.93 (4.99-n.a.)
HR (95% CI)[a]	0.51 (0.15-1.77)	
p-value[a]	0.307	

ACT: Appropriate comparative therapy; CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Figure 2: Comparison of progression free survival Pop c vs. ACT, Kaplan-Meier plot, Naive comparison



1.1.1.3 Overall response rate (ORR)

Table 3: Overall response rate analysis for Pop c vs. ACT, Naive comparison

Parameter	**Capmatinib** N = 9	**ACT** N = 7
Overall response rate- n (%)	5 (55.6)	0 (0.0)
OR (95% CI) [a]; p-value	>1000.00 (n.a.-n.a.); n.a.	
RR (95% CI) [b]; p-value	>1000.00 (n.a.-n.a.); n.a.	
ARR (95% CI) [c]; p-value	n.a. (n.a.-n.a.); n.a.	

ACT: Appropriate comparative therapy; ARR: Absolute risk reduction; CI: Confidence interval; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available; OR: Odds ratio; RR: Relative Risk

a: Binomial regression model (treatment arm as fixed effect) with logit link function. Estimates for OR and RR from binomial regression models are a result of extreme values due to 0 events in the comparator arm and are reported for completeness.

b: Binomial regression model (treatment arm as fixed effect) with log-link function. Estimates for OR and RR from binomial regression models are a result of extreme values due to 0 events in the comparator arm and are reported for completeness.

c: GLM (treatment arm as fixed effect) with identity link function

1.1.1.4 Time to CNS progression (CNSprog)

Table 4: Time to CNS progression analysis for Pop c vs. ACT, Naive comparison

Parameter	**Capmatinib** N = 6	**ACT** N = 7
Patients with Event - n (%)[a]	0 (0.0)	1 (14.3)
Censored -n (%)[a]	6 (100.0)	6 (85.7)
Median observation time (month)	17.22	13.17
Median time to event with 95% confidence intervals (month)	n.a. (n.a.-n.a.)	n.a. (n.a.-n.a.)
HR (95% CI)[a]	<0.005 (<0.005-<0.005)	
p-value[a]	0.414	

ACT: Appropriate comparative therapy; CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used. Estimate for HR from Cox regression is a result of extreme values due to 0 events in the capmatinib arm and is reported for completeness.

Figure 3: Comparison of time to CNS progression for Pop c vs. ACT, Kaplan-Meier plot, Naive comparison



1.1.2 Safety results

1.1.2.1 Time to treatment discontinuation due to adverse events (TDAE)

Table 5: Time to treatment discontinuation due to adverse events analysis for Pop c vs. ACT, Naive comparison

Parameter	**Capmatinib**	**ACT**
	N = 9	N = 7
Patients with Event - n (%)[a]	3 (33.3)	3 (42.9)
Censored -n (%)[a]	6 (66.7)	4 (57.1)
Median observation time (month)	6.93	8.74
Median time to event with 95% confidence intervals (month)	n.a. (n.a.-n.a.)	n.a. (n.a.-n.a.)
HR (95% CI)[a]	0.92 (0.20-4.22)	
p-value[a]	0.917	

ACT: Appropriate comparative therapy; CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Figure 4: Comparison of time to treatment discontinuation due to adverse events for Pop c vs. ACT, Kaplan-Meier plot, Naive comparison



1.1.2.2 Time to unplanned or prolonged hospitalizations (upHOSP)

Table 6: Time to unplanned or prolonged hospitalizations analysis for Pop c vs. ACT, Naive comparison

Parameter	**Capmatinib** N = 9	**ACT** N = 7
Patients with Event - n (%)[a]	4 (44.4)	3 (42.9)
Censored -n (%)[a]	5 (55.6)	4 (57.1)
Median observation time (month)	5.98	8.57
Median time to event with 95% confidence intervals (month)	n.a. (n.a.-n.a.)	n.a. (n.a.-n.a.)
HR (95% CI)[a]	1.37 (0.35-5.32)	
p-value[a]	0.683	

ACT: Appropriate comparative therapy; CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Figure 5: Comparison of time to unplanned or prolonged hospitalizations for Pop c vs. ACT, Kaplan-Meier plot, Naive comparison



1.1.2.3 Time to unplanned or prolonged hospitalizations or death (upHOSP+D)

Table 7: Time to unplanned or prolonged hospitalizations or death analysis for Pop c vs. ACT, Naive comparison

Parameter	**Capmatinib**	**ACT**
	N = 9	N = 7
Patients with Event - n (%)[a]	5 (55.6)	4 (57.1)
Censored -n (%)[a]	4 (44.4)	3 (42.9)
Median observation time (month)	5.98	8.57
Median time to event with 95% confidence intervals (month)	5.98 (0.23-n.a.)	9.00 (5.75-n.a.)
HR (95% CI)[a]	1.22 (0.37-4.04)	
p-value[a]	0.772	

ACT: Appropriate comparative therapy; CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Figure 6: Comparison of time to unplanned or prolonged hospitalizations or death for Pop c vs. ACT, Kaplan-Meier plot, Naive comparison



1.2 Pop c vs. SoC

1.2.1 Effectiveness results

1.2.1.1 Overall survival (OS)

Table 8: Overall survival analysis for Pop c vs. SoC, Naive comparison

Parameter	**Capmatinib**	**SoC**
	N = 9	N = 17
Patients with Event - n (%)[a]	4 (44.4)	7 (41.2)
Censored -n (%)[a]	5 (55.6)	10 (58.8)
Median observation time (month)	23.26	12.55
Median time to event with 95% confidence intervals (month)	n.a. (n.a.-n.a.)	15.24 (6.60-n.a.)
HR (95% CI)[a]	0.92 (0.27-3.12)	
p-value[a]	0.899	

CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available; SoC: Standard of care

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Figure 7: Comparison of overall survival for Pop c vs. SoC, Kaplan-Meier plot, Naive comparison



1.2.1.2 Progression free survival (PFS)

Table 9: Progression free survival analysis for Pop c vs. SoC, Naive comparison

Parameter	**Capmatinib** N = 9	**SoC** N = 17
Patients with Event - n (%)[a]	5 (55.6)	14 (82.4)
Censored -n (%)[a]	4 (44.4)	3 (17.7)
Median observation time (month)	5.42	4.99
Median time to event with 95% confidence intervals (month)	22.24 (1.25-n.a.)	6.01 (2.76-10.55)
HR (95% CI)[a]	0.43 (0.15-1.27)	
p-value[a]	0.114	

CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available; SoC: Standard of care

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Figure 8: Comparison of progression free survival Pop c vs. SoC, Kaplan-Meier plot, Naive comparison



1.2.1.3 Overall response rate (ORR)

Table 10: Overall response rate analysis for Pop c vs. SoC, Naive comparison

Parameter	**Capmatinib** N = 9	**SoC** N = 17
Overall response rate- n (%)	5 (55.6)	3 (17.7)
OR (95% CI) [a]; p-value	5.83 (0.95-35.72); 0.057	
RR (95% CI) [b]; p-value	3.15 (0.97-10.26); 0.057	
ARR (95% CI) [c]; p-value	0.38 (0.01-0.75); 0.046	

ARR: Absolute risk reduction; CI: Confidence interval; n: Number of patients with event; N: Total number of patients within analysis; OR: Odds ratio; RR: Relative Risk; SoC: Standard of care

a: Binomial regression model (treatment arm as fixed effect) with logit link function

b: Binomial regression model (treatment arm as fixed effect) with log-link function

c: GLM (treatment arm as fixed effect) with identity link function

1.2.1.4 Time to CNS progression (CNSprog)

Table 11: Time to CNS progression analysis for Pop c vs. SoC, Naive comparison

Parameter	**Capmatinib**	**SoC**
	N = 6	N = 13
Patients with Event - n (%)[a]	0 (0.0)	1 (7.7)
Censored -n (%)[a]	6 (100.0)	12 (92.3)
Median observation time (month)	17.22	13.17
Median time to event with 95% confidence intervals (month)	n.a. (n.a.-n.a.)	n.a. (n.a.-n.a.)
HR (95% CI)[a]	<0.005 (<0.005-<0.005)	
p-value[a]	0.527	

CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available; SoC: Standard of care

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used. Estimate for HR from Cox regression is a result of extreme values due to 0 events in the capmatinib arm and is reported for completeness.

Figure 9: Comparison of time to CNS progression for Pop c vs. SoC, Kaplan-Meier plot, Naive comparison



1.2.2 Safety results

1.2.2.1 Time to treatment discontinuation due to adverse events (TDAE)

Table 12: Time to treatment discontinuation due to adverse events analysis for Pop c vs. SoC, Naive comparison

Parameter	**Capmatinib**	**SoC**
	N = 9	N = 17
Patients with Event - n (%)[a]	3 (33.3)	5 (29.4)
Censored -n (%)[a]	6 (66.7)	12 (70.6)
Median observation time (month)	6.93	5.32
Median time to event with 95% confidence intervals (month)	n.a. (n.a.-n.a.)	n.a. (n.a.-n.a.)
HR (95% CI)[a]	1.08 (0.27-4.32)	
p-value[a]	0.917	

CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available; SoC: Standard of care

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Figure 10: Comparison of time to treatment discontinuation due to adverse events for Pop c vs. SoC, Kaplan-Meier plot, Naive comparison



1.2.2.2 Time to unplanned or prolonged hospitalizations (upHOSP)

Table 13: Time to unplanned or prolonged hospitalizations analysis for Pop c vs. SoC, Naive comparison

Parameter	**Capmatinib** N = 9	**SoC** N = 17
Patients with Event - n (%)[a]	4 (44.4)	7 (41.2)
Censored -n (%)[a]	5 (55.6)	10 (58.8)
Median observation time (month)	5.98	6.97
Median time to event with 95% confidence intervals (month)	n.a. (n.a.-n.a.)	14.39 (5.75-n.a.)
HR (95% CI)[a]	1.13 (0.30-4.23)	
p-value[a]	0.841	

CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available; SoC: Standard of care

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Figure 11: Comparison of time to unplanned or prolonged hospitalizations for Pop c vs. SoC, Kaplan-Meier plot, Naive comparison



1.2.2.3 Time to unplanned or prolonged hospitalizations or death (upHOSP+D)

Table 14: Time to unplanned or prolonged hospitalizations or death analysis for Pop c vs. SoC, Naive comparison

Parameter	**Capmatinib**	**SoC**
	N = 9	N = 17
Patients with Event - n (%)[a]	5 (55.6)	10 (58.8)
Censored -n (%)[a]	4 (44.4)	7 (41.2)
Median observation time (month)	5.98	6.97
Median time to event with 95% confidence intervals (month)	5.98 (0.23-n.a.)	8.67 (5.75-n.a.)
HR (95% CI)[a]	1.01 (0.31-3.31)	
p-value[a]	0.991	

CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available; SoC: Standard of care

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Figure 12: Comparison of time to unplanned or prolonged hospitalizations or death for Pop c vs. SoC, Kaplan-Meier plot, Naive comparison



1.3 Pop d vs. ACT

1.3.1 Effectiveness results

1.3.1.1 Overall survival (OS)

Table 15: Overall survival analysis for Pop d vs. ACT, Naive comparison

Parameter	**Capmatinib**	**ACT**
	N = 64	N = 12
Patients with Event - n (%)[a]	47 (73.4)	8 (66.7)
Censored -n (%)[a]	17 (26.6)	4 (33.3)
Median observation time (month)	12.39	9.63
Median time to event with 95% confidence intervals (month)	14.75 (11.47-24.28)	11.10 (3.15-n.a.)
HR (95% CI)[a]	0.78 (0.34-1.78)	
p-value[a]	0.523	

ACT: Appropriate comparative therapy; CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Figure 13: Comparison of overall survival for Pop d vs. ACT, Kaplan-Meier plot, Naive comparison



1.3.1.2 Progression free survival (PFS)

Table 16: Progression free survival analysis for Pop d vs. ACT, Naive comparison

Parameter	**Capmatinib** N = 64	**ACT** N = 12
Patients with Event - n (%)[a]	54 (84.4)	10 (83.3)
Censored -n (%)[a]	10 (15.6)	2 (16.7)
Median observation time (month)	4.19	3.56
Median time to event with 95% confidence intervals (month)	4.67 (4.17-6.93)	3.98 (1.48-8.15)
HR (95% CI)[a]	0.75 (0.35-1.63)	
p-value[a]	0.404	

ACT: Appropriate comparative therapy; CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Figure 14: Comparison of progression free survival Pop d vs. ACT, Kaplan-Meier plot, Naive comparison



1.3.1.3 Overall response rate (ORR)

Table 17: Overall response rate analysis for Pop d vs. ACT, Naive comparison

Parameter	**Capmatinib** N = 64	**ACT** N = 12
Overall response rate- n (%)	23 (35.9)	5 (41.7)
OR (95% CI) [a]; p-value	0.79 (0.22-2.76); 0.706	
RR (95% CI) [b]; p-value	0.86 (0.41-1.82); 0.697	
ARR (95% CI) [c]; p-value	-0.06 (-0.36-0.25); 0.711	

ACT: Appropriate comparative therapy; ARR: Absolute risk reduction; CI: Confidence interval; n: Number of patients with event; N: Total number of patients within analysis; OR: Odds ratio; RR: Relative Risk

a: Binomial regression model (treatment arm as fixed effect) with logit link function

b: Binomial regression model (treatment arm as fixed effect) with log-link function

c: GLM (treatment arm as fixed effect) with identity link function

1.3.1.4 Time to CNS progression (CNSprog)

Table 18: Time to CNS progression analysis for Pop d vs. ACT, Naive comparison

Parameter	Capmatinib	ACT
	N = 52	N = 11
Patients with Event - n (%)[a]	0 (0.0)	3 (27.3)
Censored -n (%)[a]	52 (100.0)	8 (72.7)
Median observation time (month)	7.64	6.24
Median time to event with 95% confidence intervals (month)	n.a. (n.a.-n.a.)	n.a. (n.a.-n.a.)
HR (95% CI)[a]	<0.005 (<0.005-<0.005)	
p-value[a]	<0.001	

ACT: Appropriate comparative therapy; CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used. Estimate for HR from Cox regression is a result of extreme values due to 0 events in the capmatinib arm and is reported for completeness.

Figure 15: Comparison of time to CNS progression for Pop d vs. ACT, Kaplan-Meier plot, Naive comparison



1.3.2 Safety results

1.3.2.1 Time to treatment discontinuation due to adverse events (TDAE)

Table 19: Time to treatment discontinuation due to adverse events analysis for Pop d vs. ACT, Naive comparison

Parameter	**Capmatinib**	**ACT**
	N = 64	N = 12
Patients with Event - n (%)[a]	9 (14.1)	1 (8.3)
Censored -n (%)[a]	55 (85.9)	11 (91.7)
Median observation time (month)	10.71	6.95
Median time to event with 95% confidence intervals (month)	n.a. (n.a.-n.a.)	n.a. (n.a.-n.a.)
HR (95% CI)[a]	1.43 (0.17-11.90)	
p-value[a]	0.735	

ACT: Appropriate comparative therapy; CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Figure 16: Comparison of time to treatment discontinuation due to adverse events for Pop d vs. ACT, Kaplan-Meier plot, Naive comparison



1.3.2.2 Time to unplanned or prolonged hospitalizations (upHOSP)

Table 20: Time to unplanned or prolonged hospitalizations analysis for Pop d vs. ACT, Naive comparison

Parameter	**Capmatinib** N = 64	**ACT** N = 12
Patients with Event - n (%)[a]	26 (40.6)	5 (41.7)
Censored -n (%)[a]	38 (59.4)	7 (58.3)
Median observation time (month)	7.67	6.39
Median time to event with 95% confidence intervals (month)	29.47 (7.52-n.a.)	9.36 (2.60-n.a.)
HR (95% CI)[a]	0.89 (0.36-2.21)	
p-value[a]	0.819	

ACT: Appropriate comparative therapy; CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Figure 17: Comparison of time to unplanned or prolonged hospitalizations for Pop d vs. ACT, Kaplan-Meier plot, Naive comparison



1.3.2.3 Time to unplanned or prolonged hospitalizations or death (upHOSP+D)

Table 21: Time to unplanned or prolonged hospitalizations or death analysis for Pop d vs. ACT, Naive comparison

Parameter	Capmatinib	ACT
	N = 64	N = 12
Patients with Event - n (%)[a]	51 (79.7)	9 (75.0)
Censored -n (%)[a]	13 (20.3)	3 (25.0)
Median observation time (month)	8.40	6.39
Median time to event with 95% confidence intervals (month)	9.00 (6.37-14.85)	7.26 (2.60-11.17)
HR (95% CI)[a]	0.84 (0.38-1.85)	
p-value[a]	0.626	

ACT: Appropriate comparative therapy; CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Figure 18: Comparison of time to unplanned or prolonged hospitalizations or death for Pop d vs. ACT, Kaplan-Meier plot, Naive comparison



1.4 Pop d vs. SoC

1.4.1 Effectiveness results

1.4.1.1 Overall survival (OS)

Table 22: Overall survival analysis for Pop d vs. SoC, Naive comparison

Parameter	Capmatinib	SoC
	N = 64	N = 23
Patients with Event - n (%)[a]	47 (73.4)	17 (73.9)
Censored -n (%)[a]	17 (26.6)	6 (26.1)
Median observation time (month)	12.39	9.66
Median time to event with 95% confidence intervals (month)	14.75 (11.47-24.28)	10.04 (4.76-18.04)
HR (95% CI)[a]	0.68 (0.38-1.20)	
p-value[a]	0.176	

CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; SoC: Standard of care

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Figure 19: Comparison of overall survival for Pop d vs. SoC, Kaplan-Meier plot, Naive comparison



1.4.1.2 Progression free survival (PFS)

Table 23: Progression free survival analysis for Pop d vs. SoC, Naive comparison

Parameter	**Capmatinib** N = 64	**SoC** N = 23
Patients with Event - n (%)[a]	54 (84.4)	21 (91.3)
Censored -n (%)[a]	10 (15.6)	2 (8.7)
Median observation time (month)	4.19	3.75
Median time to event with 95% confidence intervals (month)	4.67 (4.17-6.93)	3.81 (1.97-6.24)
HR (95% CI)[a]	0.70 (0.41-1.20)	
p-value[a]	0.165	

CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; SoC: Standard of care

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Figure 20: Comparison of progression free survival Pop d vs. SoC, Kaplan-Meier plot, Naive comparison



1.4.1.3 Overall response rate (ORR)

Table 24: Overall response rate analysis for Pop d vs. SoC, Naive comparison

Parameter	**Capmatinib** N = 64	**SoC** N = 23
Overall response rate- n (%)	23 (35.9)	8 (34.8)
OR (95% CI) [a]; p-value	1.05 (0.39-2.85); 0.921	
RR (95% CI) [b]; p-value	1.03 (0.54-1.98); 0.921	
ARR (95% CI) [c]; p-value	0.01 (-0.22-0.24); 0.921	

ARR: Absolute risk reduction; CI: Confidence interval; n: Number of patients with event; N: Total number of patients within analysis; OR: Odds ratio; RR: Relative Risk; SoC: Standard of care

a: Binomial regression model (treatment arm as fixed effect) with logit link function

b: Binomial regression model (treatment arm as fixed effect) with log-link function

c: GLM (treatment arm as fixed effect) with identity link function

1.4.1.4 Time to CNS progression (CNSprog)

Table 25: Time to CNS progression analysis for Pop d vs. SoC, Naive comparison

Parameter	**Capmatinib**	**SoC**
	N = 52	N = 20
Patients with Event - n (%)[a]	0 (0.0)	5 (25.0)
Censored -n (%)[a]	52 (100.0)	15 (75.0)
Median observation time (month)	7.64	7.20
Median time to event with 95% confidence intervals (month)	n.a. (n.a.-n.a.)	n.a. (n.a.-n.a.)
HR (95% CI)[a]	<0.005 (<0.005-<0.005)	
p-value[a]	<0.001	

CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available; SoC: Standard of care

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used. Estimate for HR from Cox regression is a result of extreme values due to 0 events in the capmatinib arm and is reported for completeness.

Figure 21: Comparison of time to CNS progression for Pop d vs. SoC, Kaplan-Meier plot, Naive comparison



1.4.2 Safety results

1.4.2.1 Time to treatment discontinuation due to adverse events (TDAE)

Table 26: Time to treatment discontinuation due to adverse events analysis for Pop d vs. SoC, Naive comparison

Parameter	**Capmatinib**	**SoC**
	N = 64	N = 23
Patients with Event - n (%)[a]	9 (14.1)	1 (4.4)
Censored -n (%)[a]	55 (85.9)	22 (95.7)
Median observation time (month)	10.71	8.74
Median time to event with 95% confidence intervals (month)	n.a. (n.a.-n.a.)	n.a. (n.a.-n.a.)
HR (95% CI)[a]	2.82 (0.35-22.62)	
p-value[a]	0.305	

CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available; SoC: Standard of care

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Figure 22: Comparison of time to treatment discontinuation due to adverse events for Pop d vs. SoC, Kaplan-Meier plot, Naive comparison



1.4.2.2 Time to unplanned or prolonged hospitalizations (upHOSP)

Table 27: Time to unplanned or prolonged hospitalizations analysis for Pop d vs. SoC, Naive comparison

Parameter	**Capmatinib** N = 64	**SoC** N = 23
Patients with Event - n (%)[a]	26 (40.6)	11 (47.8)
Censored -n (%)[a]	38 (59.4)	12 (52.2)
Median observation time (month)	7.67	7.79
Median time to event with 95% confidence intervals (month)	29.47 (7.52-n.a.)	10.28 (4.21-n.a.)
HR (95% CI)[a]	0.80 (0.41-1.56)	
p-value[a]	0.528	

CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available; SoC: Standard of care

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Figure 23: Comparison of time to unplanned or prolonged hospitalizations for Pop d vs. SoC, Kaplan-Meier plot, Naive comparison



1.4.2.3 Time to unplanned or prolonged hospitalizations or death (upHOSP+D)

Table 28: Time to unplanned or prolonged hospitalizations or death analysis for Pop d vs. SoC, Naive comparison

Parameter	**Capmatinib**	**SoC**
	N = 64	N = 23
Patients with Event - n (%)[a]	51 (79.7)	18 (78.3)
Censored -n (%)[a]	13 (20.3)	5 (21.7)
Median observation time (month)	8.40	7.79
Median time to event with 95% confidence intervals (month)	9.00 (6.37-14.85)	8.15 (2.60-11.17)
HR (95% CI)[a]	0.80 (0.46-1.39)	
p-value[a]	0.417	

CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; SoC: Standard of care

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Figure 24: Comparison of time to unplanned or prolonged hospitalizations or death for Pop d vs. SoC, Kaplan-Meier plot, Naive comparison



1.5 Pop e vs. ACT

1.5.1 Effectiveness results

1.5.1.1 Overall survival (OS)

Table 29: Overall survival analysis for Pop e vs. ACT, Naive comparison

Parameter	Capmatinib	ACT
	N = 8	N = 2
Patients with Event - n (%)[a]	5 (62.5)	1 (50.0)
Censored -n (%)[a]	3 (37.5)	1 (50.0)
Median observation time (month)	13.80	14.82
Median time to event with 95% confidence intervals (month)	14.06 (8.38-n.a.)	n.a. (n.a.-n.a.)
HR (95% CI)[a]	1.07 (0.08-14.25)	
p-value[a]	0.955	

ACT: Appropriate comparative therapy; CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Figure 25: Comparison of overall survival for Pop e vs. ACT, Kaplan-Meier plot, Naive comparison



1.5.1.2 Progression free survival (PFS)

Table 30: Progression free survival analysis for Pop e vs. ACT, Naive comparison

Parameter	**Capmatinib** N = 8	**ACT** N = 2
Patients with Event - n (%)[a]	7 (87.5)	2 (100.0)
Censored -n (%)[a]	1 (12.5)	0 (0.0)
Median observation time (month)	7.64	8.89
Median time to event with 95% confidence intervals (month)	7.64 (2.83-12.48)	8.89 (0.03-n.a.)
HR (95% CI)[a]	1.02 (0.18-5.70)	
p-value[a]	0.981	

ACT: Appropriate comparative therapy; CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Figure 26: Comparison of progression free survival Pop e vs. ACT, Kaplan-Meier plot, Naive comparison



1.5.1.3 Overall response rate (ORR)

Table 31: Overall response rate analysis for Pop e vs. ACT, Naive comparison

Parameter	**Capmatinib** N = 8	**ACT** N = 2
Overall response rate- n (%)	6 (75.0)	1 (50.0)
OR (95% CI) [a]; p-value	3.00 (0.12-73.64); 0.501	
RR (95% CI) [b]; p-value	1.50 (0.35-6.35); 0.582	
ARR (95% CI) [c]; p-value	0.25 (-0.51-1.01); 0.516	

ACT: Appropriate comparative therapy; ARR: Absolute risk reduction; CI: Confidence interval; n: Number of patients with event; N: Total number of patients within analysis; OR: Odds ratio; RR: Relative Risk

a: Binomial regression model (treatment arm as fixed effect) with logit link function

b: Binomial regression model (treatment arm as fixed effect) with log-link function

c: GLM (treatment arm as fixed effect) with identity link function

1.5.1.4 Time to CNS progression (CNSprog)

Table 32: Time to CNS progression analysis for Pop e vs. ACT, Naive comparison

Parameter	**Capmatinib** N = 7	**ACT** N = 2
Patients with Event - n (%)[a]	0 (0.0)	0 (0.0)
Censored -n (%)[a]	7 (100.0)	2 (100.0)
Median observation time (month)	11.04	14.82
Median time to event with 95% confidence intervals (month)	n.a. (n.a.-n.a.)	n.a. (n.a.-n.a.)
HR (95% CI)[a]	n.a. (n.a.-n.a.)	
p-value[a]	n.a.	

ACT: Appropriate comparative therapy; CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Figure 27: Comparison of time to CNS progression for Pop e vs. ACT, Kaplan-Meier plot, Naive comparison



1.5.2 Safety results

1.5.2.1 Time to treatment discontinuation due to adverse events (TDAE)

Table 33: Time to treatment discontinuation due to adverse events analysis for Pop e vs. ACT, Naive comparison

Parameter	**Capmatinib**	**ACT**
	N = 8	N = 2
Patients with Event - n (%)[a]	2 (25.0)	0 (0.0)
Censored -n (%)[a]	6 (75.0)	2 (100.0)
Median observation time (month)	12.95	14.82
Median time to event with 95% confidence intervals (month)	29.77 (0.95-n.a.)	n.a. (n.a.-n.a.)
HR (95% CI)[a]	>1000.00 (>1000.00->1000.00)	
p-value[a]	0.617	

ACT: Appropriate comparative therapy; CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used. Estimate for HR from Cox regression is a result of extreme values due to 0 events in the comparator arm and is reported for completeness.

Figure 28: Comparison of time to treatment discontinuation due to adverse events for Pop e vs. ACT, Kaplan-Meier plot, Naive comparison



1.5.2.2 Time to unplanned or prolonged hospitalizations (upHOSP)

Table 34: Time to unplanned or prolonged hospitalizations analysis for Pope vs. ACT, Naive comparison

Parameter	Capmatinib	ACT
	N = 8	N = 2
Patients with Event - n (%)[a]	4 (50.0)	1 (50.0)
Censored -n (%)[a]	4 (50.0)	1 (50.0)
Median observation time (month)	9.91	14.49
Median time to event with 95% confidence intervals (month)	n.a. (n.a.-n.a.)	n.a. (n.a.-n.a.)
HR (95% CI)[a]	0.98 (0.13-7.13)	
p-value[a]	0.984	

ACT: Appropriate comparative therapy; CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Figure 29: Comparison of time to unplanned or prolonged hospitalizations for Pop e vs. ACT, Kaplan-Meier plot, Naive comparison



1.5.2.3 Time to unplanned or prolonged hospitalizations or death (upHOSP+D)

Table 35: Time to unplanned or prolonged hospitalizations or death analysis for Pop e vs. ACT, Naive comparison

Parameter	Capmatinib	ACT
	N = 8	N = 2
Patients with Event - n (%)[a]	6 (75.0)	1 (50.0)
Censored -n (%)[a]	2 (25.0)	1 (50.0)
Median observation time (month)	10.19	14.49
Median time to event with 95% confidence intervals (month)	10.19 (0.76-n.a.)	n.a. (n.a.-n.a.)
HR (95% CI)[a]	1.55 (0.17-13.85)	
p-value[a]	0.685	

ACT: Appropriate comparative therapy; CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Figure 30: Comparison of time to unplanned or prolonged hospitalizations or death for Pop e vs. ACT, Kaplan-Meier plot, Naive comparison



1.6 Pop e vs. SoC

1.6.1 Effectiveness results

1.6.1.1 Overall survival (OS)

Table 36: Overall survival analysis for Pop e vs. SoC, Naive comparison

Parameter	Capmatinib	SoC
	N = 8	N = 6
Patients with Event - n (%)[a]	5 (62.5)	4 (66.7)
Censored -n (%)[a]	3 (37.5)	2 (33.3)
Median observation time (month)	13.80	4.94
Median time to event with 95% confidence intervals (month)	14.06 (8.38-n.a.)	4.94 (0.89-n.a.)
HR (95% CI)[a]	0.53 (0.13-2.13)	
p-value[a]	0.343	

CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available; SoC: Standard of care

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Figure 31: Comparison of overall survival for Pop e vs. SoC, Kaplan-Meier plot, Naive comparison



1.6.1.2 Progression free survival (PFS)

Table 37: Progression free survival analysis for Pop e vs. SoC, Naive comparison

Parameter	**Capmatinib** N = 8	**SoC** N = 6
Patients with Event - n (%)[a]	7 (87.5)	5 (83.3)
Censored -n (%)[a]	1 (12.5)	1 (16.7)
Median observation time (month)	7.64	1.95
Median time to event with 95% confidence intervals (month)	7.64 (2.83-12.48)	1.95 (0.03-n.a.)
HR (95% CI)[a]	0.72 (0.21-2.51)	
p-value[a]	0.580	

CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available; SoC: Standard of care

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Figure 32: Comparison of progression free survival Pop e vs. SoC, Kaplan-Meier plot, Naive comparison



1.6.1.3 Overall response rate (ORR)

Table 38: Overall response rate analysis for Pop e vs. SoC, Naive comparison

Parameter	**Capmatinib** N = 8	**SoC** N = 6
Overall response rate- n (%)	6 (75.0)	2 (33.3)
OR (95% CI) [a]; p-value	6.00 (0.58-61.84); 0.132	
RR (95% CI) [b]; p-value	2.25 (0.68-7.47); 0.185	
ARR (95% CI) [c]; p-value	0.42 (-0.07-0.90); 0.090	

ARR: Absolute risk reduction; CI: Confidence interval; n: Number of patients with event; N: Total number of patients within analysis; OR: Odds ratio; RR: Relative Risk; SoC: Standard of care

a: Binomial regression model (treatment arm as fixed effect) with logit link function

b: Binomial regression model (treatment arm as fixed effect) with log-link function

c: GLM (treatment arm as fixed effect) with identity link function

1.6.1.4 Time to CNS progression (CNSprog)

Table 39: Time to CNS progression analysis for Pop e vs. SoC, Naive comparison

Parameter	**Capmatinib** N = 7	**SoC** N = 3
Patients with Event - n (%)[a]	0 (0.0)	0 (0.0)
Censored -n (%)[a]	7 (100.0)	3 (100.0)
Median observation time (month)	11.04	15.77
Median time to event with 95% confidence intervals (month)	n.a. (n.a.-n.a.)	n.a. (n.a.-n.a.)
HR (95% CI)[a]	n.a. (n.a.-n.a.)	
p-value[a]	n.a.	

CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available; SoC: Standard of care

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Figure 33: Comparison of time to CNS progression for Pop e vs. SoC, Kaplan-Meier plot, Naive comparison



1.6.2 Safety results

1.6.2.1 Time to treatment discontinuation due to adverse events (TDAE)

Table 40: Time to treatment discontinuation due to adverse events analysis for Pop e vs. SoC, Naive comparison

Parameter	**Capmatinib**	**SoC**
	N = 8	N = 6
Patients with Event - n (%)[a]	2 (25.0)	0 (0.0)
Censored -n (%)[a]	6 (75.0)	6 (100.0)
Median observation time (month)	12.95	4.94
Median time to event with 95% confidence intervals (month)	29.77 (0.95-n.a.)	n.a. (n.a.-n.a.)
HR (95% CI)[a]	>1000.00 (>1000.00->1000.00)	
p-value[a]	0.429	

CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available; SoC: Standard of care

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used. Estimate for HR from Cox regression is a result of extreme values due to 0 events in the comparator arm and is reported for completeness.

Figure 34: Comparison of time to treatment discontinuation due to adverse events for Pop e vs. SoC, Kaplan-Meier plot, Naive comparison



1.6.2.2 Time to unplanned or prolonged hospitalizations (upHOSP)

Table 41: Time to unplanned or prolonged hospitalizations analysis for Pop e vs. SoC, Naive comparison

Parameter	Capmatinib	SoC
	N = 8	N = 6
Patients with Event - n (%)[a]	4 (50.0)	1 (16.7)
Censored -n (%)[a]	4 (50.0)	5 (83.3)
Median observation time (month)	9.91	4.62
Median time to event with 95% confidence intervals (month)	n.a. (n.a.-n.a.)	n.a. (n.a.-n.a.)
HR (95% CI)[a]	2.25 (0.28-18.35)	
p-value[a]	0.461	

CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available; SoC: Standard of care

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Figure 35: Comparison of time to unplanned or prolonged hospitalizations for Pop e vs. SoC, Kaplan-Meier plot, Naive comparison



1.6.2.3 Time to unplanned or prolonged hospitalizations or death (upHOSP+D)

Table 42: Time to unplanned or prolonged hospitalizations or death analysis for Pop e vs. SoC, Naive comparison

Parameter	**Capmatinib** N = 8	**SoC** N = 6
Patients with Event - n (%)[a]	6 (75.0)	4 (66.7)
Censored -n (%)[a]	2 (25.0)	2 (33.3)
Median observation time (month)	10.19	4.62
Median time to event with 95% confidence intervals (month)	10.19 (0.76-n.a.)	4.62 (0.89-n.a.)
HR (95% CI)[a]	0.84 (0.24-3.04)	
p-value[a]	0.797	

CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available; SoC: Standard of care

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Figure 36: Comparison of time to unplanned or prolonged hospitalizations or death for Pop e vs. SoC, Kaplan-Meier plot, Naive comparison



2 Subgruppen

2.1 Pool 1 vs. ACT

2.1.1 Overall survival

Table 43: Overview of interaction p-values of overall survival by confounder categories for Pool 1 vs. ACT, Naive comparison

Soubgroup	**p-value interaction-test**[a]
Age category at start of therapy (years)	0.132
Gender	0.322
T-stage T4 at start of therapy	0.960
Lymph node me-tastases at start of therapy	0.961
Brain metastases at start of therapy	0.141
Liver metastases at start of therapy	0.078
Response to first line therapy	0.141

T: Size or direct extent of the primary tumor

Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Only subgroup characteristics in which at least one subgroup category included at least 10 patients in both treatment arms were included in the analysis.

a: Likelihood-Ratio-Test. The interaction test is based only on the valid subgroup categories (without "unknown").

Table 44: Comparison of overall survival by confounder categories for Pool 1 vs. ACT, Naive comparison

Soubgroup	**Category**	**Parameter**	**Capmatinib**[a]	**ACT**[a]	**HR (95% CI)**[a]	**p-value** [a]	**p-value interaction-test**[c]
Age category at start of therapy (years)							0.132
	<65						
		Univariate Cox-Regression			1.22 (0.25 - 6.08)	0.796	
		N	12	3			
		Patients with Event n (%)	10 (83.3)	2 (66.7)			
		Censored n (%)	2 (16.7)	1 (33.3)			
		Median time to event with 95% CI[b]	8.82 (2.60 - 24.28)	5.75 (5.52 - n.a.)			
	≥65						

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Univariate Cox-Regression			0.99 (0.47 - 2.10)	0.982	
		N	69	18			
		Patients with Event n (%)	46 (66.7)	9 (50.0)			
		Censored n (%)	23 (33.3)	9 (50.0)			
		Median time to event with 95% CI[b]	18.30 (11.63 - 25.95)	23.62 (8.15 - n.a.)			
Gender							0.322
	Female						
		Univariate Cox-Regression			1.47 (0.55 - 3.91)	0.419	
		N	44	11			
		Patients with Event n (%)	34 (77.3)	5 (45.5)			
		Censored n (%)	10 (22.7)	6 (54.6)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	14.06 (11.47 - 24.51)	23.62 (3.38 - n.a.)			
	Male						
		Univariate Cox-Regression			0.69 (0.27 - 1.76)	0.429	
		N	37	10			
		Patients with Event n (%)	22 (59.5)	6 (60.0)			
		Censored n (%)	15 (40.5)	4 (40.0)			
		Median time to event with 95% CI[b]	18.30 (8.61 - n.a.)	8.74 (1.05 - n.a.)			
T-stage T4 at start of therapy							0.960
	Yes						
		Univariate Cox-Regression			2.23 (0.24 - 21.12)	0.435	

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		N	14	3			
		Patients with Event n (%)	10 (71.4)	1 (33.3)			
		Censored n (%)	4 (28.6)	2 (66.7)			
		Median time to event with 95% CI[b]	14.65 (4.99 - 29.50)	n.a. (n.a. - n.a.)			
	No						
		Univariate Cox-Regression			11128211.00 (2528887.40 - 48969000.00)	0.184	
		N	18	4			
		Patients with Event n (%)	15 (83.3)	0 (0.0)			
		Censored n (%)	3 (16.7)	4 (100.0)			
		Median time to event with 95% CI[b]	16.57 (6.64 - 25.79)	n.a. (n.a. - n.a.)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	49	14			
		Patients with Event n (%)	31 (63.3)	10 (71.4)			
		Censored n (%)	18 (36.7)	4 (28.6)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
Lymph node metastases at start of therapy							0.961
	Yes						
		Univariate Cox-Regression			2.17 (0.23 - 20.73)	0.433	
		N	54	5			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Patients with Event n (%)	35 (64.8)	1 (20.0)			
		Censored n (%)	19 (35.2)	4 (80.0)			
		Median time to event with 95% CI[b]	14.75 (9.40 - 24.28)	n.a. (n.a. - n.a.)			
	No						
		Univariate Cox-Regression			1293118.60 (165945.52 - 10076535.00)	0.499	
		N	27	1			
		Patients with Event n (%)	21 (77.8)	0 (0.0)			
		Censored n (%)	6 (22.2)	1 (100.0)			
		Median time to event with 95% CI[b]	18.30 (8.61 - 27.37)	n.a. (n.a. - n.a.)			
	Unknown						

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	n.a.	15			
		Patients with Event n (%)	n.a. (n.a.)	10 (66.7)			
		Censored n (%)	n.a. (n.a.)	5 (33.3)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
Brain metastases at start of therapy							0.141
	Yes						
		Univariate Cox-Regression			0.14 (0.04 - 0.53)	0.057	
		N	16	1			
		Patients with Event n (%)	13 (81.3)	1 (100.0)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Censored n (%)	3 (18.8)	0 (0.0)			
		Median time to event with 95% CI[b]	11.63 (6.64 - 16.79)	5.52 (n.a. - n.a.)			
	No						
		Univariate Cox-Regression			1.02 (0.50 - 2.10)	0.947	
		N	65	20			
		Patients with Event n (%)	43 (66.2)	10 (50.0)			
		Censored n (%)	22 (33.9)	10 (50.0)			
		Median time to event with 95% CI[b]	18.96 (11.63 - 25.95)	23.62 (8.15 - n.a.)			
Liver metastases at start of therapy							0.078
	Yes						

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Univariate Cox-Regression			2.18 (0.25 - 18.67)	0.447	
		N	18	3			
		Patients with Event n (%)	14 (77.8)	1 (33.3)			
		Censored n (%)	4 (22.2)	2 (66.7)			
		Median time to event with 95% CI[b]	11.63 (4.80 - 24.28)	n.a. (n.a. - n.a.)			
	No						
		Univariate Cox-Regression			0.99 (0.47 - 2.08)	0.972	
		N	63	17			
		Patients with Event n (%)	42 (66.7)	9 (52.9)			
		Censored n (%)	21 (33.3)	8 (47.1)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	17.68 (11.63 - 25.95)	11.17 (8.15 - n.a.)			
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	n.a.	1			
		Patients with Event n (%)	n.a. (n.a.)	1 (100.0)			
		Censored n (%)	n.a. (n.a.)	0 (0.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
Response to first line therapy							0.141
	Progression						
		Univariate Cox-Regression			0.82 (0.31 - 2.15)	0.697	

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		N	27	9			
		Patients with Event n (%)	15 (55.6)	5 (55.6)			
		Censored n (%)	12 (44.4)	4 (44.4)			
		Median time to event with 95% CI[b]	18.96 (8.61 - n.a.)	16.18 (3.15 - n.a.)			
	Non-progression						
		Univariate Cox-Regression			1.35 (0.50 - 3.66)	0.499	
		N	39	11			
		Patients with Event n (%)	31 (79.5)	6 (54.6)			
		Censored n (%)	8 (20.5)	5 (45.5)			
		Median time to event with 95% CI[b]	14.06 (8.38 - 21.19)	11.14 (1.05 - n.a.)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	15	1			
		Patients with Event n (%)	10 (66.7)	0 (0.0)			
		Censored n (%)	5 (33.3)	1 (100.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			

CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available; T: Size or direct extent of the primary tumor

Only subgroup characteristics in which at least one subgroup category included at least 10 patients in both treatment arms were included in the analysis.

Subgroup category "unknown": These values are only shown descriptively and are not included in statistical calculations.

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

b: Median calculation using 50th quantile.

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
c: Likelihood-Ratio-Test. The interaction test is based only on the valid subgroup categories (without "unknown").							

Figure 37: Comparison of overall survival for population Pool 1 vs. ACT and subgroup: Age category: < 65, Kaplan-Meier plot, Naive comparison



Figure 38: Comparison of overall survival for population Pool 1 vs. ACT and subgroup: Age category: ≥ 65, Kaplan-Meier plot, Naive comparison



Figure 39: Comparison of overall survival for population Pool 1 vs. ACT and subgroup: Gender: female, Kaplan-Meier plot, Naive comparison



Figure 40: Comparison of overall survival for population Pool 1 vs. ACT and subgroup: Gender: male, Kaplan-Meier plot, Naive comparison



Figure 41: Comparison of overall survival for population Pool 1 vs. ACT and subgroup: T-stage T4: Yes, Kaplan-Meier plot, Naive comparison



Figure 42: Comparison of overall survival for population Pool 1 vs. ACT and subgroup: T-stage T4: No, Kaplan-Meier plot, Naive comparison



Figure 43: Comparison of overall survival for population Pool 1 vs. ACT and subgroup: Lymph node metastases: Yes, Kaplan-Meier plot, Naive comparison



Figure 44: Comparison of overall survival for population Pool 1 vs. ACT and subgroup: Lymph node metastases: No, Kaplan-Meier plot, Naive comparison



Figure 45: Comparison of overall survival for population Pool 1 vs. ACT and subgroup: Brain metasases: Yes, Kaplan-Meier plot, Naive comparison



Figure 46: Comparison of overall survival for population Pool 1 vs. ACT and subgroup: Brain metasases: No, Kaplan-Meier plot, Naive comparison



Figure 47: Comparison of overall survival for population Pool 1 vs. ACT and subgroup: Liver metasases: Yes, Kaplan-Meier plot, Naive comparison



Figure 48: Comparison of overall survival for population Pool 1 vs. ACT and subgroup: Liver metasases: No, Kaplan-Meier plot, Naive comparison



Figure 49: Comparison of overall survival for population Pool 1 vs. ACT and subgroup: Response to first line: Progression, Kaplan-Meier plot, Naive comparison



Figure 50: Comparison of overall survival for population Pool 1 vs. ACT and subgroup: Response to first line: Non-progression, Kaplan-Meier plot, Naive comparison



2.1.2 Progression free survival

Table 45: Overview of interaction p-values of progression free survival by confounder categories for Pool 1 vs. ACT, Naive comparison

Soubgroup	**p-value interaction-test**[a]
Age category at start of therapy (years)	0.443
Gender	0.094
T-stage T4 at start of therapy	0.047
Lymph node me-tastases at start of therapy	0.220
Brain metastases at start of therapy	0.486
Liver metastases at start of therapy	0.271
Response to first line therapy	0.251

T: Size or direct extent of the primary tumor

Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Only subgroup characteristics in which at least one subgroup category included at least 10 patients in both treatment arms were included in the analysis.

a: Likelihood-Ratio-Test. The interaction test is based only on the valid subgroup categories (without "unknown").

Table 46: Comparison of progression free survival by confounder categories for Pool 1 vs. ACT, Naive comparison

Soubgroup	**Category**	**Parameter**	**Capmatinib**[a]	**ACT**[a]	**HR (95% CI)**[a]	**p-value** [a]	**p-value interaction-test**[c]
Age category at start of therapy (years)							0.443
	<65						
		Univariate Cox-Regression			0.14 (0.03 - 0.70)	0.014	
		N	12	3			
		Patients with Event n (%)	11 (91.7)	3 (100.0)			
		Censored n (%)	1 (8.3)	0 (0.0)			
		Median time to event with 95% CI[b]	4.83 (1.41 - 13.14)	1.97 (1.48 - n.a.)			
	≥65						
		Univariate Cox-Regression			0.89 (0.53 - 1.47)	0.678	

Soubgroup	**Category**	**Parameter**	**Capmatinib**[a]	**ACT**[a]	**HR (95% CI)**[a]	**p-value** [a]	**p-value interaction-test**[c]
		N	69	18			
		Patients with Event n (%)	55 (79.7)	15 (83.3)			
		Censored n (%)	14 (20.3)	3 (16.7)			
		Median time to event with 95% CI[b]	5.42 (4.17 - 8.18)	7.00 (3.98 - 9.23)			
Gender							0.094
	Female						
		Univariate Cox-Regression			0.82 (0.46 - 1.45)	0.576	
		N	44	11			
		Patients with Event n (%)	40 (90.9)	10 (90.9)			
		Censored n (%)	4 (9.1)	1 (9.1)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	4.67 (4.14 - 8.11)	6.01 (1.48 - 8.87)			
	Male						
		Univariate Cox-Regression			0.75 (0.35 - 1.59)	0.477	
		N	37	10			
		Patients with Event n (%)	26 (70.3)	8 (80.0)			
		Censored n (%)	11 (29.7)	2 (20.0)			
		Median time to event with 95% CI[b]	6.60 (4.17 - 11.07)	7.00 (0.07 - 12.06)			
T-stage T4 at start of therapy							0.047
	Yes						
		Univariate Cox-Regression			1.95 (0.36 - 10.45)	0.380	

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		N	14	3			
		Patients with Event n (%)	12 (85.7)	2 (66.7)			
		Censored n (%)	2 (14.3)	1 (33.3)			
		Median time to event with 95% CI[b]	4.14 (2.33 - 5.39)	3.98 (3.15 - n.a.)			
	No						
		Univariate Cox-Regression			1.06 (0.55 - 2.06)	0.940	
		N	18	4			
		Patients with Event n (%)	16 (88.9)	2 (50.0)			
		Censored n (%)	2 (11.1)	2 (50.0)			
		Median time to event with 95% CI[b]	5.57 (4.17 - 10.61)	8.28 (6.01 - n.a.)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	49	14			
		Patients with Event n (%)	38 (77.6)	14 (100.0)			
		Censored n (%)	11 (22.5)	0 (0.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
Lymph node metastases at start of therapy							0.220
	Yes						
		Univariate Cox-Regression			1.76 (0.43 - 7.20)	0.426	
		N	54	5			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Patients with Event n (%)	41 (75.9)	2 (40.0)			
		Censored n (%)	13 (24.1)	3 (60.0)			
		Median time to event with 95% CI[b]	5.49 (4.17 - 10.38)	10.55 (3.15 - n.a.)			
	No						
		Univariate Cox-Regression			0.31 (0.15 - 0.64)	0.240	
		N	27	1			
		Patients with Event n (%)	25 (92.6)	1 (100.0)			
		Censored n (%)	2 (7.4)	0 (0.0)			
		Median time to event with 95% CI[b]	5.42 (4.07 - 8.11)	3.98 (n.a. - n.a.)			
	Unknown						

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	n.a.	15			
		Patients with Event n (%)	n.a. (n.a.)	15 (100.0)			
		Censored n (%)	n.a. (n.a.)	0 (0.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
Brain metastases at start of therapy							0.486
	Yes						
		Univariate Cox-Regression			0.06 (0.01 - 0.45)	0.009	
		N	16	1			
		Patients with Event n (%)	14 (87.5)	1 (100.0)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Censored n (%)	2 (12.5)	0 (0.0)			
		Median time to event with 95% CI[b]	4.67 (4.11 - 10.38)	1.48 (n.a. - n.a.)			
	No						
		Univariate Cox-Regression			0.80 (0.48 - 1.32)	0.416	
		N	65	20			
		Patients with Event n (%)	52 (80.0)	17 (85.0)			
		Censored n (%)	13 (20.0)	3 (15.0)			
		Median time to event with 95% CI[b]	5.55 (4.17 - 8.34)	6.24 (3.15 - 8.87)			
Liver metastases at start of therapy							0.271
	Yes						

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Univariate Cox-Regression			1.06 (0.36 - 3.13)	0.924	
		N	18	3			
		Patients with Event n (%)	16 (88.9)	3 (100.0)			
		Censored n (%)	2 (11.1)	0 (0.0)			
		Median time to event with 95% CI[b]	6.93 (2.66 - 8.18)	10.55 (0.03 - n.a.)			
	No						
		Univariate Cox-Regression			0.80 (0.47 - 1.38)	0.472	
		N	63	17			
		Patients with Event n (%)	50 (79.4)	14 (82.4)			
		Censored n (%)	13 (20.6)	3 (17.7)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	5.42 (4.17 - 8.34)	6.01 (3.15 - 8.87)			
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	n.a.	1			
		Patients with Event n (%)	n.a. (n.a.)	1 (100.0)			
		Censored n (%)	n.a. (n.a.)	0 (0.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
Response to first line therapy							0.251
	Progression						
		Univariate Cox-Regression			0.56 (0.29 - 1.08)	0.173	

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		N	27	9			
		Patients with Event n (%)	20 (74.1)	8 (88.9)			
		Censored n (%)	7 (25.9)	1 (11.1)			
		Median time to event with 95% CI[b]	5.49 (4.17 - 17.31)	6.24 (0.03 - 8.87)			
	Non-progression						
		Univariate Cox-Regression			1.02 (0.48 - 2.14)	0.967	
		N	39	11			
		Patients with Event n (%)	32 (82.1)	9 (81.8)			
		Censored n (%)	7 (18.0)	2 (18.2)			
		Median time to event with 95% CI[b]	5.39 (4.11 - 8.18)	6.01 (1.48 - 9.23)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	15	1			
		Patients with Event n (%)	14 (93.3)	1 (100.0)			
		Censored n (%)	1 (6.7)	0 (0.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			

CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available; T: Size or direct extent of the primary tumor

Only subgroup characteristics in which at least one subgroup category included at least 10 patients in both treatment arms were included in the analysis.

Subgroup category "unknown": These values are only shown descriptively and are not included in statistical calculations.

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

b: Median calculation using 50th quantile.

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
c: Likelihood-Ratio-Test. The interaction test is based only on the valid subgroup categories (without "unknown").							

Figure 51: Comparison of progression free survival for population Pool 1 vs. ACT and subgroup: Age category: < 65, Kaplan-Meier plot, Naive comparison



Figure 52: Comparison of progression free survival for population Pool 1 vs. ACT and subgroup: Age category: ≥ 65, Kaplan-Meier plot, Naive comparison



Figure 53: Comparison of progression free survival for population Pool 1 vs. ACT and subgroup: Gender: female, Kaplan-Meier plot, Naive comparison



Figure 54: Comparison of progression free survival for population Pool 1 vs. ACT and subgroup: Gender: male, Kaplan-Meier plot, Naive comparison



Figure 55: Comparison of progression free survival for population Pool 1 vs. ACT and subgroup: T-stage T4: Yes, Kaplan-Meier plot, Naive comparison



Figure 56: Comparison of progression free survival for population Pool 1 vs. ACT and subgroup: T-stage T4: No, Kaplan-Meier plot, Naive comparison



Figure 57: Comparison of progression free survival for population Pool 1 vs. ACT and subgroup: Lymph node metastases: Yes, Kaplan-Meier plot, Naive comparison



Figure 58: Comparison of progression free survival for population Pool 1 vs. ACT and subgroup: Lymph node metastases: No, Kaplan-Meier plot, Naive comparison



Figure 59: Comparison of progression free survival for population Pool 1 vs. ACT and subgroup: Brain metasases: Yes, Kaplan-Meier plot, Naive comparison



Figure 60: Comparison of progression free survival for population Pool 1 vs. ACT and subgroup: Brain metasases: No, Kaplan-Meier plot, Naive comparison



Figure 61: Comparison of progression free survival for population Pool 1 vs. ACT and subgroup: Liver metasases: Yes, Kaplan-Meier plot, Naive comparison



Figure 62: Comparison of progression free survival for population Pool 1 vs. ACT and subgroup: Liver metasases: No, Kaplan-Meier plot, Naive comparison



Figure 63: Comparison of progression free survival for population Pool 1 vs. ACT and subgroup: Response to first line: Progression, Kaplan-Meier plot, Naive comparison



Figure 64: Comparison of progression free survival for population Pool 1 vs. ACT and subgroup: Response to first line: Non-progression, Kaplan-Meier plot, Naive comparison



2.1.3 Overall response rate

Table 47: Overview of interaction p-values of overall response rate by confounder categories for Pool 1 vs. ACT, Naive comparison

Subgroup	**OR; p-value interaction test[a]**	**RR; p-value interaction test[a]**	**ARR; p-value interaction test[a]**
Age category at start of therapy	0.507	0.507	0.507
Gender	0.832	0.832	0.832
Lymph node metastases at start of therapy	0.427	0.427	0.427
Brain metastases at start of therapy	0.873	0.873	0.873
Liver metastases at start of therapy	0.436	0.436	0.436
Response to first line therapy	0.627	0.627	0.627

ARR: Absolute risk reduction; OR: Odds ratio; RR: Relative Risk

Only subgroup characteristics with more than 10 patients per subgroup category and at least 10 events in at least 1 subgroup category were considered in the analysis.

a: Likelihood-Ratio-Test. The interaction test is based only on the valid subgroup categories (without "unknown").

Table 48: Comparison of overall response rate by confounder categories for Pool 1 vs. ACT, Naive comparison

Subgroup	Category	Capmatinib	ACT	Capmatinib - Overall response rate n (%)	ACT - Overall response rate n (%)	OR (95% CI); p-value[a]	OR; p-value interaction test	RR (95% CI); p-value[b]	RR; p-value interaction test	ARR (95% CI); p-value[c]	ARR; p-value interaction test
Age category at start of therapy							0.507		0.507		0.507
	<65	12	3	4 (33.3)	3 (100.0)	<0.005 (n.a.-n.a.); n.a.		0.36 (n.a.-n.a.); n.a.		n.a. (n.a.-n.a.); n.a.	
	≥65	69	18	30 (43.5)	3 (16.7)	3.85 (1.02-14.51); 0.047		2.61 (0.90-7.59); 0.078		0.27 (0.06-0.48); 0.012	
Gender							0.832		0.832		0.832
	Female	44	11	18 (40.9)	3 (27.3)	1.85 (0.43-7.92); 0.409		1.50 (0.54-4.19); 0.440		0.14 (-0.16-0.44); 0.374	
	Male	37	10	16 (43.2)	3 (30.0)	1.78 (0.40-7.97); 0.452		1.44 (0.52-3.98); 0.481		0.13 (-0.19-0.46); 0.426	

Subgroup	Category	Capmatinib	ACT	Capmatinib - Overall response rate n (%)	ACT - Overall response rate n (%)	OR (95% CI); p-value[a]	OR; p-value interaction test	RR (95% CI); p-value[b]	RR; p-value interaction test	ARR (95% CI); p-value[c]	ARR; p-value interaction test
Lymph node metastases at start of therapy							0.427		0.427		0.427
	Yes	54	5	21 (38.9)	0 (0.0)	66027000000.00 (n.a.-n.a.); n.a.		37088000000.00 (n.a.-n.a.); n.a.		0.39 (n.a.-n.a.); n.a.	
	No	27	1	13 (48.2)	1 (100.0)	<0.005 (n.a.-n.a.); n.a.		0.49 (n.a.-n.a.); n.a.		-0.52 (n.a.-n.a.); n.a.	
	Unknown	n.a.	15	n.a. (n.a.)	5 (33.3)	n.a. (n.a.-n.a.); n.a.		n.a. (n.a.-n.a.); n.a.		n.a. (n.a.-n.a.); n.a.	
Brain metastases at start of therapy							0.873		0.873		0.873
	Yes	16	1	7 (43.8)	1 (100.0)	<0.005 (n.a.-n.a.);		0.45 (n.a.-		n.a. (n.a.-	

Subgroup	Category	Capmatinib	ACT	Capmatinib - Overall response rate n (%)	ACT - Overall response rate n (%)	OR (95% CI); p-value[a]	OR; p-value interaction test	RR (95% CI); p-value[b]	RR; p-value interaction test	ARR (95% CI); p-value[c]	ARR; p-value interaction test
						n.a.		n.a.); n.a.		n.a.); n.a.	
	No	65	20	27 (41.5)	5 (25.0)	2.13 (0.69-6.57); 0.188		1.66 (0.74-3.74); 0.220		0.17 (-0.06-0.39); 0.149	
Liver metastases at start of therapy							0.436		0.436		0.436
	Yes	18	3	9 (50.0)	1 (33.3)	2.00 (0.15-26.19); 0.597		1.50 (0.28-7.93); 0.633		0.17 (-0.41-0.75); 0.574	
	No	63	17	25 (39.7)	4 (23.5)	2.14 (0.63-7.31); 0.226		1.69 (0.68-4.19); 0.260		0.16 (-0.07-0.40); 0.178	
	Unknown	n.a.	1	n.a. (n.a.)	1 (100.0)	n.a. (n.a.-n.a.); n.a.		n.a. (n.a.-n.a.); n.a.		n.a. (n.a.-n.a.); n.a.	
Response to first line							0.627		0.627		0.627

Subgroup	Category	Capmatinib	ACT	Capmatinib - Overall response rate n (%)	ACT - Overall response rate n (%)	OR (95% CI); p-value[a]	OR; p-value interaction test	RR (95% CI); p-value[b]	RR; p-value interaction test	ARR (95% CI); p-value[c]	ARR; p-value interaction test
therapy											
	Progression	27	9	12 (44.4)	3 (33.3)	1.60 (0.33-7.77); 0.560		1.33 (0.48-3.68); 0.579		0.11 (-0.25-0.47); 0.546	
	Non-progression	39	11	15 (38.5)	3 (27.3)	1.67 (0.38-7.29); 0.497		1.41 (0.50-4.00); 0.519		0.11 (-0.19-0.42); 0.471	
	Unknown	15	1	7 (46.7)	0 (0.0)	n.a. (n.a.-n.a.); n.a.		n.a. (n.a.-n.a.); n.a.		n.a. (n.a.-n.a.); n.a.	

ACT: Appropriate comparative therapy; ARR: Absolute risk reduction; CI: Confidence interval; n: Number of patients with event; n.a.: Not available; OR: Odds ratio; RR: Relative Risk

Only subgroup characteristics with more than 10 patients per subgroup category and at least 10 events in at least 1 subgroup category were considered in the analysis.

Subgroup category "unknown": These values are only shown descriptively and are not included in statistical calculations.

a: Binomial regression model (treatment arm as fixed effect) with logit-link function

b: Binomial regression model (treatment arm as fixed effect) with log-link function

Subgroup	Category	Capmatinib	ACT	Capmatinib - Overall response rate n (%)	ACT - Overall response rate n (%)	OR (95% CI); p-value[a]	OR; p-value interaction test	RR (95% CI); p-value[b]	RR; p-value interaction test	ARR (95% CI); p-value[c]	ARR; p-value interaction test
c: GLM (treatment arm as fixed effect) with identity link function d: Likelihood-Ratio-Test. The interaction test is based only on the valid subgroup categories (without "unknown").											

2.1.4 Time to treatment discontinuation due to adverse events

Table 49: Overview of interaction p-values of time to treatment discontinuation due to adverse events by confounder categories for Pool 1 vs. ACT, Naive comparison

Soubgroup	**p-value interaction-test**[a]
Age category at start of therapy (years)	0.483
Gender	0.735
T-stage T4 at start of therapy	0.455
Lymph node me-tastases at start of therapy	0.538
Brain metastases at start of therapy	0.267
Liver metastases at start of therapy	0.629
Response to first line therapy	0.289

T: Size or direct extent of the primary tumor

Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Only subgroup characteristics in which at least one subgroup category included at least 10 patients in both treatment arms were included in the analysis.

a: Likelihood-Ratio-Test. The interaction test is based only on the valid subgroup categories (without "unknown").

Table 50: Comparison of time to treatment discontinuation due to adverse events by confounder categories for Pool 1 vs. ACT, Naive comparison

Soubgroup	**Category**	**Parameter**	**Capmatinib**[a]	**ACT**[a]	**HR (95% CI)**[a]	**p-value** [a]	**p-value interaction-test**[c]
Age category at start of therapy (years)							0.483
	<65						
		Univariate Cox-Regression			239760000000.00 (33773000000.00 - 1702100000000.00)	0.317	
		N	12	3			
		Patients with Event n (%)	1 (8.3)	0 (0.0)			
		Censored n (%)	11 (91.7)	3 (100.0)			
		Median time to event with 95% CI[b]	29.77 (n.a. - n.a.)	n.a. (n.a. - n.a.)			
	≥65						

Soubgroup	**Category**	**Parameter**	**Capmatinib**[a]	**ACT**[a]	**HR (95% CI)**[a]	**p-value** [a]	**p-value interaction-test**[c]
		Univariate Cox-Regression			0.75 (0.25 - 2.27)	0.611	
		N	69	18			
		Patients with Event n (%)	13 (18.8)	4 (22.2)			
		Censored n (%)	56 (81.2)	14 (77.8)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
Gender							0.735
	Female						
		Univariate Cox-Regression			0.48 (0.14 - 1.63)	0.215	
		N	44	11			
		Patients with Event n (%)	8 (18.2)	4 (36.4)			
		Censored n (%)	36 (81.8)	7 (63.6)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
	Male						
		Univariate Cox-Regression			12902010.00 (4515271.60 - 36866414.00)	0.212	
		N	37	10			
		Patients with Event n (%)	6 (16.2)	0 (0.0)			
		Censored n (%)	31 (83.8)	10 (100.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
T-stage T4 at start of therapy							0.455
	Yes						

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Univariate Cox-Regression			38144532.00 (7978912.80 - 182356337.00)	0.328	
		N	14	3			
		Patients with Event n (%)	3 (21.4)	0 (0.0)			
		Censored n (%)	11 (78.6)	3 (100.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
	No						
		Univariate Cox-Regression			0.20 (0.04 - 1.00)	0.053	
		N	18	4			
		Patients with Event n (%)	3 (16.7)	2 (50.0)			
		Censored n (%)	15 (83.3)	2 (50.0)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	4.57 (0.95 - n.a.)			
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	49	14			
		Patients with Event n (%)	8 (16.3)	2 (14.3)			
		Censored n (%)	41 (83.7)	12 (85.7)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
Lymph node metastases at start of therapy							0.538
	Yes						

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Univariate Cox-Regression			0.30 (0.06 - 1.45)	0.096	
		N	54	5			
		Patients with Event n (%)	10 (18.5)	2 (40.0)			
		Censored n (%)	44 (81.5)	3 (60.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	4.57 (0.95 - n.a.)			
	No						
		Univariate Cox-Regression			1279149.20 (134479.72 - 12167058.00)	0.730	
		N	27	1			
		Patients with Event n (%)	4 (14.8)	0 (0.0)			
		Censored n (%)	23 (85.2)	1 (100.0)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	n.a.	15			
		Patients with Event n (%)	n.a. (n.a.)	2 (13.3)			
		Censored n (%)	n.a. (n.a.)	13 (86.7)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
Brain metastases at start of therapy							0.267
	Yes						

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Univariate Cox-Regression			3678157.90 (242787.43 - 55723006.00)	0.782	
		N	16	1			
		Patients with Event n (%)	1 (6.3)	0 (0.0)			
		Censored n (%)	15 (93.8)	1 (100.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
	No						
		Univariate Cox-Regression			0.93 (0.30 - 2.85)	0.900	
		N	65	20			
		Patients with Event n (%)	13 (20.0)	4 (20.0)			
		Censored n (%)	52 (80.0)	16 (80.0)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
Liver metastases at start of therapy							0.629
	Yes						
		Univariate Cox-Regression			0.32 (0.05 - 2.32)	0.333	
		N	18	3			
		Patients with Event n (%)	2 (11.1)	1 (33.3)			
		Censored n (%)	16 (88.9)	2 (66.7)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
	No						
		Univariate Cox-Regression			0.99 (0.27 - 3.58)	0.982	

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		N	63	17			
		Patients with Event n (%)	12 (19.1)	3 (17.7)			
		Censored n (%)	51 (81.0)	14 (82.4)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	n.a.	1			
		Patients with Event n (%)	n.a. (n.a.)	0 (0.0)			
		Censored n (%)	n.a. (n.a.)	1 (100.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			

Soubgroup	**Category**	**Parameter**	**Capmatinib**[a]	**ACT**[a]	**HR (95% CI)**[a]	**p-value** [a]	**p-value interaction-test**[c]
Response to first line therapy							0.289
	Progression						
		Univariate Cox-Regression			0.17 (0.03 - 0.94)	0.033	
		N	27	9			
		Patients with Event n (%)	2 (7.4)	3 (33.3)			
		Censored n (%)	25 (92.6)	6 (66.7)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
	Non-progression						
		Univariate Cox-Regression			1.79 (0.25 - 12.91)	0.584	
		N	39	11			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Patients with Event n (%)	6 (15.4)	1 (9.1)			
		Censored n (%)	33 (84.6)	10 (90.9)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	15	1			
		Patients with Event n (%)	6 (40.0)	0 (0.0)			
		Censored n (%)	9 (60.0)	1 (100.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			

CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available; T: Size or direct extent of the primary tumor

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
Only subgroup characteristics in which at least one subgroup category included at least 10 patients in both treatment arms were included in the analysis. Subgroup category "unknown": These values are only shown descriptively and are not included in statistical calculations. a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used. b: Median calculation using 50th quantile. c: Likelihood-Ratio-Test. The interaction test is based only on the valid subgroup categories (without "unknown").							

Figure 65: Comparison of time to treatment discontinuation due to adverse events for population Pool 1 vs. ACT and subgroup: Age category: < 65, Kaplan-Meier plot, Naive comparison



Figure 66: Comparison of time to treatment discontinuation due to adverse events for population Pool 1 vs. ACT and subgroup: Age category: ≥ 65, Kaplan-Meier plot, Naive comparison



Figure 67: Comparison of time to treatment discontinuation due to adverse events for population Pool 1 vs. ACT and subgroup: Gender: female, Kaplan-Meier plot, Naive comparison



Figure 68: Comparison of time to treatment discontinuation due to adverse events for population Pool 1 vs. ACT and subgroup: Gender: male, Kaplan-Meier plot, Naive comparison



Figure 69: Comparison of time to treatment discontinuation due to adverse events for population Pool 1 vs. ACT and subgroup: T-stage T4: Yes, Kaplan-Meier plot, Naive comparison



Figure 70: Comparison of time to treatment discontinuation due to adverse events for population Pool 1 vs. ACT and subgroup: T-stage T4: No, Kaplan-Meier plot, Naive comparison



Figure 71: Comparison of time to treatment discontinuation due to adverse events for population Pool 1 vs. ACT and subgroup: Lymph node metastases: Yes, Kaplan-Meier plot, Naive comparison



Figure 72: Comparison of time to treatment discontinuation due to adverse events for population Pool 1 vs. ACT and subgroup: Lymph node metastases: No, Kaplan-Meier plot, Naive comparison



Figure 73: Comparison of time to treatment discontinuation due to adverse events for population Pool 1 vs. ACT and subgroup: Brain metasases: Yes, Kaplan-Meier plot, Naive comparison



Figure 74: Comparison of time to treatment discontinuation due to adverse events for population Pool 1 vs. ACT and subgroup: Brain metasases: No, Kaplan-Meier plot, Naive comparison



Figure 75: Comparison of time to treatment discontinuation due to adverse events for population Pool 1 vs. ACT and subgroup: Liver metasases: Yes, Kaplan-Meier plot, Naive comparison



Figure 76: Comparison of time to treatment discontinuation due to adverse events for population Pool 1 vs. ACT and subgroup: Liver metasases: No, Kaplan-Meier plot, Naive comparison



Figure 77: Comparison of time to treatment discontinuation due to adverse events for population Pool 1 vs. ACT and subgroup: Response to first line: Progression, Kaplan-Meier plot, Naive comparison



Figure 78: Comparison of time to treatment discontinuation due to adverse events for population Pool 1 vs. ACT and subgroup: Response to first line: Non-progression, Kaplan-Meier plot, Naive comparison



2.1.5 Time to unplanned or prolonged hospitalizations

Table 51: Overview of interaction p-values of time to unplanned or prolonged hospitalizations by confounder categories for Pool 1 vs. ACT, Naive comparison

Soubgroup	**p-value interaction-test**[a]
Age category at start of therapy (years)	0.973
Gender	0.811
T-stage T4 at start of therapy	0.585
Lymph node me-tastases at start of therapy	0.791
Brain metastases at start of therapy	0.564
Liver metastases at start of therapy	0.158
Response to first line therapy	0.213
T: Size or direct extent of the primary tumor Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used. Only subgroup characteristics in which at least one subgroup category included at least 10 patients in both treatment arms were included in the analysis. a: Likelihood-Ratio-Test. The interaction test is based only on the valid subgroup categories (without "unknown").	

Table 52: Comparison of time to unplanned or prolonged hospitalizations by confounder categories for Pool 1 vs. ACT, Naive comparison

Soubgroup	**Category**	**Parameter**	**Capmatinib**[a]	**ACT**[a]	**HR (95% CI)**[a]	**p-value** [a]	**p-value interaction-test**[c]
Age category at start of therapy (years)							0.973
	<65						
		Univariate Cox-Regression			1.24 (0.18 - 8.37)	0.842	
		N	12	3			
		Patients with Event n (%)	5 (41.7)	1 (33.3)			
		Censored n (%)	7 (58.3)	2 (66.7)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
	≥65						
		Univariate Cox-Regression			0.94 (0.46 - 1.95)	0.887	

Soubgroup	**Category**	**Parameter**	**Capmatinib**[a]	**ACT**[a]	**HR (95% CI)**[a]	**p-value** [a]	**p-value interaction-test**[c]
		N	69	18			
		Patients with Event n (%)	29 (42.0)	8 (44.4)			
		Censored n (%)	40 (58.0)	10 (55.6)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	9.36 (5.75 - n.a.)			
Gender							0.811
	Female						
		Univariate Cox-Regression			1.31 (0.49 - 3.54)	0.621	
		N	44	11			
		Patients with Event n (%)	19 (43.2)	4 (36.4)			
		Censored n (%)	25 (56.8)	7 (63.6)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
	Male						
		Univariate Cox-Regression			0.77 (0.31 - 1.91)	0.604	
		N	37	10			
		Patients with Event n (%)	15 (40.5)	5 (50.0)			
		Censored n (%)	22 (59.5)	5 (50.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	8.57 (0.07 - n.a.)			
T-stage T4 at start of therapy							0.585
	Yes						
		Univariate Cox-Regression			1.45 (0.24 - 8.64)	0.732	

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		N	14	3			
		Patients with Event n (%)	6 (42.9)	1 (33.3)			
		Censored n (%)	8 (57.1)	2 (66.7)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
	No						
		Univariate Cox-Regression			1.16 (0.18 - 7.61)	0.891	
		N	18	4			
		Patients with Event n (%)	8 (44.4)	1 (25.0)			
		Censored n (%)	10 (55.6)	3 (75.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	49	14			
		Patients with Event n (%)	20 (40.8)	7 (50.0)			
		Censored n (%)	29 (59.2)	7 (50.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
Lymph node metastases at start of therapy							0.791
	Yes						
		Univariate Cox-Regression			1.55 (0.25 - 9.72)	0.664	
		N	54	5			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Patients with Event n (%)	21 (38.9)	1 (20.0)			
		Censored n (%)	33 (61.1)	4 (80.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
	No						
		Univariate Cox-Regression			0.25 (0.11 - 0.55)	0.167	
		N	27	1			
		Patients with Event n (%)	13 (48.2)	1 (100.0)			
		Censored n (%)	14 (51.9)	0 (0.0)			
		Median time to event with 95% CI[b]	29.47 (7.46 - n.a.)	4.21 (n.a. - n.a.)			
	Unknown						

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	n.a.	15			
		Patients with Event n (%)	n.a. (n.a.)	7 (46.7)			
		Censored n (%)	n.a. (n.a.)	8 (53.3)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
Brain metastases at start of therapy							0.564
	Yes						
		Univariate Cox-Regression			3624338.30 (383973.20 - 34210274.00)	0.654	
		N	16	1			
		Patients with Event n (%)	6 (37.5)	0 (0.0)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Censored n (%)	10 (62.5)	1 (100.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
	No						
		Univariate Cox-Regression			1.01 (0.50 - 2.03)	0.984	
		N	65	20			
		Patients with Event n (%)	28 (43.1)	9 (45.0)			
		Censored n (%)	37 (56.9)	11 (55.0)			
		Median time to event with 95% CI[b]	29.47 (7.46 - n.a.)	9.36 (5.75 - n.a.)			
Liver metastases at start of therapy							0.158
	Yes						

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Univariate Cox-Regression			0.56 (0.26 - 1.20)	0.390	
		N	18	3			
		Patients with Event n (%)	10 (55.6)	3 (100.0)			
		Censored n (%)	8 (44.4)	0 (0.0)			
		Median time to event with 95% CI[b]	7.52 (1.41 - n.a.)	5.75 (2.73 - n.a.)			
	No						
		Univariate Cox-Regression			1.10 (0.47 - 2.57)	0.830	
		N	63	17			
		Patients with Event n (%)	24 (38.1)	6 (35.3)			
		Censored n (%)	39 (61.9)	11 (64.7)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	n.a.	1			
		Patients with Event n (%)	n.a. (n.a.)	0 (0.0)			
		Censored n (%)	n.a. (n.a.)	1 (100.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
Response to first line therapy							0.213
	Progression						
		Univariate Cox-Regression			0.35 (0.13 - 0.96)	0.056	

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		N	27	9			
		Patients with Event n (%)	7 (25.9)	6 (66.7)			
		Censored n (%)	20 (74.1)	3 (33.3)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	5.75 (2.60 - 8.57)			
	Non-progression						
		Univariate Cox-Regression			2.60 (0.61 - 11.08)	0.182	
		N	39	11			
		Patients with Event n (%)	17 (43.6)	2 (18.2)			
		Censored n (%)	22 (56.4)	9 (81.8)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	15	1			
		Patients with Event n (%)	10 (66.7)	1 (100.0)			
		Censored n (%)	5 (33.3)	0 (0.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			

CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available; T: Size or direct extent of the primary tumor

Only subgroup characteristics in which at least one subgroup category included at least 10 patients in both treatment arms were included in the analysis.

Subgroup category "unknown": These values are only shown descriptively and are not included in statistical calculations.

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

b: Median calculation using 50th quantile.

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
c: Likelihood-Ratio-Test. The interaction test is based only on the valid subgroup categories (without "unknown").							

Figure 79: Comparison of time to unplanned or prolonged hospitalizations for population Pool 1 vs. ACT and subgroup: Age category: < 65, Kaplan-Meier plot, Naive comparison



Figure 80: Comparison of time to unplanned or prolonged hospitalizations for population Pool 1 vs. ACT and subgroup: Age category: ≥ 65, Kaplan-Meier plot, Naive comparison



Figure 81: Comparison of time to unplanned or prolonged hospitalizations for population Pool 1 vs. ACT and subgroup: Gender: female, Kaplan-Meier plot, Naive comparison



Figure 82: Comparison of time to unplanned or prolonged hospitalizations for population Pool 1 vs. ACT and subgroup: Gender: male, Kaplan-Meier plot, Naive comparison



Figure 83: Comparison of time to unplanned or prolonged hospitalizations for population Pool 1 vs. ACT and subgroup: T-stage T4: Yes, Kaplan-Meier plot, Naive comparison



Figure 84: Comparison of time to unplanned or prolonged hospitalizations for population Pool 1 vs. ACT and subgroup: T-stage T4: No, Kaplan-Meier plot, Naive comparison



Figure 85: Comparison of time to unplanned or prolonged hospitalizations for population Pool 1 vs. ACT and subgroup: Lymph node metastases: Yes, Kaplan-Meier plot, Naive comparison



Figure 86: Comparison of time to unplanned or prolonged hospitalizations for population Pool 1 vs. ACT and subgroup: Lymph node metastases: No, Kaplan-Meier plot, Naive comparison



Figure 87: Comparison of time to unplanned or prolonged hospitalizations for population Pool 1 vs. ACT and subgroup: Brain metasases: Yes, Kaplan-Meier plot, Naive comparison



Figure 88: Comparison of time to unplanned or prolonged hospitalizations for population Pool 1 vs. ACT and subgroup: Brain metasases: No, Kaplan-Meier plot, Naive comparison



Figure 89: Comparison of time to unplanned or prolonged hospitalizations for population Pool 1 vs. ACT and subgroup: Liver metasases: Yes, Kaplan-Meier plot, Naive comparison



Figure 90: Comparison of time to unplanned or prolonged hospitalizations for population Pool 1 vs. ACT and subgroup: Liver metasases: No, Kaplan-Meier plot, Naive comparison



Figure 91: Comparison of time to unplanned or prolonged hospitalizations for population Pool 1 vs. ACT and subgroup: Response to first line: Progression, Kaplan-Meier plot, Naive comparison



Figure 92: Comparison of time to unplanned or prolonged hospitalizations for population Pool 1 vs. ACT and subgroup: Response to first line: Non-progression, Kaplan-Meier plot, Naive comparison



2.1.6 Time to unplanned or prolonged hospitalizations or death

Table 53: Overview of interaction p-values of time to unplanned or prolonged hospitalizations or death by confounder categories for Pool 1 vs. ACT, Naive comparison

Soubgroup	**p-value interaction-test**[a]
Age category at start of therapy (years)	0.538
Gender	0.152
T-stage T4 at start of therapy	0.460
Lymph node me-tastases at start of therapy	0.882
Brain metastases at start of therapy	0.648
Liver metastases at start of therapy	0.110
Response to first line therapy	0.093

T: Size or direct extent of the primary tumor

Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Only subgroup characteristics in which at least one subgroup category included at least 10 patients in both treatment arms were included in the analysis.

a: Likelihood-Ratio-Test. The interaction test is based only on the valid subgroup categories (without "unknown").

Table 54: Comparison of time to unplanned or prolonged hospitalizations or death by confounder categories for Pool 1 vs. ACT, Naive comparison

Soubgroup	**Category**	**Parameter**	**Capmatinib**[a]	**ACT**[a]	**HR (95% CI)**[a]	**p-value** [a]	**p-value interaction-test**[c]
Age category at start of therapy (years)							0.538
	<65						
		Univariate Cox-Regression			1.22 (0.25 - 6.08)	0.796	
		N	12	3			
		Patients with Event n (%)	10 (83.3)	2 (66.7)			
		Censored n (%)	2 (16.7)	1 (33.3)			
		Median time to event with 95% CI[b]	7.26 (0.99 - 24.28)	5.52 (2.60 - n.a.)			
	≥65						
		Univariate Cox-Regression			0.96 (0.51 - 1.81)	0.910	

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		N	69	18			
		Patients with Event n (%)	52 (75.4)	12 (66.7)			
		Censored n (%)	17 (24.6)	6 (33.3)			
		Median time to event with 95% CI[b]	9.00 (6.64 - 16.79)	8.57 (4.21 - 11.17)			
Gender							0.152
	Female						
		Univariate Cox-Regression			1.30 (0.56 - 3.03)	0.519	
		N	44	11			
		Patients with Event n (%)	38 (86.4)	7 (63.6)			
		Censored n (%)	6 (13.6)	4 (36.4)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	9.00 (5.91 - 14.75)	9.43 (4.21 - n.a.)			
	Male						
		Univariate Cox-Regression			0.76 (0.34 - 1.73)	0.531	
		N	37	10			
		Patients with Event n (%)	24 (64.9)	7 (70.0)			
		Censored n (%)	13 (35.1)	3 (30.0)			
		Median time to event with 95% CI[b]	8.74 (5.98 - 29.47)	8.15 (0.07 - n.a.)			
T-stage T4 at start of therapy							0.460
	Yes						
		Univariate Cox-Regression			1.38 (0.29 - 6.52)	0.680	

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		N	14	3			
		Patients with Event n (%)	10 (71.4)	2 (66.7)			
		Censored n (%)	4 (28.6)	1 (33.3)			
		Median time to event with 95% CI[b]	8.25 (0.79 - 29.50)	4.21 (3.15 - n.a.)			
	No						
		Univariate Cox-Regression			1.61 (0.20 - 12.94)	0.644	
		N	18	4			
		Patients with Event n (%)	15 (83.3)	1 (25.0)			
		Censored n (%)	3 (16.7)	3 (75.0)			
		Median time to event with 95% CI[b]	13.83 (3.35 - 25.79)	n.a. (n.a. - n.a.)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	49	14			
		Patients with Event n (%)	37 (75.5)	11 (78.6)			
		Censored n (%)	12 (24.5)	3 (21.4)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
Lymph node metastases at start of therapy							0.882
	Yes						
		Univariate Cox-Regression			1.25 (0.29 - 5.45)	0.761	
		N	54	5			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Patients with Event n (%)	39 (72.2)	2 (40.0)			
		Censored n (%)	15 (27.8)	3 (60.0)			
		Median time to event with 95% CI[b]	9.40 (5.91 - 14.85)	5.75 (3.15 - n.a.)			
	No						
		Univariate Cox-Regression			0.25 (0.11 - 0.55)	0.167	
		N	27	1			
		Patients with Event n (%)	23 (85.2)	1 (100.0)			
		Censored n (%)	4 (14.8)	0 (0.0)			
		Median time to event with 95% CI[b]	8.61 (6.64 - 24.51)	4.21 (n.a. - n.a.)			
	Unknown						

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	n.a.	15			
		Patients with Event n (%)	n.a. (n.a.)	11 (73.3)			
		Censored n (%)	n.a. (n.a.)	4 (26.7)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
Brain metastases at start of therapy							0.648
	Yes						
		Univariate Cox-Regression			0.21 (0.07 - 0.63)	0.133	
		N	16	1			
		Patients with Event n (%)	14 (87.5)	1 (100.0)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Censored n (%)	2 (12.5)	0 (0.0)			
		Median time to event with 95% CI[b]	10.12 (5.98 - 16.79)	5.52 (n.a. - n.a.)			
	No						
		Univariate Cox-Regression			1.05 (0.57 - 1.92)	0.886	
		N	65	20			
		Patients with Event n (%)	48 (73.9)	13 (65.0)			
		Censored n (%)	17 (26.2)	7 (35.0)			
		Median time to event with 95% CI[b]	9.00 (6.14 - 18.96)	8.57 (4.21 - 11.17)			
Liver metastases at start of therapy							0.110
	Yes						

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Univariate Cox-Regression			0.63 (0.30 - 1.28)	0.481	
		N	18	3			
		Patients with Event n (%)	16 (88.9)	3 (100.0)			
		Censored n (%)	2 (11.1)	0 (0.0)			
		Median time to event with 95% CI[b]	6.80 (1.41 - 18.96)	5.75 (2.73 - n.a.)			
	No						
		Univariate Cox-Regression			1.14 (0.57 - 2.28)	0.714	
		N	63	17			
		Patients with Event n (%)	46 (73.0)	10 (58.8)			
		Censored n (%)	17 (27.0)	7 (41.2)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	9.40 (6.64 - 17.68)	9.36 (4.21 - n.a.)			
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	n.a.	1			
		Patients with Event n (%)	n.a. (n.a.)	1 (100.0)			
		Censored n (%)	n.a. (n.a.)	0 (0.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
Response to first line therapy							0.093
	Progression						
		Univariate Cox-Regression			0.56 (0.23 - 1.34)	0.205	

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		N	27	9			
		Patients with Event n (%)	16 (59.3)	7 (77.8)			
		Censored n (%)	11 (40.7)	2 (22.2)			
		Median time to event with 95% CI[b]	14.75 (4.30 - n.a.)	5.75 (2.60 - 8.57)			
	Non-progression						
		Univariate Cox-Regression			1.75 (0.70 - 4.39)	0.201	
		N	39	11			
		Patients with Event n (%)	33 (84.6)	6 (54.6)			
		Censored n (%)	6 (15.4)	5 (45.5)			
		Median time to event with 95% CI[b]	8.25 (5.98 - 16.79)	11.17 (5.52 - n.a.)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	15	1			
		Patients with Event n (%)	13 (86.7)	1 (100.0)			
		Censored n (%)	2 (13.3)	0 (0.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			

CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available; T: Size or direct extent of the primary tumor

Only subgroup characteristics in which at least one subgroup category included at least 10 patients in both treatment arms were included in the analysis.

Subgroup category "unknown": These values are only shown descriptively and are not included in statistical calculations.

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

b: Median calculation using 50th quantile.

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
c: Likelihood-Ratio-Test. The interaction test is based only on the valid subgroup categories (without "unknown").							

Figure 93: Comparison of time to unplanned or prolonged hospitalizations or death for population Pool 1 vs. ACT and subgroup: Age category: < 65, Kaplan-Meier plot, Naive comparison



Figure 94: Comparison of time to unplanned or prolonged hospitalizations or death for population Pool 1 vs. ACT and subgroup: Age category: ≥ 65, Kaplan-Meier plot, Naive comparison



Figure 95: Comparison of time to unplanned or prolonged hospitalizations or death for population Pool 1 vs. ACT and subgroup: Gender: female, Kaplan-Meier plot, Naive comparison



Figure 96: Comparison of time to unplanned or prolonged hospitalizations or death for population Pool 1 vs. ACT and subgroup: Gender: male, Kaplan-Meier plot, Naive comparison



Figure 97: Comparison of time to unplanned or prolonged hospitalizations or death for population Pool 1 vs. ACT and subgroup: T-stage T4: Yes, Kaplan-Meier plot, Naive comparison



Figure 98: Comparison of time to unplanned or prolonged hospitalizations or death for population Pool 1 vs. ACT and subgroup: T-stage T4: No, Kaplan-Meier plot, Naive comparison



Figure 99: Comparison of time to unplanned or prolonged hospitalizations or death for population Pool 1 vs. ACT and subgroup: Lymph node metastases: Yes, Kaplan-Meier plot, Naive comparison



Figure 100: Comparison of time to unplanned or prolonged hospitalizations or death for population Pool 1 vs. ACT and subgroup: Lymph node metastases: No, Kaplan-Meier plot, Naive comparison



Figure 101: Comparison of time to unplanned or prolonged hospitalizations or death for population Pool 1 vs. ACT and subgroup: Brain metasases: Yes, Kaplan-Meier plot, Naive comparison



Figure 102: Comparison of time to unplanned or prolonged hospitalizations or death for population Pool 1 vs. ACT and subgroup: Brain metasases: No, Kaplan-Meier plot, Naive comparison



Figure 103: Comparison of time to unplanned or prolonged hospitalizations or death for population Pool 1 vs. ACT and subgroup: Liver metasases: Yes, Kaplan-Meier plot, Naive comparison



Figure 104: Comparison of time to unplanned or prolonged hospitalizations or death for population Pool 1 vs. ACT and subgroup: Liver metasases: No, Kaplan-Meier plot, Naive comparison



Figure 105: Comparison of time to unplanned or prolonged hospitalizations or death for population Pool 1 vs. ACT and subgroup: Response to first line: Progression, Kaplan-Meier plot, Naive comparison



Figure 106: Comparison of time to unplanned or prolonged hospitalizations or death for population Pool 1 vs. ACT and subgroup: Response to first line: Non-progression, Kaplan-Meier plot, Naive comparison



2.2 Pop d vs. ACT

2.2.1 Overall survival

Table 55: Overview of interaction p-values of overall survival by confounder categories for Pop d vs. ACT, Naive comparison

Soubgroup	**p-value interaction-test**[a]
Age category at start of therapy (years)	0.004
Gender	0.449
T-stage T4 at start of therapy	0.377
Lymph node me-tastases at start of therapy	0.645
Brain metastases at start of therapy	0.140
Liver metastases at start of therapy	0.019
Response to first line therapy	0.306

T: Size or direct extent of the primary tumor

Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Only subgroup characteristics in which at least one subgroup category included at least 10 patients in both treatment arms were included in the analysis.

a: Likelihood-Ratio-Test. The interaction test is based only on the valid subgroup categories (without "unknown").

Table 56: Comparison of overall survival by confounder categories for Pop d vs. ACT, Naive comparison

Soubgroup	**Category**	**Parameter**	**Capmatinib**[a]	**ACT**[a]	**HR (95% CI)**[a]	**p-value** [a]	**p-value interaction-test**[c]
Age category at start of therapy (years)							0.004
	<65						
		Univariate Cox-Regression			1.87 (0.35 - 9.88)	0.417	
		N	10	3			
		Patients with Event n (%)	10 (100.0)	2 (66.7)			
		Censored n (%)	0 (0.0)	1 (33.3)			
		Median time to event with 95% CI[b]	8.61 (0.89 - 14.75)	5.75 (5.52 - n.a.)			
	≥65						
		Univariate Cox-Regression			0.61 (0.25 - 1.53)	0.270	
		N	54	9			
		Patients with Event n (%)	37 (68.5)	6 (66.7)			
		Censored n (%)	17 (31.5)	3 (33.3)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	18.30 (11.63 - 26.28)	11.14 (1.05 - n.a.)			
Gender							0.449
	Female						
		Univariate Cox-Regression			0.69 (0.28 - 1.66)	0.544	
		N	35	4			
		Patients with Event n (%)	29 (82.9)	3 (75.0)			
		Censored n (%)	6 (17.1)	1 (25.0)			
		Median time to event with 95% CI[b]	13.57 (9.03 - 25.79)	17.40 (5.52 - n.a.)			
	Male						
		Univariate Cox-Regression			0.69 (0.24 - 1.99)	0.467	
		N	29	8			
		Patients with Event n (%)	18 (62.1)	5 (62.5)			
		Censored n (%)	11 (37.9)	3 (37.5)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	17.68 (8.61 - 48.03)	8.15 (1.05 - n.a.)			
T-stage T4 at start of therapy							0.377
	Yes						
		Univariate Cox-Regression			1.93 (0.22 - 17.01)	0.532	
		N	12	3			
		Patients with Event n (%)	8 (66.7)	1 (33.3)			
		Censored n (%)	4 (33.3)	2 (66.7)			
		Median time to event with 95% CI[b]	20.47 (0.89 - n.a.)	n.a. (n.a. - n.a.)			
	No						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	15	1			
		Patients with Event n (%)	14 (93.3)	0 (0.0)			
		Censored n (%)	1 (6.7)	1 (100.0)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	14.75 (3.29 - 21.19)	n.a. (n.a. - n.a.)			
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	37	8			
		Patients with Event n (%)	25 (67.6)	7 (87.5)			
		Censored n (%)	12 (32.4)	1 (12.5)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
Lymph node metastases at start of therapy							0.645
	Yes						
		Univariate Cox-Regression			1.46 (0.12 - 17.74)	0.710	
		N	41	3			
		Patients with Event n (%)	29 (70.7)	1 (33.3)			
		Censored n (%)	12 (29.3)	2 (66.7)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	14.65 (8.74 - 22.74)	n.a. (n.a. - n.a.)			
	No						
		Univariate Cox-Regression			1311325.60 (166688.73 - 10316084.00)	0.483	
		N	23	1			
		Patients with Event n (%)	18 (78.3)	0 (0.0)			
		Censored n (%)	5 (21.7)	1 (100.0)			
		Median time to event with 95% CI[b]	18.30 (8.61 - 28.78)	n.a. (n.a. - n.a.)			
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	n.a.	8			
		Patients with Event n (%)	n.a. (n.a.)	7 (87.5)			
		Censored n (%)	n.a. (n.a.)	1 (12.5)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
Brain metastases at start of therapy							0.140
	Yes						
		Univariate Cox-Regression			0.18 (0.05 - 0.71)	0.119	
		N	12	1			
		Patients with Event n (%)	11 (91.7)	1 (100.0)			
		Censored n (%)	1 (8.3)	0 (0.0)			
		Median time to event with 95% CI[b]	12.39 (3.15 - 17.68)	5.52 (n.a. - n.a.)			
	No						
		Univariate Cox-Regression			0.78 (0.33 - 1.83)	0.549	
		N	52	11			
		Patients with Event n (%)	36 (69.2)	7 (63.6)			
		Censored n (%)	16 (30.8)	4 (36.4)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	18.30 (9.40 - 25.95)	11.14 (1.05 - n.a.)			
Liver metastases at start of therapy							0.019
	Yes						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	13	n.a.			
		Patients with Event n (%)	12 (92.3)	n.a. (n.a.)			
		Censored n (%)	1 (7.7)	n.a. (n.a.)			
		Median time to event with 95% CI[b]	11.53 (1.08 - 24.28)	n.a. (n.a. - n.a.)			
	No						
		Univariate Cox-Regression			0.74 (0.31 - 1.75)	0.465	
		N	51	11			
		Patients with Event n (%)	35 (68.6)	7 (63.6)			
		Censored n (%)	16 (31.4)	4 (36.4)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	17.68 (9.40 - 25.95)	11.14 (1.05 - n.a.)			
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	n.a.	1			
		Patients with Event n (%)	n.a. (n.a.)	1 (100.0)			
		Censored n (%)	n.a. (n.a.)	0 (0.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
Response to first line therapy							0.306
	Progression						
		Univariate Cox-Regression			0.67 (0.24 - 1.85)	0.532	
		N	20	4			
		Patients with Event n (%)	12 (60.0)	3 (75.0)			
		Censored n (%)	8 (40.0)	1 (25.0)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	11.47 (4.30 - n.a.)	14.69 (3.15 - n.a.)			
	Non-progression						
		Univariate Cox-Regression			1.11 (0.34 - 3.61)	0.828	
		N	30	8			
		Patients with Event n (%)	26 (86.7)	5 (62.5)			
		Censored n (%)	4 (13.3)	3 (37.5)			
		Median time to event with 95% CI[b]	14.65 (8.25 - 24.51)	11.10 (1.05 - n.a.)			
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	14	n.a.			
		Patients with Event n (%)	9 (64.3)	n.a. (n.a.)			
		Censored n (%)	5 (35.7)	n.a. (n.a.)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available; T: Size or direct extent of the primary tumor Only subgroup characteristics in which at least one subgroup category included at least 10 patients in both treatment arms were included in the analysis. Subgroup category "unknown": These values are only shown descriptively and are not included in statistical calculations. a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used. b: Median calculation using 50th quantile. c: Likelihood-Ratio-Test. The interaction test is based only on the valid subgroup categories (without "unknown").							

Figure 107: Comparison of overall survival for population Pop d vs. ACT and subgroup: Age category: < 65, Kaplan-Meier plot, Naive comparison



Figure 108: Comparison of overall survival for population Pop d vs. ACT and subgroup: Age category: ≥ 65, Kaplan-Meier plot, Naive comparison



Figure 109: Comparison of overall survival for population Pop d vs. ACT and subgroup: Gender: female, Kaplan-Meier plot, Naive comparison



Figure 110: Comparison of overall survival for population Pop d vs. ACT and subgroup: Gender: male, Kaplan-Meier plot, Naive comparison



Figure 111: Comparison of overall survival for population Pop d vs. ACT and subgroup: T-stage T4: Yes, Kaplan-Meier plot, Naive comparison



Figure 112: Comparison of overall survival for population Pop d vs. ACT and subgroup: T-stage T4: No, Kaplan-Meier plot, Naive comparison



Figure 113: Comparison of overall survival for population Pop d vs. ACT and subgroup: Lymph node metastases: Yes, Kaplan-Meier plot, Naive comparison



Figure 114: Comparison of overall survival for population Pop d vs. ACT and subgroup: Lymph node metastases: No, Kaplan-Meier plot, Naive comparison



Figure 115: Comparison of overall survival for population Pop d vs. ACT and subgroup: Brain metasases: Yes, Kaplan-Meier plot, Naive comparison



Figure 116: Comparison of overall survival for population Pop d vs. ACT and subgroup: Brain metasases: No, Kaplan-Meier plot, Naive comparison



Figure 117: Comparison of overall survival for population Pop d vs. ACT and subgroup: Liver metasases: Yes, Kaplan-Meier plot, Naive comparison



Figure 118: Comparison of overall survival for population Pop d vs. ACT and subgroup: Liver metasases: No, Kaplan-Meier plot, Naive comparison



Figure 119: Comparison of overall survival for population Pop d vs. ACT and subgroup: Response to first line: Progression, Kaplan-Meier plot, Naive comparison



Figure 120: Comparison of overall survival for population Pop d vs. ACT and subgroup: Response to first line: Non-progression, Kaplan-Meier plot, Naive comparison



2.2.2 Progression free survival

Table 57: Overview of interaction p-values of progression free survival by confounder categories for Pop d vs. ACT, Naive comparison

Soubgroup	**p-value interaction-test**[a]
Age category at start of therapy (years)	0.196
Gender	0.380
T-stage T4 at start of therapy	0.221
Lymph node me-tastases at start of therapy	0.595
Brain metastases at start of therapy	0.594
Liver metastases at start of therapy	0.257
Response to first line therapy	0.295
T: Size or direct extent of the primary tumor Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used. Only subgroup characteristics in which at least one subgroup category included at least 10 patients in both treatment arms were included in the analysis. a: Likelihood-Ratio-Test. The interaction test is based only on the valid subgroup categories (without "unknown").	

Table 58: Comparison of progression free survival by confounder categories for Pop d vs. ACT, Naive comparison

Soubgroup	**Category**	**Parameter**	**Capmatinib**[a]	**ACT**[a]	**HR (95% CI)**[a]	**p-value**[a]	**p-value interaction-test**[c]
Age category at start of therapy (years)							0.196
	<65						
		Univariate Cox-Regression			0.17 (0.03 - 0.86)	0.033	
		N	10	3			
		Patients with Event n (%)	10 (100.0)	3 (100.0)			
		Censored n (%)	0 (0.0)	0 (0.0)			
		Median time to event with 95% CI[b]	4.17 (0.89 - 6.60)	1.97 (1.48 - n.a.)			
	≥65						
		Univariate Cox-Regression			0.94 (0.41 - 2.16)	0.874	
		N	54	9			
		Patients with Event n (%)	44 (81.5)	7 (77.8)			
		Censored n (%)	10 (18.5)	2 (22.2)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	5.39 (4.17 - 8.18)	6.24 (0.07 - 9.23)			
Gender							0.380
	Female						
		Univariate Cox-Regression			0.57 (0.27 - 1.19)	0.289	
		N	35	4			
		Patients with Event n (%)	32 (91.4)	4 (100.0)			
		Censored n (%)	3 (8.6)	0 (0.0)			
		Median time to event with 95% CI[b]	4.21 (4.07 - 6.97)	4.47 (1.48 - n.a.)			
	Male						
		Univariate Cox-Regression			0.80 (0.30 - 2.12)	0.631	
		N	29	8			
		Patients with Event n (%)	22 (75.9)	6 (75.0)			
		Censored n (%)	7 (24.1)	2 (25.0)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	5.59 (3.98 - 8.74)	3.15 (0.07 - 9.23)			
T-stage T4 at start of therapy							0.221
	Yes						
		Univariate Cox-Regression			1.84 (0.35 - 9.79)	0.429	
		N	12	3			
		Patients with Event n (%)	10 (83.3)	2 (66.7)			
		Censored n (%)	2 (16.7)	1 (33.3)			
		Median time to event with 95% CI[b]	4.14 (0.89 - 5.39)	3.98 (3.15 - n.a.)			
	No						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	15	1			
		Patients with Event n (%)	14 (93.3)	0 (0.0)			
		Censored n (%)	1 (6.7)	1 (100.0)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	5.55 (1.84 - 8.11)	n.a. (n.a. - n.a.)			
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	37	8			
		Patients with Event n (%)	30 (81.1)	8 (100.0)			
		Censored n (%)	7 (18.9)	0 (0.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
Lymph node metastases at start of therapy							0.595
	Yes						
		Univariate Cox-Regression			2.65 (0.25 - 28.61)	0.318	
		N	41	3			
		Patients with Event n (%)	33 (80.5)	1 (33.3)			
		Censored n (%)	8 (19.5)	2 (66.7)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	4.21 (4.14 - 10.38)	n.a. (n.a. - n.a.)			
	No						
		Univariate Cox-Regression			0.31 (0.14 - 0.68)	0.247	
		N	23	1			
		Patients with Event n (%)	21 (91.3)	1 (100.0)			
		Censored n (%)	2 (8.7)	0 (0.0)			
		Median time to event with 95% CI[b]	5.42 (3.98 - 8.11)	3.98 (n.a. - n.a.)			
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	n.a.	8			
		Patients with Event n (%)	n.a. (n.a.)	8 (100.0)			
		Censored n (%)	n.a. (n.a.)	0 (0.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
Brain metastases at start of therapy							0.594
	Yes						
		Univariate Cox-Regression			0.09 (0.01 - 0.60)	0.029	
		N	12	1			
		Patients with Event n (%)	11 (91.7)	1 (100.0)			
		Censored n (%)	1 (8.3)	0 (0.0)			
		Median time to event with 95% CI[b]	4.42 (2.60 - 10.38)	1.48 (n.a. - n.a.)			
	No						
		Univariate Cox-Regression			0.80 (0.36 - 1.77)	0.537	
		N	52	11			
		Patients with Event n (%)	43 (82.7)	9 (81.8)			
		Censored n (%)	9 (17.3)	2 (18.2)			
		Median time to event with 95% CI[b]	5.39 (4.14 - 8.18)	4.96 (1.97 - 8.15)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
Liver metastases at start of therapy							0.257
	Yes						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	13	n.a.			
		Patients with Event n (%)	12 (92.3)	n.a. (n.a.)			
		Censored n (%)	1 (7.7)	n.a. (n.a.)			
		Median time to event with 95% CI[b]	6.97 (0.89 - 10.38)	n.a. (n.a. - n.a.)			
	No						
		Univariate Cox-Regression			0.78 (0.35 - 1.71)	0.486	
		N	51	11			
		Patients with Event n (%)	42 (82.4)	9 (81.8)			
		Censored n (%)	9 (17.7)	2 (18.2)			
		Median time to event with 95% CI[b]	4.67 (4.17 - 6.60)	4.96 (1.97 - 8.15)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	n.a.	1			
		Patients with Event n (%)	n.a. (n.a.)	1 (100.0)			
		Censored n (%)	n.a. (n.a.)	0 (0.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
Response to first line therapy							0.295
	Progression						
		Univariate Cox-Regression			0.46 (0.20 - 1.08)	0.175	
		N	20	4			
		Patients with Event n (%)	15 (75.0)	4 (100.0)			
		Censored n (%)	5 (25.0)	0 (0.0)			
		Median time to event with 95% CI[b]	4.21 (2.76 - 12.48)	3.56 (2.07 - n.a.)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
	Non-progression						
		Univariate Cox-Regression			1.08 (0.40 - 2.94)	0.863	
		N	30	8			
		Patients with Event n (%)	26 (86.7)	6 (75.0)			
		Censored n (%)	4 (13.3)	2 (25.0)			
		Median time to event with 95% CI[b]	4.67 (2.76 - 8.11)	4.96 (0.07 - 9.23)			
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	14	n.a.			
		Patients with Event n (%)	13 (92.9)	n.a. (n.a.)			
		Censored n (%)	1 (7.1)	n.a. (n.a.)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			

CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available; T: Size or direct extent of the primary tumor

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
Only subgroup characteristics in which at least one subgroup category included at least 10 patients in both treatment arms were included in the analysis. Subgroup category "unknown": These values are only shown descriptively and are not included in statistical calculations. a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used. b: Median calculation using 50th quantile. c: Likelihood-Ratio-Test. The interaction test is based only on the valid subgroup categories (without "unknown").							

Figure 121: Comparison of progression free survival for population Pop d vs. ACT and subgroup: Age category: < 65, Kaplan-Meier plot, Naive comparison



Figure 122: Comparison of progression free survival for population Pop d vs. ACT and subgroup: Age category: ≥ 65, Kaplan-Meier plot, Naive comparison



Figure 123: Comparison of progression free survival for population Pop d vs. ACT and subgroup: Gender: female, Kaplan-Meier plot, Naive comparison



Figure 124: Comparison of progression free survival for population Pop d vs. ACT and subgroup: Gender: male, Kaplan-Meier plot, Naive comparison



Figure 125: Comparison of progression free survival for population Pop d vs. ACT and subgroup: T-stage T4: Yes, Kaplan-Meier plot, Naive comparison



Figure 126: Comparison of progression free survival for population Pop d vs. ACT and subgroup: T-stage T4: No, Kaplan-Meier plot, Naive comparison



Figure 127: Comparison of progression free survival for population Pop d vs. ACT and subgroup: Lymph node metastases: Yes, Kaplan-Meier plot, Naive comparison



Figure 128: Comparison of progression free survival for population Pop d vs. ACT and subgroup: Lymph node metastases: No, Kaplan-Meier plot, Naive comparison



Figure 129: Comparison of progression free survival for population Pop d vs. ACT and subgroup: Brain metasases: Yes, Kaplan-Meier plot, Naive comparison



Figure 130: Comparison of progression free survival for population Pop d vs. ACT and subgroup: Brain metasases: No, Kaplan-Meier plot, Naive comparison



Figure 131: Comparison of progression free survival for population Pop d vs. ACT and subgroup: Liver metasases: Yes, Kaplan-Meier plot, Naive comparison



Figure 132: Comparison of progression free survival for population Pop d vs. ACT and subgroup: Liver metasases: No, Kaplan-Meier plot, Naive comparison



Figure 133: Comparison of progression free survival for population Pop d vs. ACT and subgroup: Response to first line: Progression, Kaplan-Meier plot, Naive comparison



Figure 134: Comparison of progression free survival for population Pop d vs. ACT and subgroup: Response to first line: Non-progression, Kaplan-Meier plot, Naive comparison



2.2.3 Overall response rate

Table 59: Overview of interaction p-values of overall response rate by confounder categories for Pop d vs. ACT, Naive comparison

Subgroup	OR; p-value interaction test[a]	RR; p-value interaction test[a]	ARR; p-value interaction test[a]
Age category at start of therapy	0.667	0.667	0.667
Gender	0.825	0.825	0.825
Lymph node metastases at start of therapy	0.140	0.140	0.140
Brain metastases at start of therapy	0.649	0.649	0.649
Liver metastases at start of therapy	0.832	0.832	0.832
Response to first line therapy	0.903	0.903	0.903

ARR: Absolute risk reduction; OR: Odds ratio; RR: Relative Risk

Only subgroup characteristics with more than 10 patients per subgroup category and at least 10 events in at least 1 subgroup category were considered in the analysis.

a: Likelihood-Ratio-Test. The interaction test is based only on the valid subgroup categories (without "unknown").

Table 60: Comparison of overall response rate by confounder categories for Pop d vs. ACT, Naive comparison

Subgroup	Category	Capmatinib	ACT	Capmatinib - Overall response rate n (%)	ACT - Overall response rate n (%)	OR (95% CI); p-value[a]	OR; p-value interaction test	RR (95% CI); p-value[b]	RR; p-value interaction test	ARR (95% CI); p-value[c]	ARR; p-value interaction test
Age category at start of therapy							0.667		0.667		0.667
	<65	10	3	3 (30.0)	3 (100.0)	<0.005 (n.a.-n.a.); n.a.		0.33 (n.a.-n.a.); n.a.		n.a. (n.a.-n.a.); n.a.	
	≥65	54	9	20 (37.0)	2 (22.2)	2.06 (0.39-10.89); 0.396		1.67 (0.47-5.94); 0.431		0.15 (-0.15-0.45); 0.334	
Gender							0.825		0.825		0.825
	Female	35	4	13 (37.1)	2 (50.0)	0.59 (0.07-4.71); 0.620		0.74 (0.25-2.17); 0.586		-0.13 (-0.64-0.39); 0.625	
	Male	29	8	10 (34.5)	3 (37.5)	0.88 (0.17-4.45); 0.874		0.92 (0.33-2.56); 0.873		-0.03 (-0.41-0.35); 0.876	
Lymph node metastases at start of therapy							0.140		0.140		0.140

Subgroup	Category	Capmatinib	ACT	Capmatinib - Overall response rate n (%)	ACT - Overall response rate n (%)	OR (95% CI); p-value[a]	OR; p-value interaction test	RR (95% CI); p-value[b]	RR; p-value interaction test	ARR (95% CI); p-value[c]	ARR; p-value interaction test
	Yes	41	3	12 (29.3)	0 (0.0)	42934000000.00 (n.a.-n.a.); n.a.		27917000000.00 (n.a.-n.a.); n.a.		n.a. (n.a.-n.a.); n.a.	
	No	23	1	11 (47.8)	1 (100.0)	<0.005 (n.a.-n.a.); n.a.		0.49 (n.a.-n.a.); n.a.		-0.52 (n.a.-n.a.); n.a.	
	Unknown	n.a.	8	n.a. (n.a.)	4 (50.0)	n.a. (n.a.-n.a.); n.a.		n.a. (n.a.-n.a.); n.a.		n.a. (n.a.-n.a.); n.a.	
Brain metastases at start of therapy							0.649		0.649		0.649
	Yes	12	1	5 (41.7)	1 (100.0)	<0.005 (n.a.-n.a.); n.a.		0.43 (n.a.-n.a.); n.a.		n.a. (n.a.-n.a.); n.a.	
	No	52	11	18 (34.6)	4 (36.4)	0.93 (0.24-3.59); 0.912		0.95 (0.40-2.26); 0.911		-0.02 (-0.33-0.29); 0.913	
Liver metastases at start of therapy							0.832		0.832		0.832

Subgroup	Category	Capmatinib	ACT	Capmatinib - Overall response rate n (%)	ACT - Overall response rate n (%)	OR (95% CI); p-value[a]	OR; p-value interaction test	RR (95% CI); p-value[b]	RR; p-value interaction test	ARR (95% CI); p-value[c]	ARR; p-value interaction test
	Yes	13	n.a.	5 (38.5)	n.a. (n.a.)	n.a. (n.a.-n.a.); n.a.		n.a. (n.a.-n.a.); n.a.		n.a. (n.a.-n.a.); n.a.	
	No	51	11	18 (35.3)	4 (36.4)	0.95 (0.25-3.70); 0.946		0.97 (0.41-2.31); 0.946		-0.01 (-0.32-0.30); 0.947	
	Unknown	n.a.	1	n.a. (n.a.)	1 (100.0)	n.a. (n.a.-n.a.); n.a.		n.a. (n.a.-n.a.); n.a.		n.a. (n.a.-n.a.); n.a.	
Response to first line therapy							0.903		0.903		0.903
	Progression	20	4	7 (35.0)	2 (50.0)	0.54 (0.06-4.69); 0.575		0.70 (0.22-2.21); 0.542		-0.15 (-0.68-0.38); 0.581	
	Non-progression	30	8	10 (33.3)	3 (37.5)	0.83 (0.16-4.21); 0.825		0.89 (0.32-2.48); 0.822		-0.04 (-0.42-0.33); 0.828	
	Unknown	14	n.a.	6 (42.9)	n.a. (n.a.)	n.a. (n.a.-n.a.); n.a.		n.a. (n.a.-n.a.); n.a.		n.a. (n.a.-n.a.); n.a.	

ACT: Appropriate comparative therapy; ARR: Absolute risk reduction; CI: Confidence interval; n: Number of patients with event; n.a.: Not available; OR: Odds ratio; RR: Relative Risk

Only subgroup characteristics with more than 10 patients per subgroup category and at least 10 events in at least 1 subgroup category were considered in the analysis.

Subgroup category "unknown": These values are only shown descriptively and are not included in statistical calculations.

Subgroup	Category	Capmatinib	ACT	Capmatinib - Overall response rate n (%)	ACT - Overall response rate n (%)	OR (95% CI); p-value[a]	OR; p-value interaction test	RR (95% CI); p-value[b]	RR; p-value interaction test	ARR (95% CI); p-value[c]	ARR; p-value interaction test
a: Binomial regression model (treatment arm as fixed effect) with logit-link function											
b: Binomial regression model (treatment arm as fixed effect) with log-link function											
c: GLM (treatment arm as fixed effect) with identity link function											
d: Likelihood-Ratio-Test. The interaction test is based only on the valid subgroup categories (without "unknown").											

2.2.4 Time to treatment discontinuation due to adverse events

Table 61: Overview of interaction p-values of time to treatment discontinuation due to adverse events by confounder categories for Pop d vs. ACT, Naive comparison

Soubgroup	**p-value interaction-test**[a]
Age category at start of therapy (years)	0.993
Gender	0.945
T-stage T4 at start of therapy	0.609
Lymph node me-tastases at start of therapy	0.258
Brain metastases at start of therapy	0.995
Liver metastases at start of therapy	0.658
Response to first line therapy	0.557

T: Size or direct extent of the primary tumor

Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Only subgroup characteristics in which at least one subgroup category included at least 10 patients in both treatment arms were included in the analysis.

a: Likelihood-Ratio-Test. The interaction test is based only on the valid subgroup categories (without "unknown").

Table 62: Comparison of time to treatment discontinuation due to adverse events by confounder categories for Pop d vs. ACT, Naive comparison

Soubgroup	**Category**	**Parameter**	**Capmatinib**[a]	**ACT**[a]	**HR (95% CI)**[a]	**p-value**[a]	**p-value interaction-test**[c]
Age category at start of therapy (years)							0.993
	<65						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	10	3			
		Patients with Event n (%)	0 (0.0)	0 (0.0)			
		Censored n (%)	10 (100.0)	3 (100.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
	≥65						
		Univariate Cox-Regression			1.10 (0.13 - 9.31)	0.926	
		N	54	9			
		Patients with Event n (%)	9 (16.7)	1 (11.1)			
		Censored n (%)	45 (83.3)	8 (88.9)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
Gender							0.945
	Female						
		Univariate Cox-Regression			0.30 (0.03 - 3.07)	0.271	
		N	35	4			
		Patients with Event n (%)	5 (14.3)	1 (25.0)			
		Censored n (%)	30 (85.7)	3 (75.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
	Male						
		Univariate Cox-Regression			12813589.00 (3719795.50 - 44139001.00)	0.314	
		N	29	8			
		Patients with Event n (%)	4 (13.8)	0 (0.0)			
		Censored n (%)	25 (86.2)	8 (100.0)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
T-stage T4 at start of therapy							0.609
	Yes						
		Univariate Cox-Regression			42006034.00 (7542277.40 - 233948823.00)	0.370	
		N	12	3			
		Patients with Event n (%)	2 (16.7)	0 (0.0)			
		Censored n (%)	10 (83.3)	3 (100.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
	No						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	15	1			
		Patients with Event n (%)	2 (13.3)	0 (0.0)			
		Censored n (%)	13 (86.7)	1 (100.0)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	37	8			
		Patients with Event n (%)	5 (13.5)	1 (12.5)			
		Censored n (%)	32 (86.5)	7 (87.5)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
Lymph node metastases at start of therapy							0.258
	Yes						
		Univariate Cox-Regression			3711185.60 (601517.87 - 22896906.00)	0.485	
		N	41	3			
		Patients with Event n (%)	7 (17.1)	0 (0.0)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Censored n (%)	34 (82.9)	3 (100.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
	No						
		Univariate Cox-Regression			3508995.10 (323824.83 - 38023788.00)	0.763	
		N	23	1			
		Patients with Event n (%)	2 (8.7)	0 (0.0)			
		Censored n (%)	21 (91.3)	1 (100.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	n.a.	8			
		Patients with Event n (%)	n.a. (n.a.)	1 (12.5)			
		Censored n (%)	n.a. (n.a.)	7 (87.5)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
Brain metastases at start of therapy							0.995
	Yes						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	12	1			
		Patients with Event n (%)	0 (0.0)	0 (0.0)			
		Censored n (%)	12 (100.0)	1 (100.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
	No						
		Univariate Cox-Regression			1.62 (0.19 - 13.65)	0.644	
		N	52	11			
		Patients with Event n (%)	9 (17.3)	1 (9.1)			
		Censored n (%)	43 (82.7)	10 (90.9)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
Liver metastases at start of therapy							0.658
	Yes						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	13	n.a.			
		Patients with Event n (%)	1 (7.7)	n.a. (n.a.)			
		Censored n (%)	12 (92.3)	n.a. (n.a.)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
	No						
		Univariate Cox-Regression			1.40 (0.17 - 11.73)	0.751	
		N	51	11			
		Patients with Event n (%)	8 (15.7)	1 (9.1)			
		Censored n (%)	43 (84.3)	10 (90.9)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	n.a.	1			
		Patients with Event n (%)	n.a. (n.a.)	0 (0.0)			
		Censored n (%)	n.a. (n.a.)	1 (100.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
Response to first line therapy							0.557
	Progression						
		Univariate Cox-Regression			0.17 (0.01 - 2.29)	0.162	
		N	20	4			
		Patients with Event n (%)	1 (5.0)	1 (25.0)			
		Censored n (%)	19 (95.0)	3 (75.0)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
	Non-progression						
		Univariate Cox-Regression			12642011.00 (3218558.20 - 49655915.00)	0.392	
		N	30	8			
		Patients with Event n (%)	3 (10.0)	0 (0.0)			
		Censored n (%)	27 (90.0)	8 (100.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	14	n.a.			
		Patients with Event n (%)	5 (35.7)	n.a. (n.a.)			
		Censored n (%)	9 (64.3)	n.a. (n.a.)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			

CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available; T: Size or direct extent of the primary tumor

Only subgroup characteristics in which at least one subgroup category included at least 10 patients in both treatment arms were included in the analysis.

Subgroup category "unknown": These values are only shown descriptively and are not included in statistical calculations.

a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

b: Median calculation using 50th quantile.

c: Likelihood-Ratio-Test. The interaction test is based only on the valid subgroup categories (without "unknown").

Figure 135: Comparison of time to treatment discontinuation due to adverse events for population Pop d vs. ACT and subgroup: Age category: < 65, Kaplan-Meier plot, Naive comparison



Figure 136: Comparison of time to treatment discontinuation due to adverse events for population Pop d vs. ACT and subgroup: Age category: ≥ 65, Kaplan-Meier plot, Naive comparison



Figure 137: Comparison of time to treatment discontinuation due to adverse events for population Pop d vs. ACT and subgroup: Gender: female, Kaplan-Meier plot, Naive comparison



Figure 138: Comparison of time to treatment discontinuation due to adverse events for population Pop d vs. ACT and subgroup: Gender: male, Kaplan-Meier plot, Naive comparison



Figure 139: Comparison of time to treatment discontinuation due to adverse events for population Pop d vs. ACT and subgroup: T-stage T4: Yes, Kaplan-Meier plot, Naive comparison



Figure 140: Comparison of time to treatment discontinuation due to adverse events for population Pop d vs. ACT and subgroup: T-stage T4: No, Kaplan-Meier plot, Naive comparison



Figure 141: Comparison of time to treatment discontinuation due to adverse events for population Pop d vs. ACT and subgroup: Lymph node metastases: Yes, Kaplan-Meier plot, Naive comparison



Figure 142: Comparison of time to treatment discontinuation due to adverse events for population Pop d vs. ACT and subgroup: Lymph node metastases: No, Kaplan-Meier plot, Naive comparison



Figure 143: Comparison of time to treatment discontinuation due to adverse events for population Pop d vs. ACT and subgroup: Brain metasases: Yes, Kaplan-Meier plot, Naive comparison



Figure 144: Comparison of time to treatment discontinuation due to adverse events for population Pop d vs. ACT and subgroup: Brain metasases: No, Kaplan-Meier plot, Naive comparison



Figure 145: Comparison of time to treatment discontinuation due to adverse events for population Pop d vs. ACT and subgroup: Liver metasases: Yes, Kaplan-Meier plot, Naive comparison



Figure 146: Comparison of time to treatment discontinuation due to adverse events for population Pop d vs. ACT and subgroup: Liver metasases: No, Kaplan-Meier plot, Naive comparison



Figure 147: Comparison of time to treatment discontinuation due to adverse events for population Pop d vs. ACT and subgroup: Response to first line: Progression, Kaplan-Meier plot, Naive comparison



Figure 148: Comparison of time to treatment discontinuation due to adverse events for population Pop d vs. ACT and subgroup: Response to first line: Non-progression, Kaplan-Meier plot, Naive comparison



2.2.5 Time to unplanned or prolonged hospitalizations

Table 63: Overview of interaction p-values of time to unplanned or prolonged hospitalizations by confounder categories for Pop d vs. ACT, Naive comparison

Soubgroup	**p-value interaction-test**[a]
Age category at start of therapy (years)	0.406
Gender	0.765
T-stage T4 at start of therapy	0.938
Lymph node me-tastases at start of therapy	0.703
Brain metastases at start of therapy	0.229
Liver metastases at start of therapy	0.206
Response to first line therapy	0.793
T: Size or direct extent of the primary tumor Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used. Only subgroup characteristics in which at least one subgroup category included at least 10 patients in both treatment arms were included in the analysis. a: Likelihood-Ratio-Test. The interaction test is based only on the valid subgroup categories (without "unknown").	

Table 64: Comparison of time to unplanned or prolonged hospitalizations by confounder categories for Pop d vs. ACT, Naive comparison

Soubgroup	**Category**	**Parameter**	**Capmatinib**[a]	**ACT**[a]	**HR (95% CI)**[a]	**p-value**[a]	**p-value interaction-test**[c]
Age category at start of therapy (years)							0.406
	<65						
		Univariate Cox-Regression			1.60 (0.24 - 10.66)	0.662	
		N	10	3			
		Patients with Event n (%)	5 (50.0)	1 (33.3)			
		Censored n (%)	5 (50.0)	2 (66.7)			
		Median time to event with 95% CI[b]	5.91 (0.99 - n.a.)	n.a. (n.a. - n.a.)			
	≥65						
		Univariate Cox-Regression			0.73 (0.27 - 1.99)	0.565	
		N	54	9			
		Patients with Event n (%)	21 (38.9)	4 (44.4)			
		Censored n (%)	33 (61.1)	5 (55.6)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	9.36 (0.07 - n.a.)			
Gender							0.765
	Female						
		Univariate Cox-Regression			0.78 (0.24 - 2.57)	0.742	
		N	35	4			
		Patients with Event n (%)	15 (42.9)	2 (50.0)			
		Censored n (%)	20 (57.1)	2 (50.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	7.26 (4.21 - n.a.)			
	Male						
		Univariate Cox-Regression			0.95 (0.28 - 3.25)	0.933	
		N	29	8			
		Patients with Event n (%)	11 (37.9)	3 (37.5)			
		Censored n (%)	18 (62.1)	5 (62.5)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	9.36 (0.07 - n.a.)			
T-stage T4 at start of therapy							0.938
	Yes						
		Univariate Cox-Regression			1.19 (0.20 - 7.04)	0.877	
		N	12	3			
		Patients with Event n (%)	4 (33.3)	1 (33.3)			
		Censored n (%)	8 (66.7)	2 (66.7)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
	No						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	15	1			
		Patients with Event n (%)	7 (46.7)	0 (0.0)			
		Censored n (%)	8 (53.3)	1 (100.0)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	37	8			
		Patients with Event n (%)	15 (40.5)	4 (50.0)			
		Censored n (%)	22 (59.5)	4 (50.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
Lymph node metastases at start of therapy							0.703
	Yes						
		Univariate Cox-Regression			3596555.50 (850848.93 - 15202713.00)	0.340	
		N	41	3			
		Patients with Event n (%)	15 (36.6)	0 (0.0)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Censored n (%)	26 (63.4)	3 (100.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
	No						
		Univariate Cox-Regression			0.25 (0.10 - 0.58)	0.165	
		N	23	1			
		Patients with Event n (%)	11 (47.8)	1 (100.0)			
		Censored n (%)	12 (52.2)	0 (0.0)			
		Median time to event with 95% CI[b]	29.47 (7.46 - n.a.)	4.21 (n.a. - n.a.)			
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	n.a.	8			
		Patients with Event n (%)	n.a. (n.a.)	4 (50.0)			
		Censored n (%)	n.a. (n.a.)	4 (50.0)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
Brain metastases at start of therapy							0.229
	Yes						
		Univariate Cox-Regression			3734928.00 (350574.42 - 39790944.00)	0.676	
		N	12	1			
		Patients with Event n (%)	3 (25.0)	0 (0.0)			
		Censored n (%)	9 (75.0)	1 (100.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
	No						
		Univariate Cox-Regression			0.95 (0.38 - 2.36)	0.915	
		N	52	11			
		Patients with Event n (%)	23 (44.2)	5 (45.5)			
		Censored n (%)	29 (55.8)	6 (54.6)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	29.47 (6.14 - n.a.)	9.36 (2.60 - n.a.)			
Liver metastases at start of therapy							0.206
	Yes						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	13	n.a.			
		Patients with Event n (%)	7 (53.9)	n.a. (n.a.)			
		Censored n (%)	6 (46.2)	n.a. (n.a.)			
		Median time to event with 95% CI[b]	7.52 (1.84 - n.a.)	n.a. (n.a. - n.a.)			
	No						
		Univariate Cox-Regression			0.74 (0.29 - 1.88)	0.546	
		N	51	11			
		Patients with Event n (%)	19 (37.3)	5 (45.5)			
		Censored n (%)	32 (62.8)	6 (54.6)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	9.36 (2.60 - n.a.)			
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	n.a.	1			
		Patients with Event n (%)	n.a. (n.a.)	0 (0.0)			
		Censored n (%)	n.a. (n.a.)	1 (100.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
Response to first line therapy							0.793
	Progression						
		Univariate Cox-Regression			0.41 (0.15 - 1.11)	0.200	
		N	20	4			
		Patients with Event n (%)	6 (30.0)	3 (75.0)			
		Censored n (%)	14 (70.0)	1 (25.0)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	4.21 (2.60 - n.a.)			
	Non-progression						
		Univariate Cox-Regression			1.35 (0.31 - 5.88)	0.690	
		N	30	8			
		Patients with Event n (%)	11 (36.7)	2 (25.0)			
		Censored n (%)	19 (63.3)	6 (75.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	14	n.a.			
		Patients with Event n (%)	9 (64.3)	n.a. (n.a.)			
		Censored n (%)	5 (35.7)	n.a. (n.a.)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available; T: Size or direct extent of the primary tumor Only subgroup characteristics in which at least one subgroup category included at least 10 patients in both treatment arms were included in the analysis. Subgroup category "unknown": These values are only shown descriptively and are not included in statistical calculations. a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used. b: Median calculation using 50th quantile. c: Likelihood-Ratio-Test. The interaction test is based only on the valid subgroup categories (without "unknown").							

Figure 149: Comparison of time to unplanned or prolonged hospitalizations for population Pop d vs. ACT and subgroup: Age category: < 65, Kaplan-Meier plot, Naive comparison



Figure 150: Comparison of time to unplanned or prolonged hospitalizations for population Pop d vs. ACT and subgroup: Age category: ≥ 65, Kaplan-Meier plot, Naive comparison



Figure 151: Comparison of time to unplanned or prolonged hospitalizations for population Pop d vs. ACT and subgroup: Gender: female, Kaplan-Meier plot, Naive comparison



Figure 152: Comparison of time to unplanned or prolonged hospitalizations for population Pop d vs. ACT and subgroup: Gender: male, Kaplan-Meier plot, Naive comparison



Figure 153: Comparison of time to unplanned or prolonged hospitalizations for population Pop d vs. ACT and subgroup: T-stage T4: Yes, Kaplan-Meier plot, Naive comparison



Figure 154: Comparison of time to unplanned or prolonged hospitalizations for population Pop d vs. ACT and subgroup: T-stage T4: No, Kaplan-Meier plot, Naive comparison



Figure 155: Comparison of time to unplanned or prolonged hospitalizations for population Pop d vs. ACT and subgroup: Lymph node metastases: Yes, Kaplan-Meier plot, Naive comparison



Figure 156: Comparison of time to unplanned or prolonged hospitalizations for population Pop d vs. ACT and subgroup: Lymph node metastases: No, Kaplan-Meier plot, Naive comparison



Figure 157: Comparison of time to unplanned or prolonged hospitalizations for population Pop d vs. ACT and subgroup: Brain metasases: Yes, Kaplan-Meier plot, Naive comparison



Figure 158: Comparison of time to unplanned or prolonged hospitalizations for population Pop d vs. ACT and subgroup: Brain metasases: No, Kaplan-Meier plot, Naive comparison



Figure 159: Comparison of time to unplanned or prolonged hospitalizations for population Pop d vs. ACT and subgroup: Liver metasases: Yes, Kaplan-Meier plot, Naive comparison



Figure 160: Comparison of time to unplanned or prolonged hospitalizations for population Pop d vs. ACT and subgroup: Liver metasases: No, Kaplan-Meier plot, Naive comparison



Figure 161: Comparison of time to unplanned or prolonged hospitalizations for population Pop d vs. ACT and subgroup: Response to first line: Progression, Kaplan-Meier plot, Naive comparison



Figure 162: Comparison of time to unplanned or prolonged hospitalizations for population Pop d vs. ACT and subgroup: Response to first line: Non-progression, Kaplan-Meier plot, Naive comparison



2.2.6 Time to unplanned or prolonged hospitalizations or death

Table 65: Overview of interaction p-values of time to unplanned or prolonged hospitalizations or death by confounder categories for Pop d vs. ACT, Naive comparison

Soubgroup	**p-value interaction-test**[a]
Age category at start of therapy (years)	0.046
Gender	0.272
T-stage T4 at start of therapy	0.945
Lymph node me-tastases at start of therapy	0.968
Brain metastases at start of therapy	0.795
Liver metastases at start of therapy	0.114
Response to first line therapy	0.400

T: Size or direct extent of the primary tumor

Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used.

Only subgroup characteristics in which at least one subgroup category included at least 10 patients in both treatment arms were included in the analysis.

a: Likelihood-Ratio-Test. The interaction test is based only on the valid subgroup categories (without "unknown").

Table 66: Comparison of time to unplanned or prolonged hospitalizations or death by confounder categories for Pop d vs. ACT, Naive comparison

Soubgroup	**Category**	**Parameter**	**Capmatinib**[a]	**ACT**[a]	**HR (95% CI)**[a]	**p-value**[a]	**p-value interaction-test**[c]
Age category at start of therapy (years)							0.046
	<65						
		Univariate Cox-Regression			1.87 (0.35 - 9.88)	0.417	
		N	10	3			
		Patients with Event n (%)	10 (100.0)	2 (66.7)			
		Censored n (%)	0 (0.0)	1 (33.3)			
		Median time to event with 95% CI[b]	5.91 (0.89 - 14.75)	5.52 (2.60 - n.a.)			
	≥65						
		Univariate Cox-Regression			0.65 (0.28 - 1.54)	0.301	
		N	54	9			
		Patients with Event n (%)	41 (75.9)	7 (77.8)			
		Censored n (%)	13 (24.1)	2 (22.2)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	11.63 (7.46 - 21.19)	8.15 (0.07 - 11.17)			
Gender							0.272
	Female						
		Univariate Cox-Regression			0.47 (0.26 - 0.88)	0.170	
		N	35	4			
		Patients with Event n (%)	31 (88.6)	4 (100.0)			
		Censored n (%)	4 (11.4)	0 (0.0)			
		Median time to event with 95% CI[b]	9.40 (6.21 - 14.75)	6.39 (4.21 - n.a.)			
	Male						
		Univariate Cox-Regression			0.92 (0.34 - 2.54)	0.874	
		N	29	8			
		Patients with Event n (%)	20 (69.0)	5 (62.5)			
		Censored n (%)	9 (31.0)	3 (37.5)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	8.74 (5.91 - 21.19)	8.15 (0.07 - n.a.)			
T-stage T4 at start of therapy							0.945
	Yes						
		Univariate Cox-Regression			1.27 (0.27 - 5.95)	0.763	
		N	12	3			
		Patients with Event n (%)	8 (66.7)	2 (66.7)			
		Censored n (%)	4 (33.3)	1 (33.3)			
		Median time to event with 95% CI[b]	14.65 (0.79 - 29.50)	4.21 (3.15 - n.a.)			
	No						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	15	1			
		Patients with Event n (%)	14 (93.3)	0 (0.0)			
		Censored n (%)	1 (6.7)	1 (100.0)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	12.91 (1.84 - 21.19)	n.a. (n.a. - n.a.)			
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	37	8			
		Patients with Event n (%)	29 (78.4)	7 (87.5)			
		Censored n (%)	8 (21.6)	1 (12.5)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
Lymph node metastases at start of therapy							0.968
	Yes						
		Univariate Cox-Regression			1.94 (0.21 - 17.77)	0.509	
		N	41	3			
		Patients with Event n (%)	31 (75.6)	1 (33.3)			
		Censored n (%)	10 (24.4)	2 (66.7)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
		Median time to event with 95% CI[b]	9.40 (4.30 - 16.79)	n.a. (n.a. - n.a.)			
	No						
		Univariate Cox-Regression			0.25 (0.10 - 0.58)	0.165	
		N	23	1			
		Patients with Event n (%)	20 (87.0)	1 (100.0)			
		Censored n (%)	3 (13.0)	0 (0.0)			
		Median time to event with 95% CI[b]	8.61 (6.64 - 24.51)	4.21 (n.a. - n.a.)			
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	n.a.	8			
		Patients with Event n (%)	n.a. (n.a.)	7 (87.5)			
		Censored n (%)	n.a. (n.a.)	1 (12.5)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
Brain metastases at start of therapy							0.795
	Yes						
		Univariate Cox-Regression			0.18 (0.05 - 0.71)	0.119	
		N	12	1			
		Patients with Event n (%)	11 (91.7)	1 (100.0)			
		Censored n (%)	1 (8.3)	0 (0.0)			
		Median time to event with 95% CI[b]	11.93 (1.84 - 17.68)	5.52 (n.a. - n.a.)			
	No						
		Univariate Cox-Regression			0.90 (0.41 - 1.98)	0.776	
		N	52	11			
		Patients with Event n (%)	40 (76.9)	8 (72.7)			
		Censored n (%)	12 (23.1)	3 (27.3)			
		Median time to event with 95% CI[b]	8.74 (5.91 - 21.19)	8.15 (2.60 - 11.17)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
Liver metastases at start of therapy							0.114
	Yes						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	13	n.a.			
		Patients with Event n (%)	12 (92.3)	n.a. (n.a.)			
		Censored n (%)	1 (7.7)	n.a. (n.a.)			
		Median time to event with 95% CI[b]	7.52 (0.89 - 24.28)	n.a. (n.a. - n.a.)			
	No						
		Univariate Cox-Regression			0.80 (0.35 - 1.83)	0.563	
		N	51	11			
		Patients with Event n (%)	39 (76.5)	8 (72.7)			
		Censored n (%)	12 (23.5)	3 (27.3)			
		Median time to event with 95% CI[b]	9.40 (6.64 - 17.68)	8.15 (2.60 - 11.17)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	n.a.	1			
		Patients with Event n (%)	n.a. (n.a.)	1 (100.0)			
		Censored n (%)	n.a. (n.a.)	0 (0.0)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			
Response to first line therapy							0.400
	Progression						
		Univariate Cox-Regression			0.41 (0.19 - 0.93)	0.137	
		N	20	4			
		Patients with Event n (%)	13 (65.0)	4 (100.0)			
		Censored n (%)	7 (35.0)	0 (0.0)			
		Median time to event with 95% CI[b]	8.61 (1.84 - 28.78)	3.68 (2.60 - n.a.)			

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
	Non-progression						
		Univariate Cox-Regression			1.36 (0.45 - 4.15)	0.528	
		N	30	8			
		Patients with Event n (%)	26 (86.7)	5 (62.5)			
		Censored n (%)	4 (13.3)	3 (37.5)			
		Median time to event with 95% CI[b]	11.63 (6.21 - 17.68)	9.36 (0.07 - n.a.)			
	Unknown						
		Univariate Cox-Regression			n.a. (n.a. - n.a.)	n.a.	
		N	14	n.a.			
		Patients with Event n (%)	12 (85.7)	n.a. (n.a.)			
		Censored n (%)	2 (14.3)	n.a. (n.a.)			
		Median time to event with 95% CI[b]	n.a. (n.a. - n.a.)	n.a. (n.a. - n.a.)			

CI: Confidence interval; HR: Hazard ratio; n: Number of patients with event; N: Total number of patients within analysis; n.a.: Not available; T: Size or direct extent of the primary tumor

Soubgroup	Category	Parameter	Capmatinib[a]	ACT[a]	HR (95% CI)[a]	p-value [a]	p-value interaction-test[c]
Only subgroup characteristics in which at least one subgroup category included at least 10 patients in both treatment arms were included in the analysis. Subgroup category "unknown": These values are only shown descriptively and are not included in statistical calculations. a: Censoring reasons per SAP. In case of censoring due to data cut or loss to follow up, last date patient known alive was used. b: Median calculation using 50th quantile. c: Likelihood-Ratio-Test. The interaction test is based only on the valid subgroup categories (without "unknown").							

Figure 163: Comparison of time to unplanned or prolonged hospitalizations or death for population Pop d vs. ACT and subgroup: Age category: < 65, Kaplan-Meier plot, Naive comparison



Figure 164: Comparison of time to unplanned or prolonged hospitalizations or death for population Pop d vs. ACT and subgroup: Age category: ≥ 65, Kaplan-Meier plot, Naive comparison



Figure 165: Comparison of time to unplanned or prolonged hospitalizations or death for population Pop d vs. ACT and subgroup: Gender: female, Kaplan-Meier plot, Naive comparison



Figure 166: Comparison of time to unplanned or prolonged hospitalizations or death for population Pop d vs. ACT and subgroup: Gender: male, Kaplan-Meier plot, Naive comparison



Figure 167: Comparison of time to unplanned or prolonged hospitalizations or death for population Pop d vs. ACT and subgroup: T-stage T4: Yes, Kaplan-Meier plot, Naive comparison



Figure 168: Comparison of time to unplanned or prolonged hospitalizations or death for population Pop d vs. ACT and subgroup: T-stage T4: No, Kaplan-Meier plot, Naive comparison



Figure 169: Comparison of time to unplanned or prolonged hospitalizations or death for population Pop d vs. ACT and subgroup: Lymph node metastases: Yes, Kaplan-Meier plot, Naive comparison



Figure 170: Comparison of time to unplanned or prolonged hospitalizations or death for population Pop d vs. ACT and subgroup: Lymph node metastases: No, Kaplan-Meier plot, Naive comparison



Figure 171: Comparison of time to unplanned or prolonged hospitalizations or death for population Pop d vs. ACT and subgroup: Brain metasases: Yes, Kaplan-Meier plot, Naive comparison



Figure 172: Comparison of time to unplanned or prolonged hospitalizations or death for population Pop d vs. ACT and subgroup: Brain metasases: No, Kaplan-Meier plot, Naive comparison



Figure 173: Comparison of time to unplanned or prolonged hospitalizations or death for population Pop d vs. ACT and subgroup: Liver metasases: Yes, Kaplan-Meier plot, Naive comparison



Figure 174: Comparison of time to unplanned or prolonged hospitalizations or death for population Pop d vs. ACT and subgroup: Liver metasases: No, Kaplan-Meier plot, Naive comparison



Figure 175: Comparison of time to unplanned or prolonged hospitalizations or death for population Pop d vs. ACT and subgroup: Response to first line: Progression, Kaplan-Meier plot, Naive comparison



Figure 176: Comparison of time to unplanned or prolonged hospitalizations or death for population Pop d vs. ACT and subgroup: Response to first line: Non-progression, Kaplan-Meier plot, Naive comparison



3 Prüfarztauswertungen

3.1 Progressionsfreies Überleben

CINC280A2201 German AMNOG Dossier - Cutoff date: 2021-08-30

Table 2-4.2_c (Page 1 of 1)

Summary of progression free survival per Investigator assessment - Teilpopulation 2L (c)

(Full analysis set)

	Capmatinib N=9
No. of events -n(%)	5 (55.6)
Progression	3 (33.3)
Death	2 (22.2)
No. of censored -n(%)	4 (44.4)
Percentiles [95% CI] (month)	
25th	5.45 [1.25, 19.38]
50th	19.38 [1.25, NE]
75th	NE [6.80, NE]
% Event-free probability estimates [95% CI]	
3 months	88.9 [43.3, 98.4]
6 months	64.8 [25.3, 87.2]
9 months	51.9 [16.4, 78.8]
12 months	51.9 [16.4, 78.8]
15 months	51.9 [16.4, 78.8]
18 months	51.9 [16.4, 78.8]
21 months	38.9 [9.3, 68.7]
24 months	38.9 [9.3, 68.7]
27 months	38.9 [9.3, 68.7]
30 months	38.9 [9.3, 68.7]
33 months	38.9 [9.3, 68.7]
36 months	NE

- N: The total number of patients in FAS. It is the denominator for percentage (%) calculation.
- n: Number of patients who are at the corresponding category.
- Percentiles with 95% CIs are calculated from PROC LIFETEST output using method of Brookmeyer and Crowley (1982).
- Event-free probability estimate is the estimated probability that a patient will remain event-free up to the specified time point. Event-free probability estimates are obtained from the Kaplan-Meier estimates for each Teilpopulation; Greenwood formula is used for CIs of KM estimates.
- Teilpopulation 2L (c)= MET mutant patients who have received capmatinib in 2nd line after PD-1/PD-L1 antibody as monotherapy.

Table 2-4.2_d (Page 1 of 2)
Summary of progression free survival per Investigator assessment - Teilpopulation 2L (d)
(Full analysis set)

	Capmatinib N=64
No. of events -n(%)	56 (87.5)
Progression	49 (76.6)
Death	7 (10.9)
No. of censored -n(%)	8 (12.5)
Percentiles [95% CI] (month)	
25th	2.83 [1.41, 4.17]
50th	5.42 [4.17, 7.39]
75th	10.38 [8.18, 15.18]
% Event-free probability estimates [95% CI]	
3 months	72.2 [59.2, 81.7]
6 months	46.0 [33.2, 57.8]
9 months	34.5 [22.9, 46.3]
12 months	19.7 [10.9, 30.5]
15 months	16.4 [8.4, 26.7]
18 months	13.1 [6.1, 22.8]
21 months	13.1 [6.1, 22.8]
24 months	13.1 [6.1, 22.8]
27 months	11.5 [5.1, 20.9]
30 months	9.2 [3.4, 18.4]
33 months	9.2 [3.4, 18.4]
36 months	9.2 [3.4, 18.4]

- N: The total number of patients in FAS. It is the denominator for percentage (%) calculation.
- n: Number of patients who are at the corresponding category.
- Percentiles with 95% CIs are calculated from PROC LIFETEST output using method of Brookmeyer and Crowley (1982).
- Event-free probability estimate is the estimated probability that a patient will remain event-free up to the specified time point. Event-free probability estimates are obtained from the Kaplan-Meier estimates for each Teilpopulation; Greenwood formula is used for CIs of KM estimates.
- Teilpopulation 2L (d) = MET mutant patients who have received capmatinib in 2nd line after cytotoxic chemotherapy without immunotherapy, regardless of any targeted therapy.

Table 2-4.2_d (Page 2 of 2)
Summary of progression free survival per Investigator assessment - Teilpopulation 2L (d)
(Full analysis set)

	Capmatinib N=64
39 months	6.9 [2.1, 15.9]
42 months	NE

- N: The total number of patients in FAS. It is the denominator for percentage (%) calculation.
- n: Number of patients who are at the corresponding category.
- Percentiles with 95% CIs are calculated from PROC LIFETEST output using method of Brookmeyer and Crowley (1982).
- Event-free probability estimate is the estimated probability that a patient will remain event-free up to the specified time point. Event-free probability estimates are obtained from the Kaplan-Meier estimates for each Teilpopulation; Greenwood formula is used for CIs of KM estimates.
- Teilpopulation 2L (d) = MET mutant patients who have received capmatinib in 2nd line after cytotoxic chemotherapy without immunotherapy, regardless of any targeted therapy.

Table 2-4.2_e (Page 1 of 1)
Summary of progression free survival per Investigator assessment - Teilpopulation 2L (e)
(Full analysis set)

	Capmatinib N=8
No. of events -n(%)	7 (87.5)
Progression	7 (87.5)
Death	0
No. of censored -n(%)	1 (12.5)
Percentiles [95% CI] (month)	
25th	6.11 [2.83, 9.86]
50th	8.38 [2.83, NE]
75th	24.46 [6.67, NE]
% Event-free probability estimates [95% CI]	
3 months	87.5 [38.7, 98.1]
6 months	75.0 [31.5, 93.1]
9 months	50.0 [15.2, 77.5]
12 months	37.5 [8.7, 67.4]
15 months	25.0 [3.7, 55.8]
18 months	25.0 [3.7, 55.8]
21 months	25.0 [3.7, 55.8]
24 months	25.0 [3.7, 55.8]
27 months	25.0 [3.7, 55.8]
30 months	25.0 [3.7, 55.8]

- N: The total number of patients in FAS. It is the denominator for percentage (%) calculation.
- n: Number of patients who are at the corresponding category.
- Percentiles with 95% CIs are calculated from PROC LIFETEST output using method of Brookmeyer and Crowley (1982).
- Event-free probability estimate is the estimated probability that a patient will remain event-free up to the specified time point. Event-free probability estimates are obtained from the Kaplan-Meier estimates for each Teilpopulation; Greenwood formula is used for CIs of KM estimates.
- Teilpopulation 2L (e) = MET mutant patients who have received capmatinib in 2nd line after PD-1/PD-L1 antibody in combination with a platinum-based chemotherapy, regardless of any targeted therapy.

Table 2-4.2_f (Page 1 of 1)
Summary of progression free survival per Investigator assessment - Teilpopulation 3L + (f)
(Full analysis set)

	Capmatinib N=19
No. of events -n(%)	18 (94.7)
Progression	17 (89.5)
Death	1 (5.3)
No. of censored -n(%)	1 (5.3)
Percentiles [95% CI] (month)	
25th	2.92 [1.08, 4.70]
50th	5.65 [2.92, 19.81]
75th	19.81 [5.65, 26.28]
% Event-free probability estimates [95% CI]	
3 months	73.7 [47.9, 88.1]
6 months	47.4 [24.4, 67.3]
9 months	42.1 [20.4, 62.5]

- N: The total number of patients in FAS. It is the denominator for percentage (%) calculation.
- n: Number of patients who are at the corresponding category.
- Percentiles with 95% CIs are calculated from PROC LIFETEST output using method of Brookmeyer and Crowley (1982).
- Event-free probability estimate is the estimated probability that a patient will remain event-free up to the specified time point. Event-free probability estimates are obtained from the Kaplan-Meier estimates for each Teilpopulation; Greenwood formula is used for CIs of KM estimates.
- Teilpopulation 3L + (f) = MET mutant patients who have received capmatinib in 3rd and 4th line therapy.

3.2 Tumoransprechen

3.2.1 Bestes Gesamtansprechen

CINC280A2201 German AMNOG Dossier - Cutoff date: 2021-08-30

Table 2-1.2_c (Page 1 of 1)
Best overall response per Investigator assessment - Teilpopulation 2L (c)
(Full analysis set)

	Capmatinib N=9	
	n (%)	95% CI [a]
Best overall response		
Complete response (CR)	0	
Partial response (PR)	4 (44.4)	
Stable disease (SD)	4 (44.4)	
Progressive disease (PD)	0	
Neither CR nor PD (NCRNPD)	0	
Unknown (UNK)	1 (11.1)	
Overall response rate (ORR: CR+PR)	4 (44.4)	(13.7- 78.8)
Disease Control Rate (DCR: CR+PR+SD+NCRNPD)	8 (88.9)	(51.8- 99.7)

- N: The total number of patients in FAS. It is the denominator for percentage (%) calculation.
- n: Number of patients who are at the corresponding category.
- [a] Exact binomial 95% Confidence Interval by Clopper-Pearson (1934).
- Teilpopulation 2L (c)= MET mutant patients who have received capmatinib in 2nd line after PD-1/PD-L1 antibody as monotherapy.

Table 2-1.2_d (Page 1 of 1)
Best overall response per Investigator assessment - Teilpopulation 2L (d)
(Full analysis set)

	Capmatinib N=64	
	n (%)	95% CI [a]
Best overall response		
Complete response (CR)	1 (1.6)	
Partial response (PR)	25 (39.1)	
Stable disease (SD)	25 (39.1)	
Progressive disease (PD)	3 (4.7)	
Neither CR nor PD (NCRNPD)	0	
Unknown (UNK)	10 (15.6)	
Overall response rate (ORR: CR+PR)	26 (40.6)	(28.5- 53.6)
Disease Control Rate (DCR: CR+PR+SD+NCRNPD)	51 (79.7)	(67.8- 88.7)

- N: The total number of patients in FAS. It is the denominator for percentage (%) calculation.
- n: Number of patients who are at the corresponding category.
- [a] Exact binomial 95% Confidence Interval by Clopper-Pearson (1934).
- Teilpopulation 2L (d) = MET mutant patients who have received capmatinib in 2nd line after cytotoxic chemotherapy without immunotherapy, regardless of any targeted therapy.

Table 2-1.2_e (Page 1 of 1)
Best overall response per Investigator assessment - Teilpopulation 2L (e)
(Full analysis set)

	Capmatinib N=8	
	n (%)	95% CI [a]
Best overall response		
Complete response (CR)	0	
Partial response (PR)	5 (62.5)	
Stable disease (SD)	1 (12.5)	
Progressive disease (PD)	0	
Neither CR nor PD (NCRNPD)	1 (12.5)	
Unknown (UNK)	1 (12.5)	
Overall response rate (ORR: CR+PR)	5 (62.5)	(24.5- 91.5)
Disease Control Rate (DCR: CR+PR+SD+NCRNPD)	7 (87.5)	(47.3- 99.7)

- N: The total number of patients in FAS. It is the denominator for percentage (%) calculation.
- n: Number of patients who are at the corresponding category.
- [a] Exact binomial 95% Confidence Interval by Clopper-Pearson (1934).
- Teilpopulation 2L (e) = MET mutant patients who have received capmatinib in 2nd line after PD-1/PD-L1 antibody in combination with a platinum-based chemotherapy, regardless of any targeted therapy.

Table 2-1.2_f (Page 1 of 1)
Best overall response per Investigator assessment - Teilpopulation 3L + (f)
(Full analysis set)

	Capmatinib N=19	
	n (%)	95% CI [a]
Best overall response		
Complete response (CR)	0	
Partial response (PR)	9 (47.4)	
Stable disease (SD)	4 (21.1)	
Progressive disease (PD)	4 (21.1)	
Neither CR nor PD (NCRNPD)	2 (10.5)	
Unknown (UNK)	0	
Overall response rate (ORR: CR+PR)	9 (47.4)	(24.4- 71.1)
Disease Control Rate (DCR: CR+PR+SD+NCRNPD)	15 (78.9)	(54.4- 93.9)

- N: The total number of patients in FAS. It is the denominator for percentage (%) calculation.
- n: Number of patients who are at the corresponding category.
- [a] Exact binomial 95% Confidence Interval by Clopper-Pearson (1934).
- Teilpopulation 3L + (f) = MET mutant patients who have received capmatinib in 3rd and 4th line therapy.

3.2.2 Ansprechdauer

Table 2-2.2_c (Page 1 of 1)
Summary of duration of response (CR+PR) per Investigator assessment - Teilpopulation 2L (c)
(Full analysis set)

	Capmatinib N=4
No. of events- n(%)	2 (50.0)
No. of censored- n(%)	2 (50.0)
Ongoing without event	2 (50.0)
Percentiles [95% CI] (month)	
25th	11.71 [5.45, NE]
50th	NE [5.45, NE]
75th	NE [5.45, NE]
Kaplan-Meier estimates (%) DOR rate [95% CI] at:	
3 months	100.0 [100.0, 100.0]
6 months	75.0 [12.8, 96.1]
9 months	75.0 [12.8, 96.1]
12 months	75.0 [12.8, 96.1]
15 months	75.0 [12.8, 96.1]
18 months	50.0 [5.8, 84.5]
21 months	50.0 [5.8, 84.5]
24 months	50.0 [5.8, 84.5]
27 months	NE

- N: The total number of patients with confirmed CR or PR in FAS. It is the denominator for percentage (%) calculation.
- n: Number of patients who are at the corresponding category.
- Percentiles with 95% CIs are calculated from PROC LIFETEST output using method of Brookmeyer and Crowley (1982).
- Event-free probability estimate is the estimated probability that a patient will remain event-free up to the specified time point. Event-free probability estimates are obtained from the Kaplan-Meier estimates for each Teilpopulation; Greenwood formula is used for CIs of KM estimates.
- Teilpopulation 2L (c)= MET mutant patients who have received capmatinib in 2nd line after PD-1/PD-L1 antibody as monotherapy.

Table 2-2.2_d (Page 1 of 2)
Summary of duration of response (CR+PR) per Investigator assessment - Teilpopulation 2L (d)
(Full analysis set)

	Capmatinib N=26
No. of events- n(%)	22 (84.6)
No. of censored- n(%)	4 (15.4)
Ongoing without event	4 (15.4)
Percentiles [95% CI] (month)	
25th	4.17 [2.79, 5.55]
50th	7.67 [4.17, 10.87]
75th	13.80 [8.31, NE]
Kaplan-Meier estimates (%) DOR rate [95% CI] at:	
3 months	76.9 [55.7, 88.9]
6 months	57.7 [36.8, 73.9]
9 months	42.3 [23.5, 60.0]
12 months	30.8 [14.6, 48.5]
15 months	23.1 [9.4, 40.3]
18 months	23.1 [9.4, 40.3]
21 months	23.1 [9.4, 40.3]
24 months	18.5 [6.3, 35.5]
27 months	18.5 [6.3, 35.5]
30 months	13.8 [3.8, 30.4]
33 months	13.8 [3.8, 30.4]
36 months	13.8 [3.8, 30.4]
39 months	13.8 [3.8, 30.4]

- N: The total number of patients with confirmed CR or PR in FAS. It is the denominator for percentage (%) calculation.
- n: Number of patients who are at the corresponding category.
- Percentiles with 95% CIs are calculated from PROC LIFETEST output using method of Brookmeyer and Crowley (1982).
- Event-free probability estimate is the estimated probability that a patient will remain event-free up to the specified time point. Event-free probability estimates are obtained from the Kaplan-Meier estimates for each Teilpopulation; Greenwood formula is used for CIs of KM estimates.
- Teilpopulation 2L (d) = MET mutant patients who have received capmatinib in 2nd line after cytotoxic chemotherapy without immunotherapy, regardless of any targeted therapy.

Table 2-2.2_d (Page 2 of 2)
Summary of duration of response (CR+PR) per Investigator assessment - Teilpopulation 2L (d)
(Full analysis set)

	Capmatinib N=26
42 months	NE

- N: The total number of patients with confirmed CR or PR in FAS. It is the denominator for percentage (%) calculation.
- n: Number of patients who are at the corresponding category.
- Percentiles with 95% CIs are calculated from PROC LIFETEST output using method of Brookmeyer and Crowley (1982).
- Event-free probability estimate is the estimated probability that a patient will remain event-free up to the specified time point. Event-free probability estimates are obtained from the Kaplan-Meier estimates for each Teilpopulation; Greenwood formula is used for CIs of KM estimates.
- Teilpopulation 2L (d) = MET mutant patients who have received capmatinib in 2nd line after cytotoxic chemotherapy without immunotherapy, regardless of any targeted therapy.

Table 2-2.2_e (Page 1 of 1)
Summary of duration of response (CR+PR) per Investigator assessment - Teilpopulation 2L (e)
(Full analysis set)

	Capmatinib N=5
No. of events- n(%)	4 (80.0)
No. of censored- n(%)	1 (20.0)
Adequate assessment no longer available	1 (20.0)
Percentiles [95% CI] (month)	
25th	5.62 [4.17, 25.36]
50th	8.38 [4.17, NE]
75th	25.36 [4.17, NE]
Kaplan-Meier estimates (%) DOR rate [95% CI] at:	
3 months	100.0 [100.0, 100.0]
6 months	60.0 [12.6, 88.2]
9 months	40.0 [5.2, 75.3]
12 months	40.0 [5.2, 75.3]
15 months	40.0 [5.2, 75.3]
18 months	40.0 [5.2, 75.3]
21 months	40.0 [5.2, 75.3]
24 months	40.0 [5.2, 75.3]
27 months	20.0 [0.8, 58.2]
30 months	NE

- N: The total number of patients with confirmed CR or PR in FAS. It is the denominator for percentage (%) calculation.
- n: Number of patients who are at the corresponding category.
- Percentiles with 95% CIs are calculated from PROC LIFETEST output using method of Brookmeyer and Crowley (1982).
- Event-free probability estimate is the estimated probability that a patient will remain event-free up to the specified time point. Event-free probability estimates are obtained from the Kaplan-Meier estimates for each Teilpopulation; Greenwood formula is used for CIs of KM estimates.
- Teilpopulation 2L (e) = MET mutant patients who have received capmatinib in 2nd line after PD-1/PD-L1 antibody in combination with a platinum-based chemotherapy, regardless of any targeted therapy.

Table 2-2.2_f (Page 1 of 1)
Summary of duration of response (CR+PR) per Investigator assessment - Teilpopulation 3L + (f)
(Full analysis set)

	Capmatinib N=9
No. of events- n(%)	8 (88.9)
No. of censored- n(%)	1 (11.1)
Event after >= 2 missing assessments	1 (11.1)
Percentiles [95% CI] (month)	
25th	4.34 [2.79, 18.10]
50th	18.10 [2.79, 23.49]
75th	23.49 [11.20, NE]
Kaplan-Meier estimates (%) DOR rate [95% CI] at:	
3 months	88.9 [43.3, 98.4]
6 months	66.7 [28.2, 87.8]
9 months	66.7 [28.2, 87.8]
12 months	53.3 [17.7, 79.6]
15 months	53.3 [17.7, 79.6]
18 months	53.3 [17.7, 79.6]
21 months	40.0 [9.8, 69.7]
24 months	13.3 [0.7, 44.1]
27 months	13.3 [0.7, 44.1]
30 months	0.0 [NE, NE]

- N: The total number of patients with confirmed CR or PR in FAS. It is the denominator for percentage (%) calculation.
- n: Number of patients who are at the corresponding category.
- Percentiles with 95% CIs are calculated from PROC LIFETEST output using method of Brookmeyer and Crowley (1982).
- Event-free probability estimate is the estimated probability that a patient will remain event-free up to the specified time point. Event-free probability estimates are obtained from the Kaplan-Meier estimates for each Teilpopulation; Greenwood formula is used for CIs of KM estimates.
- Teilpopulation 3L + (f) = MET mutant patients who have received capmatinib in 3rd and 4th line therapy.

3.2.3 Zeit bis zum Ansprechen

Table 2-3.2_c (Page 1 of 1)
Summary of time to response (CR+PR) per Investigator assessment - Teilpopulation 2L (c)
(Full analysis set)

	Capmatinib N=9
No. of responders - n(%)	4 (44.4)
No. of censored - n(%)	5 (55.6)
Percentiles [95% CI] (months)	
25th	1.45 [1.38, NE]
50th	NE [1.38, NE]
75th	NE [9.69, NE]
% Event probability estimates [95% CI]	
3 months	33.3 [12.2, 71.8]
6 months	33.3 [12.2, 71.8]
9 months	33.3 [12.2, 71.8]
12 months	46.7 [20.4, 82.3]

- N: The total number of patients with confirmed CR or PR in FAS. It is the denominator for percentage (%) calculation.
- n: Number of patients who are at the corresponding category.
- Percentiles with 95% CIs are calculated from PROC LIFETEST output using method of Brookmeyer and Crowley (1982).
- Event-free probability estimate is the estimated probability that a patient will remain event-free up to the specified time point. Event-free probability estimates are obtained from the Kaplan-Meier estimates for each Teilpopulation; Greenwood formula is used for CIs of KM estimates.
- Teilpopulation 2L (c)= MET mutant patients who have received capmatinib in 2nd line after PD-1/PD-L1 antibody as monotherapy.

Table 2-3.2_d (Page 1 of 1)
Summary of time to response (CR+PR) per Investigator assessment - Teilpopulation 2L (d)
(Full analysis set)

	Capmatinib N=64
No. of responders - n(%)	26 (40.6)
No. of censored - n(%)	38 (59.4)
Percentiles [95% CI] (months)	
25th	1.41 [1.35, 1.41]
50th	NE [1.51, NE]
75th	NE
% Event probability estimates [95% CI]	
3 months	37.6 [26.8, 51.0]
6 months	39.3 [28.3, 52.6]
9 months	39.3 [28.3, 52.6]
12 months	40.9 [29.8, 54.3]
15 months	42.5 [31.3, 55.9]

- N: The total number of patients with confirmed CR or PR in FAS. It is the denominator for percentage (%) calculation.
- n: Number of patients who are at the corresponding category.
- Percentiles with 95% CIs are calculated from PROC LIFETEST output using method of Brookmeyer and Crowley (1982).
- Event-free probability estimate is the estimated probability that a patient will remain event-free up to the specified time point. Event-free probability estimates are obtained from the Kaplan-Meier estimates for each Teilpopulation; Greenwood formula is used for CIs of KM estimates.
- Teilpopulation 2L (d) = MET mutant patients who have received capmatinib in 2nd line after cytotoxic chemotherapy without immunotherapy, regardless of any targeted therapy.

Table 2-3.2_e (Page 1 of 1)
Summary of time to response (CR+PR) per Investigator assessment - Teilpopulation 2L (e)
(Full analysis set)

	Capmatinib N=8
No. of responders - n(%)	5 (62.5)
No. of censored - n(%)	3 (37.5)
Percentiles [95% CI] (months)	
25th	1.45 [1.08, 11.10]
50th	6.31 [1.08, NE]
75th	NE [1.48, NE]
% Event probability estimates [95% CI]	
3 months	50.0 [22.5, 84.8]
6 months	50.0 [22.5, 84.8]
9 months	50.0 [22.5, 84.8]
12 months	62.5 [32.6, 91.3]

- N: The total number of patients with confirmed CR or PR in FAS. It is the denominator for percentage (%) calculation.
- n: Number of patients who are at the corresponding category.
- Percentiles with 95% CIs are calculated from PROC LIFETEST output using method of Brookmeyer and Crowley (1982).
- Event-free probability estimate is the estimated probability that a patient will remain event-free up to the specified time point. Event-free probability estimates are obtained from the Kaplan-Meier estimates for each Teilpopulation; Greenwood formula is used for CIs of KM estimates.
- Teilpopulation 2L (e) = MET mutant patients who have received capmatinib in 2nd line after PD-1/PD-L1 antibody in combination with a platinum-based chemotherapy, regardless of any targeted therapy.

Table 2-3.2_f (Page 1 of 1)
Summary of time to response (CR+PR) per Investigator assessment - Teilpopulation 3L + (f)
(Full analysis set)

	Capmatinib N=19
No. of responders - n(%)	9 (47.4)
No. of censored - n(%)	10 (52.6)
Percentiles [95% CI] (months)	
25th	1.38 [1.31, 2.83]
50th	NE [1.38, NE]
75th	NE
% Event probability estimates [95% CI]	
3 months	47.4 [28.1, 71.3]

- N: The total number of patients with confirmed CR or PR in FAS. It is the denominator for percentage (%) calculation.
- n: Number of patients who are at the corresponding category.
- Percentiles with 95% CIs are calculated from PROC LIFETEST output using method of Brookmeyer and Crowley (1982).
- Event-free probability estimate is the estimated probability that a patient will remain event-free up to the specified time point. Event-free probability estimates are obtained from the Kaplan-Meier estimates for each Teilpopulation; Greenwood formula is used for CIs of KM estimates.
- Teilpopulation 3L + (f) = MET mutant patients who have received capmatinib in 3rd and 4th line therapy.

4 Gesundheitszustand (EQ-5D VAS) – Veränderung ≥ 7 % der Skalenspannweite gegenüber dem Ausgangswert

Tabelle 67: Ergebnisse für den Endpunkt Gesundheitszustand (EQ-5D VAS, Zeit bis zur definitiven Verschlechterung um mindestens 7 % der Skalenspannweite gegenüber dem Ausgangswert aus weiteren Untersuchungen zum Datenschnitt vom 30. August 2021 – Capmatinib

EQ-5D VAS ≥ 7 % der Skalenspannweite gegenüber dem Ausgangswert	**Zweitlinie**			**Drittlinie**
Teilpopulation	**c** **N=9**	**d** **N=64**	**e** **N=8**	**f** **N=19**
Ereignisse – n (%)	1 (11,1)	31 (48,4)	2 (25,0)	4 (21,1)
Schätzer für Zeit bis zum Ereignis (Monate) †				
Median [95 %-KI]	NE [2,69; NE]	8,38 [4,21; 16,59]	NE [0,95; NE]	NE [2,79; NE]
Kaplan-Meier-Schätzer (%) [95 %-KI]				
Monat 3	85,7 [33,4; 97,9]	69,4 [55,0; 80,1]	87,5 [38,7; 98,1]	80,0 [50,0; 93,1]
Monat 6	85,7 [33,4; 97,9]	60,5 [45,5; 72,6]	87,5 [38,7; 98,1]	80,0 [50,0; 93,1]
Monat 9	85,7 [33,4; 97,9]	45,6 [30,0; 60,0]	87,5 [38,7; 98,1]	80,0 [50,0; 93,1]
Monat 12	85,7 [33,4; 97,9]	45,6 [30,0; 60,0]	87,5 [38,7; 98,1]	80,0 [50,0; 93,1]
Monat 15	85,7 [33,4; 97,9]	35,8 [20,9; 51,0]	58,3 [7,7; 89,3]	80,0 [50,0; 93,1]
Monat 18	85,7 [33,4; 97,9]	31,9 [17,2; 47,5]	58,3 [7,7; 89,3]	80,0 [50,0; 93,1]
Monat 21	85,7 [33,4; 97,9]	27,9 [13,9; 43,8]	58,3 [7,7; 89,3]	60,0 [17,9; 85,9]
Monat 24	85,7 [33,4; 97,9]	23,9 [10,8; 39,9]	58,3 [7,7; 89,3]	60,0 [17,9; 85,9]

EQ-5D VAS ≥ 7 % der Skalenspannweite gegenüber dem Ausgangswert	**Zweitlinie**			**Drittlinie**
Monat 27	85,7 [33,4; 97,9]	23,9 [10,8; 39,9]	58,3 [7,7; 89,3]	60,0 [17,9; 85,9]
Monat 30	85,7 [33,4; 97,9]	23,9 [10,8; 39,9]	-	60,0 [17,9; 85,9]
Monat 33	85,7 [33,4; 97,9]	23,9 [10,8; 39,9]	-	60,0 [17,9; 85,9]
Monat 36	85,7 [33,4; 97,9]	23,9 [10,8; 39,9]	-	-
Monat 39	85,7 [33,4; 97,9]	23,9 [10,8; 39,9]	-	-

* eine Verminderung des Scores um mindestens 7 % der Skalenspannweite gegenüber dem Ausgangswert wurde als Verschlechterung angesehen

† Schätzung mit Hilfe der Brookmeyer-Crowley-Methode

Abkürzungen: c: Zweitlinientherapie nach Erstlinientherapie mit einem PD-(L)1-Antikörper als Monotherapie; d: Zweitlinientherapie nach Erstlinientherapie mit einer zytotoxischen Chemotherapie; e: Zweitlinientherapie nach Erstlinientherapie mit einem PD-(L)1-Antikörper in Kombination mit einer platinhaltigen Chemotherapie; f: Drittlinientherapie; KI: Konfidenzintervall

Quelle: CINC280A2201 Zusatzanalysen 2021 Tabellen 3-3.4_c, 3-3.4_d, 3-3.4_e, 3-3.4_f



Abbildung 177: Ergebnisse für den Endpunkt Zeit bis zur definitiven Verschlechterung des EQ-5D VAS um mindestens 7 % der Skalenspannweite gegenüber dem Ausgangswert bei Patienten, die in der Erstlinientherapie mit einer zytotoxischen Chemotherapie vorbehandelt wurden (Teilpopulation d) aus weiteren Untersuchungen – Kaplan-Meier-Kurve und 95 %-Konfidenzintervall

5 Verträglichkeit – Teilpopulationen

Tabelle 68: Ergebnisse für den Endpunkt Verträglichkeit aus der Studie GEOMETRY mono-1 zum Datenschnitt vom 30. August 2021 – „unerwünschte Ereignisse“ und „schwere unerwünschte Ereignisse (CTCAE-Grad 3/4)“ – vortherapierte Patienten (Zweitlinie)

Teilpopulation	**c** **N=9**		**d** **N=64**		**e** **N=8**	
Unerwünschte Ereignisse	Gesamt n (%)	Grad 3/4 n (%)	Gesamt n (%)	Grad 3/4 n (%)	Gesamt n (%)	Grad 3/4 n (%)
Jegliches UE	9 (100)	7 (77,8)	63 (98,4)	44 (68,8)	8 (100)	5 (62,5)
Erkrankungen des Blutes und des Lymphsystems	2 (22,2)	1 (11,1)	12 (18,8)	3 (4,7)	-	-
Anämie	2 (22,2)	1 (11,1)	7 (10,9)	2 (3,1)	-	-
Lymphopenie	1 (11,1)	0	-	-	-	-
Herzerkrankungen	-	-	11 (17,2)	1 (1,6)	1 (12,5)	0
Perikarderguss	-	-	-	-	1 (12,5)	0
Erkrankungen des Ohrs und des Labyrinths	1 (11,1)	0	9 (14,1)	0	2 (25,0)	0
Hörverlust	1 (11,1)	0	-	-	-	-
Tinnitus	-	-	-	-	1 (12,5)	0
Zerumen Impaktion	-	-	-	-	1 (12,5)	0
Augenerkrankungen	1 (11,1)	1 (11,1)	9 (14,1)	0	1 (12,5)	
Katarakt	1 (11,1)	1 (11,1)	-	-	-	-
Verschwommenes Sehen	-	-	-	-	1 (12,5)	0
Erkrankungen des Gastrointestinaltrakts	9 (100)	0	45 (70,3)	2 (3,1)	5 (62,5)	1 (12,5)
Abdominale Schmerzen	-	-	-	-	1 (12,5)	1 (12,5)
Aszites	-	-	-	-	1 (12,5)	0
Schmerzen im oberen Abdomen	2 (22,2)	0	-	-	-	-
Konstipation	1 (11,1)	0	10 (15,6)	2 (3,1)	1 (12,5)	0

Teilpopulation	**c** **N=9**		**d** **N=64**		**e** **N=8**	
Unerwünschte Ereignisse	Gesamt n (%)	Grad 3/4 n (%)	Gesamt n (%)	Grad 3/4 n (%)	Gesamt n (%)	Grad 3/4 n (%)
Diarrhoe	3 (33,3)	0	9 (14,1)	0	2 (25,0)	0
Dyspepsie	-	-	-	-	1 (12,5)	0
Hiatushernie	-	-	-	-	1 (12,5)	0
Refluxkrankheit	1 (11,1)	0	-	-	-	-
Übelkeit	7 (77,8)	0	23 (35,9)	0	2 (25,0)	1 (12,5)
Odynophagie	1 (11,1)	0	-	-	-	-
Stomatitis	1 (11,1)	0	-	-	1 (12,5)	0
Erbrechen	4 (44,4)	0	14 (21,9)	0	3 (37,5)	0
Allgemeine Erkrankungen und Beschwerden am Verabreichungsort	8 (88,9)	3 (33,3)	44 (68,8)	17 (26,6)	8 (100)	2 (25,0)
Wärme am Verabreichungsort	1 (11,1)	0	-	-	-	-
Asthenie	1 (11,1)	0	-	-	1 (12,5)	0
Gesichtsödem	1 (11,1)	0	-	-	-	-
Fatigue	5 (55,6)	0	17 (26,6)	4 (6,3)	3 (37,5)	0
Gangstörungen					1 (12,5)	0
Generalisiertes Ödem	1 (11,1)	1 (11,1)	-	-	-	-
Nichtkardialer Brustschmerz	-	-	8 (12,5)	1 (1,6)	-	-
Ödem	-	-	-	-	-	-
Schüttelfrost	-	-	-	-	2 (25,0)	0
Schwäche	-	-	-	-	1 (12,5)	0
Peripheres Ödem	7 (77,8)	2 (22,2)	37 (57,8)	8 (12,5)	7 (87,5)	2 (25,0)
Pyrexie	1 (11,1)	0	-	-	3 (37,5)	1 (12,5)

Teilpopulation	**c** **N=9**		**d** **N=64**		**e** **N=8**	
Unerwünschte Ereignisse	Gesamt n (%)	Grad 3/4 n (%)	Gesamt n (%)	Grad 3/4 n (%)	Gesamt n (%)	Grad 3/4 n (%)
Schmerzen am Verabreichungsort der Impfung	1 (11,1)	0	-	-	-	-
Leber- und Gallenerkrankungen	2 (22,2)	1 (11,1)	-	-	-	-
Medikamenten-assoziierte Schädigung der Leber	1 (11,1)	1 (11,1)	-	-	-	-
Lebersteatose	1 (11,1)	0	-	-	-	-
Hyperbilirubinämie	1 (11,1)	1 (11,1)	-	-	-	-
Erkrankungen des Immunsystems	-	-	-	-	1 (12,5)	0
Hypersensitivität	-	-	-	-	1 (12,5)	0
Infektionen und parasitäre Erkrankungen	3 (33,3)	1 (11,1)	22 (34,4)	8 (12,5)	4 (50,0)	1 (12,5)
Bronchitis	-	-	-	-	1 (12,5)	0
Entzündung des Unterhautgewebes	-	-	-	-	1 (12,5)	0
Herpes zoster	1 (11,1)	0	-	-	-	-
Infektiöser Pleuraerguss					1 (12,5)	1 (12,5)
Nasopharyngitis	2 (22,2)	0	-	-	1 (12,5)	0
Pneumonie	1 (11,1)	0	-	-	1 (12,5)	0
Influenzapneumonie	1 (11,1)	1 (11,1)	-	-	-	-
Infektion des Respirationstrakts	1 (11,1)	0	-	-	-	-
Infektion der Harnwege	-	-	-	-	1 (12,5)	0
Septischer Schock	1 (11,1)	1 (11,1)	-	-		
Sinusitis	-	-	-	-	1 (12,5)	0
Verletzung, Vergiftung und durch Eingriffe bedingte Komplikationen	7 (77,8)	0	10 (15,6)	2 (3,1)	2 (25,0)	0

Teilpopulation	**c** **N=9**		**d** **N=64**		**e** **N=8**	
Unerwünschte Ereignisse	Gesamt n (%)	Grad 3/4 n (%)	Gesamt n (%)	Grad 3/4 n (%)	Gesamt n (%)	Grad 3/4 n (%)
Prellung	2 (22,2)	0	-	-	-	-
Fraktur der Hüftpfanne	-	-	-	-	1 (12,5)	0
Sturz	1 (11,1)	0	-	-	1 (12,5)	0
Verletzungen der Gliedmaßen	1 (11,1)	0	-	-	-	-
Überdosierung	1 (11,1)	0	-	-	-	-
Strahlenproktitis	1 (11,1)	0	-	-	-	-
Verletzungen der Haut	1 (11,1)	0	-	-	-	-
Verbrennungen	1 (11,1)	0	-	-	-	-
Hämorrhagie der Trachea	1 (11,1)	0	-	-	-	-
Untersuchungen	8 (88,9)	2 (22,2)	39 (60,9)	17 (26,6)	5 (62,5)	3 (37,5)
Abnormale Atemgeräusche	-	-	-	-	1 (12,5)	0
Alanin-Aminotransferase erhöht	3 (33,3)	2 (22,2)	10 (15,6)	4 (6,3)	1 (12,5)	0
Amylase erhöht	-	-	9 (14,1)	5 (7,8)	-	-
Aspartat-Aminotransferase erhöht	1 (11,1)	1 (11,1)	7 (10,9)	2 (3,1)	-	-
Alkalische Phopshatase im Blut erhöht	1 (11,1)	0	-	-	1 (12,5)	0
Bilirubin im Blut erhöht	1 (11,1)	0	-	-	-	-
Kreatin-Phosphokinase im Blut erniedrigt	1 (11,1)	0	-	-	-	-
Kreatin-Phopshokinase im Blut erhöht	1 (11,1)	0	-	-	-	-
Blut-Kreatinin erhöht	2 (22,2)	0	22 (34,4)	0	3 (37,5)	0
Testosteron im Blut erniedrigt	-	-	-	-	1 (12,5)	0
Gamma-Glutamyltransferase erhöht	1 (11,1)	0	-	-	-	-

Teilpopulation	**c** **N=9**		**d** **N=64**		**e** **N=8**	
Unerwünschte Ereignisse	Gesamt n (%)	Grad 3/4 n (%)	Gesamt n (%)	Grad 3/4 n (%)	Gesamt n (%)	Grad 3/4 n (%)
Granulozytenzahl erniedrigt	1 (11,1)	0	-	-	-	-
Hämoglobin erniedrigt	1 (11,1)	0	-	-	-	-
Gewichtsabnahme	1 (11,1)	0	7 (10,9)	0	1 (12,5)	0
Gewichtszunahme	1 (11,1)	0	-	-	1 (12,5)	1 (12,5)
Lipase erhöht	-	-	8 (12,5)	7 (10,9)	1 (12,5)	1 (12,5)
Neutrophilenzahl erniedrigt	-	-	-	-	1 (12,5)	1 (12,5)
Leukozytenzahl erniedrigt	-	-	-	-	1 (12,5)	1 (12,5)
Lymphozytenzahl erniedrigt	1 (11,1)	0	-	-	-	-
Thrombozytenzahl erniedrigt	-	-	-	-	1 (12,5)	0
Thrombozytenzahl erhöht	-	-	-	-	1 (12,5)	0
Gesamtprotein erniedrigt	1 (11,1)	0	-	-	-	-
Stoffwechsel- und Ernährungsstörungen	7 (77,8)	3 (33,3)	29 (45,3)	4 (6,3)	3 (37,5)	1 (12,5)
Appetit verringert	2 (22,2)	0	14 (21,9)	1 (1,6)	2 (25,0)	0
Dehydratation	1 (11,1)	1 (11,1)	-	-	1 (12,5)	1 (12,5)
Hyperglykämie	1 (11,1)	0	-	-	-	-
Hyperkalämie	1 (11,1)	0	-	-	1 (12,5)	0
Hypoalbuminämie	2 (22,2)	0	7 (10,9)	0	1 (12,5)	0
Hypokalzämie	2 (22,2)	0	-	-	-	-
Hyponatriämie	1 (11,1)	1 (11,1)	-	-	-	-
Hypophosphatämie	3 (33,3)	1 (11,1)	-	-	-	-
Hypoproteinämie	1 (11,1)	0	-	-	-	-

Teilpopulation	**c** **N=9**		**d** **N=64**		**e** **N=8**	
Unerwünschte Ereignisse	Gesamt n (%)	Grad 3/4 n (%)	Gesamt n (%)	Grad 3/4 n (%)	Gesamt n (%)	Grad 3/4 n (%)
Skelettmuskulatur-, Bindegewebs- und Knochenerkrankungen	3 (33,3)	1 (11,1)	28 (43,8)	3 (4,7)	4 (50,0)	0
Arthralgie	-	-	10 (15,6)	0	-	-
Hyperthrophe Osteoathropathie	-	-	-	-	1 (12,5)	0
Rückenschmerzen	3 (33,3)	0	13 (20,3)	1 (1,6)	3 (37,5)	0
Muskelschwäche	1 (11,1)	1 (11,1)	-	-	1 (12,5)	0
Muskelkrämpfe	-	-	-	-	1 (12,5)	0
Myalgie	1 (11,1)	0	-	-	1 (12,5)	0
Nackenschmerzen	1 (11,1)	0	-	-	-	-
Schmerzen in den Extremitäten	1 (11,1)	0	7 (10,9)	0	2 (25,0)	0
Schmerzen der Skelettmuskulatur in der Brust	-	-	7 (10,9)	1 (1,6)	-	-
Kieferschmerzen	1 (11,1)	0	-	-	-	-
Unwohlsein in den Gliedmaßen	-	-	-	-	1 (12,5)	0
Gutartige, bösartige und unspezifische Neubildungen (einschließlich Zysten und Polypen)	-	-	-	-	1 (12,5)	1 (12,5)
Brustkrebs	-	-	-	-	1 (12,5)	1 (12,5)
Erkrankungen des Nervensystems	4 (44,4)	0	18 (28,1)	0	2 (25,0)	0
Aphasie	1 (11,1)	0	-	-	-	-
Schwindel	1 (11,1)	0	8 (12,5)	0	-	-
Dysarthrie	1 (11,1)	0	-	-	-	-
Gedächtnisstörungen	-	-	-	-	1 (12,5)	0

Teilpopulation	**c** **N=9**		**d** **N=64**		**e** **N=8**	
Unerwünschte Ereignisse	Gesamt n (%)	Grad 3/4 n (%)	Gesamt n (%)	Grad 3/4 n (%)	Gesamt n (%)	Grad 3/4 n (%)
Kopfschmerzen	1 (11,1)	0	-	-	-	-
Erkrankung des Nervensystems	1 (11,1)	0	-	-	-	-
Periphere Neuropathie	1 (11,1)	0	-	-	-	-
Periphere sensorische Neuropathie	-	-	-	-	1 (12,5)	0
Parästhesie	2 (22,2)	0	-	-	-	-
Tremor	1 (11,1)	0	-	-	-	-
Psychiatrische Erkrankungen	1 (11,1)	0	15 (23,4)	0	1 (12,5)	0
Depression	1 (11,1)	0	-	-	1 (12,5)	0
Insomnie	1 (11,1)	0	7 (10,9)	0	1 (12,5)	0
Erkrankungen der Nieren und Harnwege	-	-	-	-	1 (12,5)	0
Pollakisurie	-	-	-	-	1 (12,5)	0
Harnverhalt	-	-	-	-	1 (12,5)	0
Erkrankungen der Geschlechtsorgane und der Brustdrüse	-	-	-	-	3 (37,5)	0
Brustschmerzen	-	-	-	-	1 (12,5)	0
Erkrankungen der Prostata	-	-	-	-	1 (12,5)	0
Vulvo-vaginale Entzündung	-	-	-	-	1 (12,5)	0
Erkrankungen der Atemwege, des Brustraums und des Mediastinums	6 (66,7)	2 (22,2)	36 (56,3)	11 (17,2)	7 (87,5)	1 (12,5)
Husten	4 (44,4)	1 (11,1)	10 (15,6)	0	2 (25,0)	0
Dysphonie	1 (11,1)	0	-	-	1 (12,5)	0
Dyspnoe	2 (22,2)	0	12 (18,8)	4 (6,3)	5 (62,5)	0

Teilpopulation	**c** **N=9**		**d** **N=64**		**e** **N=8**	
Unerwünschte Ereignisse	Gesamt n (%)	Grad 3/4 n (%)	Gesamt n (%)	Grad 3/4 n (%)	Gesamt n (%)	Grad 3/4 n (%)
Bluthusten	-	-	-	-	2 (25,0)	0
Epistaxis	1 (11,1)	0	-	-	-	-
Hypoxie	1 (11,1)	0	-	-	1 (12,5)	0
Schmerzen des Oropharynx	-	-	-	-	1 (12,5)	0
Unwohlsein in der Nasennebenhöhle	-	-	-	-	1 (12,5)	0
Pleuraerguss	-	-	-	-	4 (50,0)	1 (12,5)
Pleuritis	-	-	-	-	1 (12,5)	0
Pneumonitis	2 (22,2)	1 (11,1)	-	-	-	-
Pneumothorax	-	-	-	-	1 (12,5)	0
Husten mit Auswurf	-	-	-	-	1 (12,5)	0
Rasselnde Atmung	-	-	-	-	1 (12,5)	0
Lungenembolie	1 (11,1)	0	-	-	-	-
Allergische Rhinitis	1 (11,1)	0	-	-	1 (12,5)	0
Rhinorrhoe	1 (11,1)	0	-	-	1 (12,5)	0
Hustensyndrom der oberen Atemwege	-	-	-	-	1 (12,5)	0
Keuchen	-	-	-	-	1 (12,5)	0
Erkrankungen der Haut und des Unterhautzellgewebes	4 (44,4)	1 (11,1)	21 (32,8)	0	4 (50,0)	1 (12,5)
Alopezie	-	-	-	-	1 (12,5)	0
Akneiforme Dermatitis	2 (22,2)	0	-	-	-	-
Pruritus	2 (22,2)	1 (11,1)	10 (15,6)	0	1 (12,5)	0
Ausschlag	2 (22,2)	0	-	-	-	-

Teilpopulation	**c** **N=9**		**d** **N=64**		**e** **N=8**	
Unerwünschte Ereignisse	Gesamt n (%)	Grad 3/4 n (%)	Gesamt n (%)	Grad 3/4 n (%)	Gesamt n (%)	Grad 3/4 n (%)
Ausschlag mit Juckreiz	1 (11,1)	0	-	-	-	-
Makulopapulöses Exanthem	-	-	-	-	1 (12,5)	0
Multiformes Erythem	-	-	-	-	1 (12,5)	0
Urtikaria	1 (11,1)	0	-	-	1 (12,5)	1 (12,5)
Gefäßerkrankungen	2 (22,2)	0	7 (10,9)	3 (4,7)	4 (50,0)	0
Bluthochdruck	-	-	-	-	2 (25,0)	0
Hypotonie	-	-	-	-	1 (12,5)	0
Orthostatische Hypotonie	-	-	-	-	1 (12,5)	0
Thrombophlebitis	-	-	-	-	1 (12,5)	0
Venenthrombose	-	-	-	-	1 (12,5)	0
Tiefe Venenthrombose	1 (11,1)	0	-	-	-	-
Embolie	1 (11,1)	0	-	-	-	-

Dargestellt sind alle unerwünschten Ereignisse, die bei ≥ 10 % *oder* ≥ 5 % (CTCAE-Grad 3/4) der Patienten *oder* ≥ 10 Patienten UND einer Häufigkeit von ≥ 1 % in der jeweiligen Teilpopulation auftraten.

Abkürzungen: c: Zweitlinientherapie nach Erstlinientherapie mit einem PD-(L)1-Antikörper als Monotherapie; d: Zweitlinientherapie nach Erstlinientherapie mit einer zytotoxischen Chemotherapie; e: Zweitlinientherapie nach Erstlinientherapie mit einem PD-(L)1-Antikörper in Kombination mit einer platinhaltigen Chemotherapie; UE: unerwünschtes Ereignis

Tabelle 69: Ergebnisse für den Endpunkt Verträglichkeit aus der Studie GEOMETRY mono-1 zum Datenschnitt vom 30. August 2021 – „unerwünschte Ereignisse“ und „schwere unerwünschte Ereignisse (CTCAE-Grad 3/4)“ – vortherapierte Patienten (Drittlinie)

Teilpopulation	**f** **N=19**	
Unerwünschte Ereignisse	Gesamt n (%)	Grad 3/4 n (%)
Jegliches UE	19 (100)	14 (73,7)
Erkrankungen des Blutes und des Lymphsystems	3 (15,8)	0
Anämie	2 (10,5)	0
Herzerkrankungen	5 (26,3)	1 (5,3)
Supraventrikuläre Tachykardie	1 (5,3)	1 (5,3)
Erkrankungen des Ohrs und des Labyrinths	2 (10,5)	0
Augenerkrankungen	2 (10,5)	0
Erkrankungen des Gastrointestinaltrakts	13 (68,4)	0
Schmerzen im oberen Abdomen	3 (15,8)	0
Diarrhoe	2 (10,5)	0
Dyspepsie	2 (10,5)	0
Übelkeit	11 (57,9)	0
Erbrechen	6 (31,6)	0
Allgemeine Erkrankungen und Beschwerden am Verabreichungsort	12 (63,2)	4 (21,1)
Asthenie	2 (10,5)	1 (5,3)
Fatigue	5 (26,3)	2 (10,5)
Peripheres Ödem	9 (47,4)	2 (10,5)
Schmerzen	2 (10,5)	0
Pyrexie	3 (15,8)	0
Infektionen und parasitäre Erkrankungen	10 (52,6)	4 (21,1)
Bronchitis	1 (5,3)	0
Entzündung des Unterhautgewebes	2 (10,5)	1 (5,3)
Pneumonie	3 (15,8)	3 (15,8)
Pyelonephritis	1 (5,3)	1 (5,3)
Harnwegsinfektion	3 (15,8)	0
Verletzung, Vergiftung und durch Eingriffe bedingte Komplikationen	2 (10,5)	0
Untersuchungen	11 (57,9)	5 (26,3)
Alanin-Aminotransferase erhöht	2 (10,5)	2 (10,5)
Amylase erhöht	2 (10,5)	0

Teilpopulation	**f** **N=19**	
Unerwünschte Ereignisse	Gesamt n (%)	Grad 3/4 n (%)
Aspartat-Aminotransferase erhöht	1 (5,3)	1 (5,3)
Blut-Kreatinin erhöht	6 (31,6)	0
Gamma-Glutamyltransferase erhöht	2 (10,5)	2 (10,5)
Lipase erhöht	1 (5,3)	1 (5,3)
Thrombozytenzahl erniedrigt	2 (10,5)	1 (5,3)
Stoffwechsel- und Ernährungsstörungen	4 (21,1)	0
Appetit verringert	2 (10,5)	0
Skelettmuskulatur-, Bindegewebs- und Knochenerkrankungen	6 (31,6)	1 (5,3)
Rückenschmerzen	3 (15,8)	1 (5,3)
Nackenschmerzen	2 (10,5)	0
Gutartige, bösartige und nicht spezifizierte Neubildungen (einschließlich Zysten und Polypen)	1 (5,3)	1 (5,3)
Metastasierendes malignes Melanom	1 (5,3)	1 (5,3)
Erkrankungen des Nervensystems	9 (47,4)	1 (5,3)
Schwindel	3 (15,8)	0
Kopfschmerzen	4 (21,1)	0
Querschnittslähmung	1 (5,3)	1 (5,3)
Psychiatrische Erkrankungen	2 (10,5)	0
Erkrankungen der Geschlechtsorgane und der Brustdrüse	1 (5,3)	1 (5,3)
Genitalprolaps	1 (5,3)	1 (5,3)
Erkrankungen der Atemwege, des Brustraums und des Mediastinums	11 (57,9)	5 (26,3)
Husten	2 (10,5)	0
Dyspnoe	6 (31,6)	3 (15,8)
Hypoxie	1 (5,3)	1 (5,3)
Pleuraerguss	1 (5,3)	1 (5,3)
Venenthrombose der Lunge	1 (5,3)	1 (5,3)
Lungenversagen	1 (5,3)	1 (5,3)
Erkrankungen der Haut und des Unterhautzellgewebes	7 (36,8)	0
Trockene Haut	2 (10,5)	0
Ausschlag	3 (15,8)	0
Gefäßerkrankungen	4 (21,1)	1 (5,3)
Kapillarlecksyndrom	1 (5,3)	1 (5,3)

Teilpopulation	**f** **N=19**	
Unerwünschte Ereignisse	Gesamt n (%)	Grad 3/4 n (%)
Dargestellt sind alle unerwünschten Ereignisse, die bei ≥ 10 % *oder* ≥ 5 % (CTCAE-Grad 3/4) der Patienten *oder* ≥ 10 Patienten UND einer Häufigkeit von ≥ 1 % in der jeweiligen Teilpopulation auftraten. Abkürzungen: f: Drittlinientherapie; UE: unerwünschtes Ereignis		

Tabelle 70: Ergebnisse für den Endpunkt Verträglichkeit aus der Studie GEOMETRY mono-1 zum Datenschnitt vom 30. August 2021 – „schwerwiegende unerwünschte Ereignisse“ – vortherapierte Patienten (Zweitlinie)

Teilpopulation	**c N=9**		**d N=64**		**e N=8**	
Schwerwiegende unerwünschte Ereignisse	Gesamt n (%)	Grad 3/4 n (%)	Gesamt n (%)	Grad 3/4 n (%)	Gesamt n (%)	Grad 3/4 n (%)
Jegliches SUE	4 (44,4)	4 (44,4)	29 (45,3)	24 (37,5)	5 (62,5)	3 (37,5)
Herzerkrankungen	-	-	-	-	1 (12,5)	0
Perikarderguss	-	-	-	-	1 (12,5)	0
Erkrankungen des Gastrointestinaltrakts	-	-	-	-	1 (12,5)	1 (12,5)
Abdominale Schmerzen	-	-	-	-	1 (12,5)	1 (12,5)
Schmerzen im Abdomen	-	-	-	-	1 (12,5)	1 (12,5)
Diarrhoe	-	-	-	-	1 (12,5)	0
Übelkeit	-	-	-	-	1 (12,5)	1 (12,5)
Erbrechen	-	-	-	-	1 (12,5)	0
Allgemeine Erkrankungen und Beschwerden am Verabreichungsort	-	-	6 (9,4)	5 (7,8)	1 (12,5)	1 (12,5)
Pyrexie	-	-	-	-	1 (12,5)	1 (12,5)
Leber- und Gallenerkrankungen	1 (11,1)	1 (11,1)	-	-	-	-
Medikamenten-assoziierte Schädigung der Leber	1 (11,1)	1 (11,1)	-	-	-	-
Hyperbilirubinämie	1 (11,1)	1 (11,1)	-	-	-	-
Infektionen und parasitäre Erkrankungen	1 (11,1)	1 (11,1)	5 (7,8)	5 (7,8)	1 (12,5)	1 (12,5)
Infektiöser Pleuraerguss	-	-	-	-	1 (12,5)	1 (12,5)
Influenzapneumonie	1 (11,1)	1 (11,1)	-	-	-	-
Septischer Schock	1 (11,1)	1 (11,1)	-	-	-	-

Teilpopulation	**c** **N=9**		**d** **N=64**		**e** **N=8**	
Schwerwiegende unerwünschte Ereignisse	Gesamt n (%)	Grad 3/4 n (%)	Gesamt n (%)	Grad 3/4 n (%)	Gesamt n (%)	Grad 3/4 n (%)
Stoffwechsel- und Ernährungsstörungen	1 (11,1)	1 (11,1)	-	-	1 (12,5)	1 (12,5)
Dehydratation	1 (11,1)	1 (11,1)	-	-	1 (12,5)	1 (12,5)
Skelettmuskulatur-, Bindegewebs- und Knochenerkrankungen	1 (11,1)	1 (11,1)	-	-	-	-
Muskelschwäche	1 (11,1)	1 (11,1)	-	-	-	-
Gutartige, bösartige und unspezifische Neubildungen (einschließlich Zysten und Polypen)	-	-	-	-	1 (12,5)	1 (12,5)
Brustkrebs	-	-	-	-	1 (12,5)	1 (12,5)
Erkrankungen der Atemwege, des Brustraums und des Mediastinums	2 (22,2)	1 (11,1)	11 (17,2)	8 (12,5)	2 (25,0)	1 (12,5)
Dyspnoe	-	-	-	-	1 (12,5)	0
Bluthusten	-	-	-	-	1 (12,5)	0
Pleuraerguss	-	-	-	-	1 (12,5)	1 (12,5)
Pneumonitis	2 (22,2)	1 (11,1)	-	-	-	-
Pneumothorax	-	-	-	-	1 (12,5)	0
Erkrankungen der Haut und des Unterhautzellgewebes	-	-	-	-	1 (12,5)	0
Urtikaria	-	-	-	-	1 (12,5)	0

Dargestellt sind alle schwerwiegenden unerwünschten Ereignisse, die bei ≥ 5 % der Patienten *oder* ≥ 10 Patienten UND einer Häufigkeit von ≥ 1 % in der jeweiligen Teilpopulation auftraten.

Abkürzungen: c: Zweitlinientherapie nach Erstlinientherapie mit einem PD-(L)1-Antikörper als Monotherapie; d: Zweitlinientherapie nach Erstlinientherapie mit einer zytotoxischen Chemotherapie; e: Zweitlinientherapie nach Erstlinientherapie mit einem PD-(L)1-Antikörper in Kombination mit einer platinhaltigen Chemotherapie; UE: unerwünschtes Ereignis

Tabelle 71: Ergebnisse für den Endpunkt Verträglichkeit aus der Studie GEOMETRY mono-1 zum Datenschnitt vom 30. August 2021 – „schwerwiegende unerwünschte Ereignisse“ – vortherapierte Patienten (Drittlinie)

Teilpopulation	**f** **N=19**	
Schwerwiegende unerwünschte Ereignisse	Gesamt n (%)	Grad 3/4 n (%)
Jegliches SUE	11 (57,9)	9 (47,4)
Herzerkrankungen	1 (5,3)	1 (5,3)
Supraventrikuläre Tachykardie	1 (5,3)	1 (5,3)
Erkrankungen des Ohrs und des Labyrinths	1 (5,3)	0
Hörverlust	1 (5,3)	0
Infektionen und parasitäre Erkrankungen	6 (31,6)	4 (21,1)
Entzündung des Unterhautgewebes	2 (10,5)	1 (5,3)
Herpes zoster	1 (5,3)	0
Pneumonie	3 (15,8)	3 (15,8)
Pyelonephritis	1 (5,3)	1 (5,3)
Erkrankungen des Nervensystems	1 (5,3)	1 (5,3)
Querschnittslähmung	1 (5,3)	1 (5,3)
Psychiatrische Erkrankungen	1 (5,3)	0
Agitiertheit	1 (5,3)	0
Erkrankungen der Geschlechtsorgane und der Brustdrüse	1 (5,3)	1 (5,3)
Genitalprolaps	1 (5,3)	1 (5,3)
Erkrankungen der Atemwege, des Brustraums und des Mediastinums	5 (26,3)	4 (21,1)
Dyspnoe	3 (15,8)	2 (10,5)
Venenthrombose der Lunge	1 (5,3)	1 (5,3)
Lungenversagen	1 (5,3)	1 (5,3)

Dargestellt sind alle schwerwiegenden unerwünschten Ereignisse, die bei ≥ 5 % der Patienten *oder* ≥ 10 Patienten UND einer Häufigkeit von ≥ 1 % in der jeweiligen Teilpopulation auftraten.

Abkürzungen: f: Drittlinientherapie; UE: unerwünschtes Ereignis

Tabelle 72: Ergebnisse für den Endpunkt Verträglichkeit aus der Studie GEOMETRY mono-1 zum Datenschnitt vom 30. August 2021 – „unerwünschte Ereignisse, die zum Therapieabbruch führten“ – Capmatinib bei vortherapierten Patienten (Zweitlinie)

Teilpopulation	**c N=9**		**d N=64**		**e N=8**	
Unerwünschte Ereignisse, die zum Therapieabbruch führten	Gesamt n (%)	Grad 3/4 n (%)	Gesamt n (%)	Grad 3/4 n (%)	Gesamt n (%)	Grad 3/4 n (%)
Gesamt	3 (33,3)	2 (22,2)	8 (12,5)	6 (9,4)	2 (25,0)	1 (12,5)
Allgemeine Erkrankungen und Beschwerden am Verabreichungsort	-	-	2 (3,1)	2 (3,1)	-	-
Fatigue	-	-	1 (1,6)	1 (1,6)	-	-
Peripheres Ödem	-	-	1 (1,6)	1 (1,6)	-	-
Leber- und Gallenerkrankungen	1 (11,1)	1 (11,1)	1 (1,6)	1 (1,6)	-	-
Abnormale Leberfunktion	-	-	1 (1,6)	1 (1,6)	-	-
Medikamenten-assoziierte Schädigung der Leber	1 (11,1)	1 (11,1)	-	-	-	-
Infektionen und parasitäre Erkrankungen	1 (11,1)	1 (11,1)	-	-	-	-
Septischer Schock	1 (11,1)	1 (11,1)	-	-	-	-
Untersuchungen	-	-	1 (1,6)	0	-	-
Alanin-Aminotransferase erhöht	-	-	1 (1,6)	0	-	-
Aspartat-Aminotransferase erhöht	-	-	1 (1,6)	0	-	-
Bilirubin im Blut erhöht	-	-	1 (1,6)	0	-	-
Gutartige, bösartige und unspezifische Neubildungen (einschließlich Zysten und Polypen)	-	-	-	-	1 (12,5)	1 (12,5)
Brustkrebs	-	-	-	-	1 (12,5)	1 (12,5)
Erkrankungen der Atemwege, des Brustraums und des Mediastinums	1 (11,1)	0	4 (6,3)	3 (4,7)	-	-
Interstitielle Lungenerkrankung	-	-	1 (1,6)	1 (1,6)	-	-
Organisierende Pneumonie	-	-	1 (1,6)	1 (1,6)	-	-
Pneumonitis	1 (11,1)	0	2 (3,1)	1 (1,6)	-	-

Teilpopulation	**c** **N=9**		**d** **N=64**		**e** **N=8**	
Unerwünschte Ereignisse, die zum Therapieabbruch führten	Gesamt n (%)	Grad 3/4 n (%)	Gesamt n (%)	Grad 3/4 n (%)	Gesamt n (%)	Grad 3/4 n (%)
Erkrankungen der Haut und des Unterhautzellgewebes	-	-	-	-	1 (12,5)	0
Urtikaria	-	-	-	-	1 (12,5)	0

Abkürzungen: c: Zweitlinientherapie nach Erstlinientherapie mit einem PD-(L)1-Antikörper als Monotherapie; d: Zweitlinientherapie nach Erstlinientherapie mit einer zytotoxischen Chemotherapie; e: Zweitlinientherapie nach Erstlinientherapie mit einem PD-(L)1-Antikörper in Kombination mit einer platinhaltigen Chemotherapie; UE: unerwünschtes Ereignis

Tabelle 73: Ergebnisse für den Endpunkt Verträglichkeit aus der Studie GEOMETRY mono-1 zum Datenschnitt vom 30. August 2021 – „unerwünschte Ereignisse, die zum Therapieabbruch führten“ – Capmatinib bei vortherapierten Patienten (Drittlinie)

Teilpopulation	**f** **N=19**	
Unerwünschte Ereignisse	Gesamt n (%)	Grad 3/4 n (%)
Gesamt	5 (26,3)	3 (15,8)
Erkrankungen des Ohrs und des Labyrinths	1 (5,3)	0
Hörverlust	1 (5,3)	0
Infektionen und parasitäre Erkrankungen	1 (5,3)	1 (5,3)
Pneumonie	1 (5,3)	1 (5,3)
Untersuchungen	2 (10,5)	1 (5,3)
Blut-Kreatinin erhöht	1 (5,3)	0
Lipase erhöht	1 (5,3)	1 (5,3)
Gutartige, bösartige und unspezifische Neubildungen (einschließlich Zysten und Polypen)	1 (5,3)	1 (5,3)
Metastasierendes malignes Melanom	1 (5,3)	1 (5,3)
Dargestellt sind alle unerwünschten Ereignisse, die bei ≥ 10 % *oder* ≥ 5 % (CTCAE-Grad 3/4) der Patienten *oder* ≥ 10 Patienten UND einer Häufigkeit von ≥ 1 % in der jeweiligen Teilpopulation auftraten. Abkürzungen: f: Drittlinientherapie; UE: unerwünschtes Ereignis		

Tabelle 74: Ergebnisse für den Endpunkt Verträglichkeit aus der Studie GEOMETRY mono-1 zum Datenschnitt vom 30. August 2021 – „unerwünschte Ereignisse von besonderem Interesse“

Teilpopulation	**Zweitlinie**			**Drittlinie**
	c **N=9**	**d** **N=64**	**e** **N=8**	**f** **N=19**
Unerwünschte Ereignisse von besonderem Interesse	n (%)	n (%)	n (%)	n (%)
Gesamt	7 (77,8)	44 (68,8)	6 (75,0)	10 (52,6)
Nierenfunktionsstörung				
Alle Schweregrade	2 (22,2)	22 (34,4)	3 (37,5)	7 (36,8)
CTCAE-Grad 1/2	2 (22,2)	22 (34,4)	3 (37,5)	7 (36,8)
CTCAE-Grad 3/4	0	0	0	0
Schwerwiegend	0	0	0	0
Hepatotoxizität				
Alle Schweregrade	5 (55,6)	21 (32,8)	4 (50,0)	4 (21,1)
CTCAE-Grad 1/2	3 (33,3)	15 (23,4)	4 (50,0)	1 (5,3)
CTCAE-Grad 3/4	2 (22,2)	6 (9,4)	0	3 (15,8)
Schwerwiegend	1 (11,1)	1 (1,6)	0	0
Pankreatitis				
Alle Schweregrade	0	11 (17,2)	1 (12,5)	2 (10,5)
CTCAE-Grad 1/2	0	2 (3,1)	0	1 (5,3)
CTCAE-Grad 3/4	0	9 (14,1)	1 (12,5)	1 (5,3)
Schwerwiegend	0	0	0	0
Toxizität des zentralen Nervensystems				
Alle Schweregrade	2 (22,2)	13 (20,3)	2 (25,0)	4 (21,1)

Teilpopulation	**Zweitlinie**			**Drittlinie**
	c **N=9**	**d** **N=64**	**e** **N=8**	**f** **N=19**
Unerwünschte Ereignisse von besonderem Interesse	n (%)	n (%)	n (%)	n (%)
CTCAE-Grad 1/2	2 (22,2)	13 (20,3)	2 (25,0)	4 (21,1)
CTCAE-Grad 3/4	0	0	0	0
Schwerwiegend	0	0	0	0
Interstitielle Lungenerkrankung und Pneumonitis				
Alle Schweregrade	2 (22,2)	4 (6,3)	0	1 (5,3)
CTCAE-Grad 1/2	1 (11,1)	2 (3,1)	0	1 (5,3)
CTCAE-Grad 3/4	1 (11,1)	2 (3,1)	0	0
Schwerwiegend	2 (22,2)	2 (3,1)	0	0
QTc-Intervall-Verlängerung				
Alle Schweregrade	0	0	0	1 (5,3)
CTCAE-Grad 1/2	0	0	0	1 (5,3)
CTCAE-Grad 3/4	0	0	0	0
Schwerwiegend	0	0	0	0
Teratogenität				
Alle Schweregrade	0	0	0	0
CTCAE-Grad 1/2	0	0	0	0
CTCAE-Grad 3/4	0	0	0	0
Schwerwiegend	0	0	0	0
Photosensitivität				

Teilpopulation	**Zweitlinie**			**Drittlinie**
	c **N=9**	**d** **N=64**	**e** **N=8**	**f** **N=19**
Unerwünschte Ereignisse von besonderem Interesse	n (%)	n (%)	n (%)	n (%)
Alle Schweregrade	0	1 (1,6)	0	0
CTCAE-Grad 1/2	0	1 (1,6)	0	0
CTCAE-Grad 3/4	0	0	0	0
Schwerwiegend	0	0	0	0

Abkürzungen: c: Zweitlinientherapie nach Erstlinientherapie mit einem PD-(L)1-Antikörper als Monotherapie; d: Zweitlinientherapie nach Erstlinientherapie mit einer zytotoxischen Chemotherapie; e: Zweitlinientherapie nach Erstlinientherapie mit einem PD-(L)1-Antikörper in Kombination mit einer platinhaltigen Chemotherapie; f: Drittlinientherapie

6 Unerwünschte Ereignisse von besonderem Interesse – Preferred Terms und MedDRA-Codes

Listing 16.2.7-1.2 (Page 1 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Central nervous system (CNS) toxicity	Central nervous system (CNS) toxicity	
	Akinesia (PT)	10001541
	Atonic seizures (PT)	10003628
	Aura (PT)	10003791
	Automatism epileptic (PT)	10003831
	Bradykinesia (PT)	10006100
	Cogwheel rigidity (PT)	10009848
	Convulsions local (PT)	10010920
	Convulsive threshold lowered (PT)	10010927
	Deja vu (PT)	10012177
	Dizziness (PT)	10013573
	Dreamy state (PT)	10013634
	Drooling (PT)	10013642

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Central nervous system (CNS) toxicity	Drop attacks (PT)	10013643
	Drug withdrawal convulsions (PT)	10013752
	Dysphonia (PT)	10013952
	Eclampsia (PT)	10014129
	Epilepsy (PT)	10015037
	Epileptic aura (PT)	10015049
	Extrapyramidal disorder (PT)	10015832
	Febrile convulsion (PT)	10016284
	Gait disturbance (PT)	10017577
	Generalised tonic-clonic seizure (PT)	10018100
	Hypertonia (PT)	10020852
	Hypokinesia (PT)	10021021
	Hypokinesia neonatal (PT)	10021022

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Central nervous system (CNS) toxicity	Infantile spasms (PT)	10021750
	Labyrinthine fistula (PT)	10023563
	Labyrinthitis (PT)	10023567
	Meniere's disease (PT)	10027183
	Motion sickness (PT)	10027990
	Movement disorder (PT)	10028035
	Muscle rigidity (PT)	10028330
	Narcolepsy (PT)	10028713
	Nystagmus (PT)	10029864
	On and off phenomenon (PT)	10030312
	Parkinsonism (PT)	10034010
	Petit mal epilepsy (PT)	10034759
	Post-traumatic epilepsy (PT)	10036312

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Central nervous system (CNS) toxicity	Seizure (PT)	10039906
	Seizure anoxic (PT)	10039907
	Simple partial seizures (PT)	10040703
	Status epilepticus (PT)	10041962
	Temporal lobe epilepsy (PT)	10043209
	Tonic convulsion (PT)	10043994
	Tremor (PT)	10044565
	Tremor neonatal (PT)	10044575
	Uncinate fits (PT)	10045476
	Vertigo (PT)	10047340
	Vertigo labyrinthine (PT)	10047344
	Vertigo positional (PT)	10047348
	Vestibular apparatus operation (PT)	10047384

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Central nervous system (CNS) toxicity	Vestibular ataxia (PT)	10047385
	Vestibular disorder (PT)	10047386
	Vestibular function test abnormal (PT)	10047390
	Vestibular neuronitis (PT)	10047393
	VIIIth nerve injury (PT)	10047409
	Mobility decreased (PT)	10048334
	Hypertonia neonatal (PT)	10048615
	Postictal state (PT)	10048727
	Hypoglycaemic seizure (PT)	10048803
	Lennox-Gastaut syndrome (PT)	10048816
	Parkinsonian crisis (PT)	10048868
	Frontal lobe epilepsy (PT)	10049424
	Autonomic seizure (PT)	10049612

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Central nervous system (CNS) toxicity	Balance disorder (PT)	10049848
	Endolymphatic hydrops (PT)	10049934
	Bradyphrenia (PT)	10050012
	Tongue biting (PT)	10050467
	Tonic clonic movements (PT)	10051171
	Acquired epileptic aphasia (PT)	10052075
	Convulsion in childhood (PT)	10052391
	Postictal paralysis (PT)	10052469
	Postictal headache (PT)	10052470
	Musculoskeletal stiffness (PT)	10052904
	Walking disability (PT)	10053204
	Clonic convulsion (PT)	10053398
	Canalith repositioning procedure (PT)	10053470

Listing 16.2.7-1.2 (Page 7 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Central nervous system (CNS) toxicity	Lafora's myoclonic epilepsy (PT)	10054030
	Myoclonic epilepsy (PT)	10054859
	Baltic myoclonic epilepsy (PT)	10054895
	Partial seizures with secondary generalisation (PT)	10056209
	Parkinsonian gait (PT)	10056242
	Alcoholic seizure (PT)	10056347
	Parkinsonian rest tremor (PT)	10056437
	Atypical benign partial epilepsy (PT)	10056699
	Micrographia (PT)	10057333
	Epileptic psychosis (PT)	10059232
	Freezing phenomenon (PT)	10060904
	Motor dysfunction (PT)	10061296
	Partial seizures (PT)	10061334

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Listing 16.2.7-1.2 (Page 8 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Central nervous system (CNS) toxicity	Inner ear disorder (PT)	10061524
	Parkinson's disease (PT)	10061536
	Ear operation (PT)	10061831
	VIIIth nerve lesion (PT)	10062177
	Foaming at mouth (PT)	10062654
	Inner ear operation (PT)	10062990
	Acute vestibular syndrome (PT)	10063559
	Sudden unexplained death in epilepsy (PT)	10063894
	Saccotomy (PT)	10066849
	Postural reflex impairment (PT)	10067206
	Benign familial neonatal convulsions (PT)	10067866
	Molybdenum cofactor deficiency (PT)	10069687
	Myoclonic epilepsy and ragged-red fibres (PT)	10069825

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Central nervous system (CNS) toxicity	Benign rolandic epilepsy (PT)	10070530
	Postictal psychosis (PT)	10070669
	Seizure like phenomena (PT)	10071048
	Idiopathic generalised epilepsy (PT)	10071081
	Juvenile myoclonic epilepsy (PT)	10071082
	Parkinsonism hyperpyrexia syndrome (PT)	10071243
	Seizure cluster (PT)	10071350
	Resting tremor (PT)	10071390
	Hyperglycaemic seizure (PT)	10071394
	Biotinidase deficiency (PT)	10071434
	Early infantile epileptic encephalopathy with burst-suppression (PT)	10071545
	Amygdalohippocampectomy (PT)	10071707
	Action tremor (PT)	10072413

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Listing 16.2.7-1.2 (Page 10 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Central nervous system (CNS) toxicity	Hypocalcaemic seizure (PT)	10072456
	Muscle tone disorder (PT)	10072889
	Hyponatraemic seizure (PT)	10073183
	Postural tremor (PT)	10073211
	Schizencephaly (PT)	10073487
	Topectomy (PT)	10073488
	Polymicrogyria (PT)	10073489
	Double cortex syndrome (PT)	10073490
	Corpus callosotomy (PT)	10073491
	Severe myoclonic epilepsy of infancy (PT)	10073677
	Preictal state (PT)	10073854
	Parkinson's disease psychosis (PT)	10074835
	Tonic posturing (PT)	10075125

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Listing 16.2.7-1.2 (Page 11 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Central nervous system (CNS) toxicity	Change in seizure presentation (PT)	10075606
	Fine motor skill dysfunction (PT)	10076288
	Endolymphatic shunt placement (PT)	10076623
	Migraine-triggered seizure (PT)	10076676
	Acute encephalitis with refractory, repetitive partial seizures (PT)	10076948
	Post stroke seizure (PT)	10076981
	Post stroke epilepsy (PT)	10076982
	Vestibular migraine (PT)	10077920
	Hemimegalencephaly (PT)	10078100
	Reduced facial expression (PT)	10078576
	Glucose transporter type 1 deficiency syndrome (PT)	10078727
	Laryngeal tremor (PT)	10078751
	CSWS syndrome (PT)	10078827

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Listing 16.2.7-1.2 (Page 12 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Central nervous system (CNS) toxicity	2-Hydroxyglutaric aciduria (PT)	10078971
	Aspartate-glutamate-transporter deficiency (PT)	10079140
	Labyrinthectomy (PT)	10079362
	Focal dyscognitive seizures (PT)	10079424
	Febrile infection-related epilepsy syndrome (PT)	10079438
	Epilepsy surgery (PT)	10079824
	Multiple subpial transection (PT)	10079825
	Superior semicircular canal dehiscence (PT)	10079888
	Tuberous sclerosis complex (PT)	10080584
	Epilepsy with myoclonic-atonic seizures (PT)	10081179
	Middle ear irrigation (PT)	10081220
	Tympanoscopy (PT)	10081281
	Otolithiasis (PT)	10081585

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Listing 16.2.7-1.2 (Page 13 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Central nervous system (CNS) toxicity	Seizure prophylaxis (PT)	10081601
	Transient epileptic amnesia (PT)	10081728
	Neonatal seizure (PT)	10082067
	Neonatal epileptic seizure (PT)	10082068
	Grey matter heterotopia (PT)	10082084
	Hypokinetic dysarthria (PT)	10082243
	Propulsive gait (PT)	10082328
	1p36 deletion syndrome (PT)	10082398
	Congenital bilateral perisylvian syndrome (PT)	10082716
	Gelastic seizure (PT)	10082918
	CDKL5 deficiency disorder (PT)	10083005
	Focal cortical resection (PT)	10083272
	Generalised onset non-motor seizure (PT)	10083376

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Central nervous system (CNS) toxicity	CEC syndrome (PT)	10083749
	Alpers disease (PT)	10083857
	GM2 gangliosidosis (PT)	10083933
	Faciobrachial dystonic seizure (PT)	10084187
	Jeavons syndrome (PT)	10084303
	Intratympanic injection (PT)	10084734
	Otoendoscopy (PT)	10084853
	Hemiconvulsion-hemiplegia-epilepsy syndrome (PT)	10085010
	Juvenile absence epilepsy (PT)	10085031
	Parietal lobe epilepsy (PT)	10085326
	Convulsions (SMQ) (broad)	20000079
	Parkinson-like events (SMQ) (broad)	20000099
	Vestibular disorders (SMQ) (broad)	20000172

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Listing 16.2.7-1.2 (Page 15 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Drug-drug interactions with strong CYP3A4 inducers	Drug ineffective (PT)	10013709
	Drug level decreased (PT)	10013718
	Drug specific antibody present (PT)	10013745
	Tachyphylaxis (PT)	10043087
	Therapeutic response decreased (PT)	10043414
	Vaccination failure (PT)	10046862
	Multiple-drug resistance (PT)	10048723
	Paradoxical drug reaction (PT)	10048958
	Drug half-life reduced (PT)	10049994
	Therapy non-responder (PT)	10051082
	Drug ineffective for unapproved indication (PT)	10051118
	Drug tolerance (PT)	10052804
	Drug tolerance increased (PT)	10052806

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Listing 16.2.7-1.2 (Page 16 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Drug-drug interactions with strong CYP3A4 inducers	Therapeutic response delayed (PT)	10053181
	Device failure (PT)	10056871
	Drug resistance (PT)	10059866
	Device ineffective (PT)	10059875
	Therapeutic product ineffective (PT)	10060769
	Therapeutic product ineffective for unapproved indication (PT)	10060770
	Therapeutic reaction time decreased (PT)	10061380
	Virologic failure (PT)	10065648
	Treatment failure (PT)	10066901
	Device defective (PT)	10074425
	Therapeutic response changed (PT)	10074941
	Diet failure (PT)	10075213
	Remission not achieved (PT)	10076313

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Drug-drug interactions with strong CYP3A4 inducers	Therapy partial responder (PT)	10078115
	Therapeutic response shortened (PT)	10078575
	Device effect delayed (PT)	10079118
	Device effect decreased (PT)	10079633
	Device effect incomplete (PT)	10079634
	Device effect variable (PT)	10079635
	Absence of immediate treatment response (PT)	10081766
	Missing dose response relationship (PT)	10081872
	Atypical dose response relationship (PT)	10081873
	Drug level abnormal (PT)	10082169
	Therapeutic product effect incomplete (PT)	10082200
	Therapeutic product effect decreased (PT)	10082201
	Therapeutic product effect delayed (PT)	10082202

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Drug-drug interactions with strong CYP3A4 inducers	Therapeutic product effect variable (PT)	10082204
	Device ineffective shock delivery (PT)	10082473
	Drug effect less than expected (PT)	10083365
	Loss of therapeutic response (PT)	10084221
	Lack of efficacy/effect (SMQ)	20000032
Hepatotoxicity	5'nucleotidase increased (PT)	10000028
	Acute hepatic failure (PT)	10000804
	Alanine aminotransferase abnormal (PT)	10001547
	Alanine aminotransferase increased (PT)	10001551
	Ammonia abnormal (PT)	10001942
	Ammonia increased (PT)	10001946
	Ascites (PT)	10003445
	Aspartate aminotransferase abnormal (PT)	10003477

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Hepatotoxicity	Aspartate aminotransferase increased (PT)	10003481
	Asterixis (PT)	10003547
	Autoimmune hepatitis (PT)	10003827
	Biliary cirrhosis (PT)	10004659
	Biliary fibrosis (PT)	10004664
	Bilirubin conjugated increased (PT)	10004685
	Biopsy liver abnormal (PT)	10004792
	Blood bilirubin increased (PT)	10005364
	Blood bilirubin unconjugated increased (PT)	10005370
	Blood cholinesterase abnormal (PT)	10005429
	Blood cholinesterase decreased (PT)	10005430
	Blood fibrinogen abnormal (PT)	10005518
	Blood fibrinogen decreased (PT)	10005520
	Blood thrombin abnormal (PT)	10005818

Listing 16.2.7-1.2 (Page 20 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Hepatotoxicity	Blood thrombin decreased (PT)	10005820
	Blood thromboplastin abnormal (PT)	10005824
	Blood thromboplastin decreased (PT)	10005826
	Bromosulphthalein test abnormal (PT)	10006408
	Cholestasis (PT)	10008635
	Chronic hepatitis (PT)	10008909
	Coagulation factor decreased (PT)	10009736
	Coagulation factor IX level decreased (PT)	10009746
	Coagulation factor V level decreased (PT)	10009754
	Coagulation factor VII level decreased (PT)	10009761
	Coagulation factor X level decreased (PT)	10009775
	Coma hepatic (PT)	10010075
	Complications of transplanted liver (PT)	10010186
	Gamma-glutamyltransferase abnormal (PT)	10017688

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Hepatotoxicity	Gamma-glutamyltransferase increased (PT)	10017693
	Granulomatous liver disease (PT)	10018704
	Hepaplastin abnormal (PT)	10019621
	Hepaplastin decreased (PT)	10019622
	Hepatic atrophy (PT)	10019637
	Hepatic cirrhosis (PT)	10019641
	Hepatic encephalopathy (PT)	10019660
	Hepatic failure (PT)	10019663
	Hepatic fibrosis (PT)	10019668
	Hepatic function abnormal (PT)	10019670
	Hepatic necrosis (PT)	10019692
	Hepatic pain (PT)	10019705
	Hepatic steatosis (PT)	10019708
	Hepatitis (PT)	10019717

Listing 16.2.7-1.2 (Page 22 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Hepatotoxicity	Hepatitis acute (PT)	10019727
	Hepatitis cholestatic (PT)	10019754
	Hepatitis chronic active (PT)	10019755
	Hepatitis chronic persistent (PT)	10019759
	Hepatitis fulminant (PT)	10019772
	Hepatitis toxic (PT)	10019795
	Hepatocellular injury (PT)	10019837
	Hepatomegaly (PT)	10019842
	Hepatorenal failure (PT)	10019845
	Hepatorenal syndrome (PT)	10019846
	Hepatosplenomegaly (PT)	10019847
	Hepatotoxicity (PT)	10019851
	Hyperammonaemia (PT)	10020575
	Hyperbilirubinaemia (PT)	10020578

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Hepatotoxicity	Hypoalbuminaemia (PT)	10020942
	Hypocoagulable state (PT)	10020973
	Hypoprothrombinaemia (PT)	10021085
	Icterus index increased (PT)	10021209
	International normalised ratio abnormal (PT)	10022592
	International normalised ratio increased (PT)	10022595
	Ischaemic hepatitis (PT)	10023025
	Jaundice (PT)	10023126
	Jaundice cholestatic (PT)	10023129
	Jaundice hepatocellular (PT)	10023136
	Kayser-Fleischer ring (PT)	10023321
	Leucine aminopeptidase increased (PT)	10024275
	Liver disorder (PT)	10024670
	Liver function test abnormal (PT)	10024690

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Hepatotoxicity	Liver tenderness (PT)	10024712
	Liver transplant (PT)	10024714
	Liver transplant rejection (PT)	10024715
	Lupoid hepatic cirrhosis (PT)	10025129
	Oesophageal varices haemorrhage (PT)	10030210
	Portal hypertension (PT)	10036200
	Portal shunt (PT)	10036204
	Protein C decreased (PT)	10037005
	Prothrombin level abnormal (PT)	10037048
	Prothrombin level decreased (PT)	10037050
	Prothrombin time abnormal (PT)	10037057
	Prothrombin time prolonged (PT)	10037063
	Prothrombin time ratio increased (PT)	10037068
	Reye's syndrome (PT)	10039012

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Hepatotoxicity	Spider naevus (PT)	10041519
	Splenorenal shunt (PT)	10041661
	Ultrasound liver abnormal (PT)	10045428
	Yellow skin (PT)	10048245
	Retinol binding protein decreased (PT)	10048473
	Cholaemia (PT)	10048611
	Hepatic cytolysis (PT)	10049199
	Glutamate dehydrogenase increased (PT)	10049483
	Antithrombin III decreased (PT)	10049547
	Oedema due to hepatic disease (PT)	10049631
	Urine bilirubin increased (PT)	10050792
	Portal hypertensive gastropathy (PT)	10050897
	Duodenal varices (PT)	10051010
	Gastric varices (PT)	10051012

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Hepatotoxicity	Radiation hepatitis (PT)	10051015
	Nodular regenerative hyperplasia (PT)	10051081
	Protein S decreased (PT)	10051120
	Hypofibrinogenaemia (PT)	10051125
	Thrombin time abnormal (PT)	10051319
	Guanase increased (PT)	10051333
	Bile output decreased (PT)	10051343
	Bile output abnormal (PT)	10051344
	Thrombin time prolonged (PT)	10051390
	Liver and pancreas transplant rejection (PT)	10051603
	Protein S abnormal (PT)	10051736
	Hypercholia (PT)	10051924
	Hepatopulmonary syndrome (PT)	10052274
	Renal and liver transplant (PT)	10052279

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Hepatotoxicity	Liver induration (PT)	10052550
	Foetor hepaticus (PT)	10052554
	Peritoneovenous shunt (PT)	10052716
	Non-alcoholic steatohepatitis (PT)	10053219
	Hepatocellular foamy cell syndrome (PT)	10053244
	Perihepatic discomfort (PT)	10054125
	Transaminases increased (PT)	10054889
	Varices oesophageal (PT)	10056091
	X-ray hepatobiliary abnormal (PT)	10056536
	Subacute hepatic failure (PT)	10056956
	Hepatic mass (PT)	10057110
	Gastric varices haemorrhage (PT)	10057572
	Chronic hepatic failure (PT)	10057573
	Ocular icterus (PT)	10058117

Listing 16.2.7-1.2 (Page 28 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Hepatotoxicity	Blood bilirubin abnormal (PT)	10058477
	Hypothrombinaemia (PT)	10058517
	Hypothromboplastinaemia (PT)	10058518
	Blood alkaline phosphatase increased (PT)	10059570
	Blood alkaline phosphatase abnormal (PT)	10059571
	Galactose elimination capacity test abnormal (PT)	10059710
	Galactose elimination capacity test decreased (PT)	10059712
	Haemorrhagic ascites (PT)	10059766
	Hepatic enzyme decreased (PT)	10060794
	Hepatic enzyme increased (PT)	10060795
	Bilirubin excretion disorder (PT)	10061009
	Coagulation factor IX level abnormal (PT)	10061770
	Coagulation factor V level abnormal (PT)	10061771
	Coagulation factor VII level abnormal (PT)	10061772

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Hepatotoxicity	Coagulation factor X level abnormal (PT)	10061774
	Prothrombin time ratio abnormal (PT)	10061918
	Liver scan abnormal (PT)	10061947
	Hepatectomy (PT)	10061997
	Hepatic lesion (PT)	10061998
	Hepatobiliary disease (PT)	10062000
	Liver operation (PT)	10062040
	Hepatic enzyme abnormal (PT)	10062685
	Transaminases abnormal (PT)	10062688
	Cryptogenic cirrhosis (PT)	10063075
	Cholestatic pruritus (PT)	10064190
	Total bile acids increased (PT)	10064558
	Hepatic infiltration eosinophilic (PT)	10064668
	Graft versus host disease in liver (PT)	10064676

Listing 16.2.7-1.2 (Page 30 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Hepatotoxicity	Mitochondrial aspartate aminotransferase increased (PT)	10064712
	Portal vein pressure increased (PT)	10064936
	Hepatic calcification (PT)	10065274
	Pneumobilia (PT)	10066004
	Hepatobiliary scan abnormal (PT)	10066195
	Hepatic sequestration (PT)	10066244
	Acute graft versus host disease in liver (PT)	10066263
	Gastrooesophageal variceal haemorrhage prophylaxis (PT)	10066597
	Hepatic encephalopathy prophylaxis (PT)	10066599
	Mixed liver injury (PT)	10066758
	Molar ratio of total branched-chain amino acid to tyrosine (PT)	10066869
	Liver injury (PT)	10067125

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Hepatotoxicity	Portopulmonary hypertension (PT)	10067281
	Portal vein flow decreased (PT)	10067337
	Retrograde portal vein flow (PT)	10067338
	Hepatic hydrothorax (PT)	10067365
	Bilirubin conjugated abnormal (PT)	10067718
	Lupus hepatitis (PT)	10067737
	Splenic varices (PT)	10067823
	Cholestatic liver injury (PT)	10067969
	Hypertransaminasaemia (PT)	10068237
	Child-Pugh-Turcotte score increased (PT)	10068287
	Hepatic vascular resistance increased (PT)	10068358
	Acquired protein S deficiency (PT)	10068370
	Cytokeratin 18 increased (PT)	10068471
	Bacterascites (PT)	10068547

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Hepatotoxicity	Splenic varices haemorrhage (PT)	10068662
	Liver sarcoidosis (PT)	10068664
	Periportal oedema (PT)	10068821
	Portal hypertensive enteropathy (PT)	10068923
	Anorectal varices (PT)	10068924
	Anorectal varices haemorrhage (PT)	10068925
	Hepatic artery flow decreased (PT)	10068997
	Peritoneal fluid protein increased (PT)	10068998
	Peritoneal fluid protein decreased (PT)	10068999
	Peritoneal fluid protein abnormal (PT)	10069000
	Small-for-size liver syndrome (PT)	10069380
	Urobilinogen urine increased (PT)	10070479
	Urobilinogen urine decreased (PT)	10070480
	Acute yellow liver atrophy (PT)	10070815

Listing 16.2.7-1.2 (Page 33 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Hepatotoxicity	Reynold's syndrome (PT)	10070953
	Allergic hepatitis (PT)	10071198
	Diabetic hepatopathy (PT)	10071265
	Intestinal varices (PT)	10071502
	Deficiency of bile secretion (PT)	10071634
	Chronic graft versus host disease in liver (PT)	10072160
	Drug-induced liver injury (PT)	10072268
	Varicose veins of abdominal wall (PT)	10072284
	Gallbladder varices (PT)	10072319
	Intrahepatic portal hepatic venous fistula (PT)	10072629
	Portal vein dilatation (PT)	10073209
	Peripancreatic varices (PT)	10073215
	Portal vein cavernous transformation (PT)	10073979
	Hepatic fibrosis marker abnormal (PT)	10074084

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Listing 16.2.7-1.2 (Page 34 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Hepatotoxicity	Biliary ascites (PT)	10074150
	Parenteral nutrition associated liver disease (PT)	10074151
	Liver iron concentration abnormal (PT)	10074352
	Liver iron concentration increased (PT)	10074354
	Hepatic fibrosis marker increased (PT)	10074413
	Acquired antithrombin III deficiency (PT)	10074561
	Portal fibrosis (PT)	10074726
	Hyperfibrinolysis (PT)	10074737
	Stomal varices (PT)	10075186
	Portal tract inflammation (PT)	10075331
	Liver palpable (PT)	10075895
	Gastric variceal injection (PT)	10076237
	Gastric variceal ligation (PT)	10076238

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Listing 16.2.7-1.2 (Page 35 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Hepatotoxicity	Spontaneous intrahepatic portosystemic venous shunt (PT)	10076239
	Hepatic hypertrophy (PT)	10076254
	Steatohepatitis (PT)	10076331
	Liver dialysis (PT)	10076640
	Child-Pugh-Turcotte score abnormal (PT)	10077020
	Hepatic steato-fibrosis (PT)	10077215
	Non-cirrhotic portal hypertension (PT)	10077259
	Splenorenal shunt procedure (PT)	10077281
	Model for end stage liver disease score abnormal (PT)	10077291
	Model for end stage liver disease score increased (PT)	10077292
	Acute on chronic liver failure (PT)	10077305
	Bilirubin urine present (PT)	10077356

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Listing 16.2.7-1.2 (Page 36 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Hepatotoxicity	Portal shunt procedure (PT)	10077479
	Anti factor X activity abnormal (PT)	10077670
	Anti factor X activity increased (PT)	10077671
	Anti factor X activity decreased (PT)	10077674
	Liver function test decreased (PT)	10077677
	Liver function test increased (PT)	10077692
	Intestinal varices haemorrhage (PT)	10078058
	Computerised tomogram liver abnormal (PT)	10078360
	White nipple sign (PT)	10078438
	Immune-mediated hepatitis (PT)	10078962
	Portal hypertensive colopathy (PT)	10079446
	Hepatic lymphocytic infiltration (PT)	10079686
	Primary biliary cholangitis (PT)	10080429
	Alloimmune hepatitis (PT)	10080576

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Listing 16.2.7-1.2 (Page 37 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Hepatotoxicity	Regenerative siderotic hepatic nodule (PT)	10080679
	Glycocholic acid increased (PT)	10080824
	Acquired hepatocerebral degeneration (PT)	10080860
	Nonalcoholic fatty liver disease (PT)	10082249
	Magnetic resonance proton density fat fraction measurement (PT)	10082443
	Increased liver stiffness (PT)	10082444
	Multivisceral transplantation (PT)	10082450
	Cardiohepatic syndrome (PT)	10082480
	Osteopontin increased (PT)	10082708
	Acquired factor VIII deficiency (PT)	10082745
	Acquired factor XI deficiency (PT)	10082746
	Acquired factor IX deficiency (PT)	10082747
	AST/ALT ratio abnormal (PT)	10082832

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Hepatotoxicity	Sugiura procedure (PT)	10083010
	Hepatic venous pressure gradient increased (PT)	10083171
	Hepatic venous pressure gradient abnormal (PT)	10083172
	Liver transplant failure (PT)	10083175
	Immune-mediated cholangitis (PT)	10083406
	Immune-mediated hepatic disorder (PT)	10083521
	Splenic artery embolisation (PT)	10083795
	Hepatic perfusion disorder (PT)	10083840
	Congestive hepatopathy (PT)	10084058
	Liver opacity (PT)	10084071
	AST to platelet ratio index increased (PT)	10084175
	Hepatic hypoperfusion (PT)	10084751
	Flood syndrome (PT)	10084797

Listing 16.2.7-1.2 (Page 39 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Hepatotoxicity	Magnetic resonance imaging hepatobiliary abnormal (PT)	10085121
	Liver related investigations, signs and symptoms (SMQ) (broad)	20000008
	Cholestasis and jaundice of hepatic origin (SMQ) (broad)	20000009
	Hepatitis, non-infectious (SMQ) (broad)	20000010
	Hepatic failure, fibrosis and cirrhosis and other liver damage-related conditions (SMQ) (broad)	20000013
	Liver-related coagulation and bleeding disturbances (SMQ) (broad)	20000015
	Hepatotoxicity (excl neoplasms) (NMQ)	90000017
Interstitial lung disease and Pneumonitis	Alveolar proteinosis (PT)	10001881
	Alveolitis (PT)	10001889
	Bronchiolitis (PT)	10006448
	Eosinophilia myalgia syndrome (PT)	10014952

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Listing 16.2.7-1.2 (Page 40 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Interstitial lung disease and Pneumonitis	Eosinophilic pneumonia (PT)	10014962
	Idiopathic pulmonary fibrosis (PT)	10021240
	Interstitial lung disease (PT)	10022611
	Lung infiltration (PT)	10025102
	Obliterative bronchiolitis (PT)	10029888
	Pneumonitis (PT)	10035742
	Progressive massive fibrosis (PT)	10036805
	Pulmonary fibrosis (PT)	10037383
	Pulmonary vasculitis (PT)	10037457
	Radiation alveolitis (PT)	10037754
	Radiation fibrosis - lung (PT)	10037758
	Radiation pneumonitis (PT)	10037765
	Alveolitis necrotising (PT)	10050343

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Interstitial lung disease and Pneumonitis	Transfusion-related acute lung injury (PT)	10052235
	Eosinophilic pneumonia acute (PT)	10052832
	Eosinophilic pneumonia chronic (PT)	10052833
	Pulmonary necrosis (PT)	10058824
	Diffuse alveolar damage (PT)	10060902
	Pulmonary radiation injury (PT)	10061473
	Pulmonary toxicity (PT)	10061924
	Idiopathic pneumonia syndrome (PT)	10063725
	Acute interstitial pneumonitis (PT)	10066728
	Necrotising bronchiolitis (PT)	10070831
	Alveolar lung disease (PT)	10073344
	Combined pulmonary fibrosis and emphysema (PT)	10076515
	Eosinophilic granulomatosis with polyangiitis (PT)	10078117

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Listing 16.2.7-1.2 (Page 42 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Interstitial lung disease and Pneumonitis	Idiopathic interstitial pneumonia (PT)	10078268
	Small airways disease (PT)	10080547
	Autoimmune lung disease (PT)	10080701
	Lung opacity (PT)	10081792
	Hypersensitivity pneumonitis (PT)	10081988
	Bronchiolitis obliterans syndrome (PT)	10083303
	Pleuroparenchymal fibroelastosis (PT)	10084305
	Probable e-cigarette or vaping product use associated lung injury (PT)	10085188
	Confirmed e-cigarette or vaping product use associated lung injury (PT)	10085189
	Immune-mediated lung disease (PT)	10085352
	Rheumatoid arthritis-associated interstitial lung disease (PT)	10085517
	Interstitial lung disease (SMQ) (narrow)	20000042

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Pancreatitis	Amylase increased (PT)	10002016
	Lipase increased (PT)	10024574
	Lipase urine increased (PT)	10024578
	Pancreatic enzyme abnormality (PT)	10033619
	Pancreatic haemorrhage (PT)	10033625
	Pancreatic pseudocyst (PT)	10033635
	Pancreatic pseudocyst drainage (PT)	10033636
	Pancreatitis (PT)	10033645
	Pancreatitis acute (PT)	10033647
	Pancreatitis haemorrhagic (PT)	10033650
	Pancreatitis necrotising (PT)	10033654
	Pancreatitis relapsing (PT)	10033657
	Pancreatic abscess (PT)	10048984
	Peripancreatic fluid collection (PT)	10050466

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Pancreatitis	Oedematous pancreatitis (PT)	10052400
	Lipase abnormal (PT)	10054821
	Pancreatorenal syndrome (PT)	10056277
	Pancreatic phlegmon (PT)	10056975
	Hereditary pancreatitis (PT)	10056976
	Cullen's sign (PT)	10059029
	Pancreatic enzymes abnormal (PT)	10061899
	Pancreatic enzymes increased (PT)	10061900
	Hyperamylasaemia (PT)	10062770
	Blood trypsin increased (PT)	10064751
	Ischaemic pancreatitis (PT)	10066127
	Hyperlipasaemia (PT)	10067725
	Amylase abnormal (PT)	10072327
	Amylase creatinine clearance ratio abnormal (PT)	10073699

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Pancreatitis	Grey Turner's sign (PT)	10075426
	Haemorrhagic necrotic pancreatitis (PT)	10076058
	Pancreatic duct rupture (PT)	10076909
	Obstructive pancreatitis (PT)	10079822
	Pancreatic pseudoaneurysm (PT)	10081762
	Immune-mediated pancreatitis (PT)	10083072
	Pancreatic pseudocyst rupture (PT)	10083811
	Pancreatic pseudocyst haemorrhage (PT)	10083813
	Subacute pancreatitis (PT)	10084554
	Acute pancreatitis (excl non-specific symptoms) (NMQ) (broad)	90000402
Photosensitivity	Juvenile spring eruption (PT)	10023269
	Photoonycholysis (PT)	10034959
	Photosensitivity reaction (PT)	10034972

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Photosensitivity	Polymorphic light eruption (PT)	10036087
	Pseudoporphyria (PT)	10037145
	Solar dermatitis (PT)	10041303
	Solar urticaria (PT)	10041307
	Sunburn (PT)	10042496
	Photodermatosis (PT)	10051246
	Injection site photosensitivity reaction (PT)	10053396
	Application site photosensitivity reaction (PT)	10058730
	Infusion site photosensitivity reaction (PT)	10065486
	Retinal phototoxicity (PT)	10069652
	Chronic actinic dermatitis (PT)	10072578
	Implant site photosensitivity (PT)	10073415
	Hydroa vacciniforme (PT)	10083442
	Photosensitivity reactions (NMQ)	90000921

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
QTc interval prolongation	Cardiac arrest (PT)	10007515
	Cardio-respiratory arrest (PT)	10007617
	Electrocardiogram QT prolonged (PT)	10014387
	Long QT syndrome (PT)	10024803
	Loss of consciousness (PT)	10024855
	Sudden death (PT)	10042434
	Syncope (PT)	10042772
	Torsade de pointes (PT)	10044066
	Ventricular arrhythmia (PT)	10047281
	Ventricular fibrillation (PT)	10047290
	Ventricular flutter (PT)	10047294
	Ventricular tachycardia (PT)	10047302
	Sudden cardiac death (PT)	10049418
	Cardiac death (PT)	10049993

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
QTc interval prolongation	Electrocardiogram repolarisation abnormality (PT)	10052464
	Electrocardiogram U-wave abnormality (PT)	10055032
	Electrocardiogram U wave present (PT)	10057913
	Long QT syndrome congenital (PT)	10057926
	Cardiac fibrillation (PT)	10061592
	Electrocardiogram U wave inversion (PT)	10062314
	Electrocardiogram QT interval abnormal (PT)	10063748
	Ventricular tachyarrhythmia (PT)	10065341
	Torsade de pointes/QT prolongation (SMQ) (broad)	20000001
Renal dysfunction	Albuminuria (PT)	10001580
	Anuria (PT)	10002847
	Azotaemia (PT)	10003885
	Blood creatinine abnormal (PT)	10005481
	Blood creatinine increased (PT)	10005483

Listing 16.2.7-1.2 (Page 49 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Renal dysfunction	Blood urea abnormal (PT)	10005846
	Blood urea increased (PT)	10005851
	Creatinine renal clearance decreased (PT)	10011372
	Glomerular filtration rate abnormal (PT)	10018356
	Glomerular filtration rate decreased (PT)	10018358
	Haemodialysis (PT)	10018875
	Nephritis (PT)	10029117
	Nephropathy toxic (PT)	10029155
	Oliguria (PT)	10030302
	Peritoneal dialysis (PT)	10034660
	Proteinuria (PT)	10037032
	Renal failure (PT)	10038435
	Renal failure neonatal (PT)	10038447
	Renal transplant (PT)	10038533

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Listing 16.2.7-1.2 (Page 50 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Renal dysfunction	Renal tubular disorder (PT)	10038537
	Renal tubular necrosis (PT)	10038540
	Urea renal clearance decreased (PT)	10046358
	Tubulointerstitial nephritis (PT)	10048302
	Oedema due to renal disease (PT)	10049630
	Renal impairment neonatal (PT)	10049776
	Neonatal anuria (PT)	10049778
	Renal tubular dysfunction (PT)	10050335
	Blood urea nitrogen/creatinine ratio increased (PT)	10050760
	Haemofiltration (PT)	10053090
	Protein urine present (PT)	10053123
	Creatinine urine decreased (PT)	10055003
	Urine output decreased (PT)	10059895
	Dialysis (PT)	10061105

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Renal dysfunction	Renal function test abnormal (PT)	10061480
	Renal impairment (PT)	10062237
	Hypercreatininaemia (PT)	10062747
	Continuous haemodiafiltration (PT)	10066338
	Creatinine renal clearance abnormal (PT)	10068447
	Kidney injury molecule-1 (PT)	10069022
	Acute kidney injury (PT)	10069339
	Acute phosphate nephropathy (PT)	10069688
	Creatinine urine abnormal (PT)	10071021
	Crystal nephropathy (PT)	10071503
	Prerenal failure (PT)	10072370
	Intradialytic parenteral nutrition (PT)	10074739
	Fractional excretion of sodium (PT)	10075142
	Hyponatriuria (PT)	10077515

Listing 16.2.7-1.2 (Page 52 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Renal dysfunction	Renal tubular injury (PT)	10078933
	Foetal renal impairment (PT)	10078987
	Subacute kidney injury (PT)	10081980
	Neutrophil gelatinase-associated lipocalin increased (PT)	10082703
	Acute renal failure (SMQ) (broad)	20000003
Teratogenicity	Eclampsia (PT)	10014129
	Hypokinesia neonatal (PT)	10021022
	Infantile spasms (PT)	10021750
	Tremor neonatal (PT)	10044575
	Hypertonia neonatal (PT)	10048615
	Lafora's myoclonic epilepsy (PT)	10054030
	Baltic myoclonic epilepsy (PT)	10054895
	Benign familial neonatal convulsions (PT)	10067866

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Molybdenum cofactor deficiency (PT)	10069687
	Myoclonic epilepsy and ragged-red fibres (PT)	10069825
	Biotinidase deficiency (PT)	10071434
	Early infantile epileptic encephalopathy with burst-suppression (PT)	10071545
	Schizencephaly (PT)	10073487
	Polymicrogyria (PT)	10073489
	Double cortex syndrome (PT)	10073490
	Severe myoclonic epilepsy of infancy (PT)	10073677
	Hemimegalencephaly (PT)	10078100
	Glucose transporter type 1 deficiency syndrome (PT)	10078727
	2-Hydroxyglutaric aciduria (PT)	10078971
	Aspartate-glutamate-transporter deficiency (PT)	10079140
	Tuberous sclerosis complex (PT)	10080584

Listing 16.2.7-1.2 (Page 54 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Epilepsy with myoclonic-atonic seizures (PT)	10081179
	Neonatal seizure (PT)	10082067
	Neonatal epileptic seizure (PT)	10082068
	Grey matter heterotopia (PT)	10082084
	1p36 deletion syndrome (PT)	10082398
	Congenital bilateral perisylvian syndrome (PT)	10082716
	CDKL5 deficiency disorder (PT)	10083005
	CEC syndrome (PT)	10083749
	Alpers disease (PT)	10083857
	GM2 gangliosidosis (PT)	10083933
	Parenteral nutrition associated liver disease (PT)	10074151
	11-beta-hydroxylase deficiency (PT)	10000002
	17,20-desmolase deficiency (PT)	10000013
	17-alpha-hydroxylase deficiency (PT)	10000014

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Listing 16.2.7-1.2 (Page 55 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	20,22-desmolase deficiency (PT)	10000020
	21-hydroxylase deficiency (PT)	10000021
	5-alpha-reductase deficiency (PT)	10000029
	Abdominal transposition (PT)	10000098
	Abdominal wall anomaly (PT)	10000101
	Abnormal labour (PT)	10000153
	Abnormal labour affecting foetus (PT)	10000154
	Abnormal palmar/plantar creases (PT)	10000162
	ABO haemolytic disease of newborn (PT)	10000205
	ABO incompatibility (PT)	10000206
	Aborted pregnancy (PT)	10000209
	Abortion (PT)	10000210
	Abortion complete complicated (PT)	10000212
	Abortion incomplete (PT)	10000217

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Abortion incomplete complicated (PT)	10000218
	Abortion induced (PT)	10000220
	Abortion induced complete complicated (PT)	10000221
	Abortion induced complicated (PT)	10000223
	Abortion induced incomplete complicated (PT)	10000225
	Abortion infected (PT)	10000228
	Abortion missed (PT)	10000230
	Abortion spontaneous (PT)	10000234
	Abortion spontaneous complete complicated (PT)	10000236
	Abortion spontaneous complicated (PT)	10000238
	Abortion spontaneous incomplete complicated (PT)	10000239
	Abortion threatened (PT)	10000242
	Accessory auricle (PT)	10000361
	Accessory carpal bone (PT)	10000362

Listing 16.2.7-1.2 (Page 57 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Accessory muscle (PT)	10000364
	Accessory salivary gland (PT)	10000368
	Acne infantile (PT)	10000507
	Acrocephalosyndactyly (PT)	10000590
	Acrodermatitis enteropathica (PT)	10000596
	Acute fatty liver of pregnancy (PT)	10000746
	Adrenal insufficiency neonatal (PT)	10001368
	Adrenocortical insufficiency neonatal (PT)	10001391
	Agitation neonatal (PT)	10001500
	Aglossia (PT)	10001501
	Albinism (PT)	10001557
	Alkaptonuria (PT)	10001689
	Alpha 1 foetoprotein abnormal (PT)	10001773
	Alpha 1 foetoprotein amniotic fluid abnormal (PT)	10001776

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Alpha 1 foetoprotein amniotic fluid increased (PT)	10001778
	Alpha 1 foetoprotein amniotic fluid normal (PT)	10001779
	Alpha 1 foetoprotein decreased (PT)	10001780
	Alpha 1 foetoprotein increased (PT)	10001781
	Alpha 1 foetoprotein normal (PT)	10001782
	Alport's syndrome (PT)	10001843
	Amblyopia congenital (PT)	10001908
	Aminoaciduria (PT)	10001939
	Amniocentesis abnormal (PT)	10001959
	Amniocentesis normal (PT)	10001963
	Amnioscopy abnormal (PT)	10001965
	Amnioscopy normal (PT)	10001966
	Anaemia neonatal (PT)	10002068
	Anal atresia (PT)	10002120

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Anencephaly (PT)	10002320
	Aniridia (PT)	10002532
	Anodontia (PT)	10002583
	Anomaly of orbit, congenital (PT)	10002633
	Anophthalmos (PT)	10002640
	Anorchism (PT)	10002641
	Anotia (PT)	10002654
	Antiphospholipid syndrome (PT)	10002817
	Antithrombin III deficiency (PT)	10002832
	Apgar score low (PT)	10002944
	Aphakia congenital (PT)	10002947
	Aplasia (PT)	10002961
	Aplasia cutis congenita (PT)	10002963
	Arnold-Chiari malformation (PT)	10003101

Listing 16.2.7-1.2 (Page 60 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Arrested labour (PT)	10003118
	Arrhythmia neonatal (PT)	10003124
	Arteriovenous malformation (PT)	10003193
	Artificial rupture of membranes (PT)	10003440
	Ataxia telangiectasia (PT)	10003594
	Atelectasis neonatal (PT)	10003599
	Atrial septal defect (PT)	10003664
	Atrial septal defect repair (PT)	10003667
	Bacteriuria in pregnancy (PT)	10004058
	Benign familial pemphigus (PT)	10004265
	Benign hydatidiform mole (PT)	10004272
	Bicuspid aortic valve (PT)	10004552
	Birth mark (PT)	10004950
	Birth trauma (PT)	10004954

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Blindness congenital (PT)	10005176
	Blood loss anaemia neonatal (PT)	10005644
	Bradycardia foetal (PT)	10006094
	Branchial cleft sinus (PT)	10006162
	Branchial cyst (PT)	10006164
	Breast engorgement (PT)	10006240
	Breast engorgement in newborn (PT)	10006241
	Breast malformation (PT)	10006271
	Breech delivery (PT)	10006346
	Breech extraction (PT)	10006348
	Breech presentation (PT)	10006356
	Brief psychotic disorder, with postpartum onset (PT)	10006362
	Bronchopulmonary dysplasia (PT)	10006475
	Caesarean section (PT)	10006924

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Carcinogenic effect in offspring (PT)	10007268
	Cardiac arrest neonatal (PT)	10007516
	Cardiac malposition (PT)	10007585
	Cardio-respiratory arrest neonatal (PT)	10007618
	Carpus curvus (PT)	10007700
	Cataract congenital (PT)	10007747
	Central nervous system dermoid tumour (PT)	10007942
	Cephalhaematoma (PT)	10008014
	Cephalo-pelvic disproportion (PT)	10008020
	Cerebellar hypoplasia (PT)	10008033
	Cerebral arteriovenous malformation haemorrhagic (PT)	10008086
	Cerebral haemorrhage neonatal (PT)	10008112
	Cerebral infarction foetal (PT)	10008119

Listing 16.2.7-1.2 (Page 63 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Cerebral palsy (PT)	10008129
	Cervical auricle (PT)	10008227
	Cervical incompetence (PT)	10008267
	Chediak-Higashi syndrome (PT)	10008415
	Chloasma (PT)	10008570
	Choanal atresia (PT)	10008587
	Choledochal cyst (PT)	10008625
	Chondrodystrophy (PT)	10008723
	Chondroectodermal dysplasia (PT)	10008724
	Chordee (PT)	10008746
	Chorioretinal degeneration congenital (PT)	10008763
	Chronic granulomatous disease (PT)	10008906
	Circulatory failure neonatal (PT)	10009196
	Cleft lip (PT)	10009259

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Listing 16.2.7-1.2 (Page 64 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Cleft lip and palate (PT)	10009260
	Cleft palate (PT)	10009269
	Cleft palate repair (PT)	10009272
	Coagulation disorder neonatal (PT)	10009732
	Coarctation of the aorta (PT)	10009807
	Cockayne's syndrome (PT)	10009835
	Collodion baby (PT)	10009926
	Coloboma (PT)	10009934
	Colour blindness (PT)	10010050
	Combined immunodeficiency (PT)	10010099
	Congenital absence of bile ducts (PT)	10010317
	Congenital absence of cranial vault (PT)	10010318
	Congenital absence of vertebra (PT)	10010320
	Congenital anaemia (PT)	10010329

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Congenital anomalies of ear ossicles (PT)	10010341
	Congenital anomaly (PT)	10010356
	Congenital aortic atresia (PT)	10010368
	Congenital aortic stenosis (PT)	10010369
	Congenital aortic valve incompetence (PT)	10010370
	Congenital aortic valve stenosis (PT)	10010371
	Congenital arteriovenous fistula (PT)	10010374
	Congenital bladder diverticulum (PT)	10010381
	Congenital bladder neck obstruction (PT)	10010382
	Congenital brain damage (PT)	10010390
	Congenital bronchiectasis (PT)	10010391
	Congenital bronchomalacia (PT)	10010392
	Congenital central nervous system anomaly (PT)	10010411
	Congenital clavicular agenesis (PT)	10010416

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Congenital claw toe (PT)	10010417
	Congenital cystic kidney disease (PT)	10010428
	Congenital cystic lung (PT)	10010429
	Congenital cytomegalovirus infection (PT)	10010430
	Congenital deformity of clavicle (PT)	10010434
	Congenital diaphragmatic eventration (PT)	10010438
	Congenital diaphragmatic hernia (PT)	10010439
	Congenital ectodermal dysplasia (PT)	10010452
	Congenital ectopic bladder (PT)	10010453
	Congenital elevation of scapula (PT)	10010455
	Congenital emphysema (PT)	10010456
	Congenital flaccid paralysis (PT)	10010474
	Congenital flat feet (PT)	10010475
	Congenital genital malformation female (PT)	10010481

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Congenital hearing disorder (PT)	10010493
	Congenital hepatitis B infection (PT)	10010496
	Congenital hiatus hernia (PT)	10010501
	Congenital HIV infection (PT)	10010504
	Congenital hydrocephalus (PT)	10010506
	Congenital hypertrichosis (PT)	10010507
	Congenital hypothyroidism (PT)	10010510
	Congenital knee dislocation (PT)	10010520
	Congenital lacrimal gland anomaly (PT)	10010523
	Congenital large intestinal atresia (PT)	10010526
	Congenital laryngeal stridor (PT)	10010527
	Congenital lip fistula (PT)	10010532
	Congenital lymphoedema (PT)	10010535
	Congenital malaria (PT)	10010538

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Congenital megacolon (PT)	10010539
	Congenital megaureter (PT)	10010540
	Congenital melanosis (PT)	10010541
	Congenital methaemoglobinaemia (PT)	10010543
	Congenital mitral valve incompetence (PT)	10010547
	Congenital mitral valve stenosis (PT)	10010548
	Congenital muscle absence (PT)	10010550
	Congenital nail disorder (PT)	10010557
	Congenital neurological degeneration (PT)	10010558
	Congenital night blindness (PT)	10010559
	Congenital nystagmus (PT)	10010562
	Congenital oesophageal stenosis (PT)	10010564
	Congenital oesophageal web (PT)	10010565
	Congenital osteodystrophy (PT)	10010582

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Congenital perforated nasal septum (PT)	10010588
	Congenital pigmentation disorder (PT)	10010593
	Congenital pneumonia (PT)	10010594
	Congenital renal cyst (PT)	10010607
	Congenital rubella infection (PT)	10010619
	Congenital salivary gland anomaly (PT)	10010620
	Congenital small intestinal atresia (PT)	10010626
	Congenital spinal fusion (PT)	10010629
	Congenital spondylolisthesis (PT)	10010633
	Congenital spondylolysis (PT)	10010634
	Congenital syphilis (PT)	10010641
	Congenital syphilitic encephalitis (PT)	10010643
	Congenital syphilitic meningitis (PT)	10010644
	Congenital torticollis (PT)	10010650

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Congenital toxoplasmosis (PT)	10010652
	Congenital tracheomalacia (PT)	10010654
	Congenital tricuspid valve stenosis (PT)	10010656
	Congenital tuberculosis (PT)	10010657
	Congenital umbilical hernia (PT)	10010658
	Congenital urinary tract obstruction (PT)	10010663
	Congenital varicella infection (PT)	10010668
	Congenital vas deferens absence (PT)	10010670
	Congenital vesicoureteric reflux (PT)	10010672
	Conjoined twins (PT)	10010688
	Conjunctivitis gonococcal neonatal (PT)	10010749
	Cor biloculare (PT)	10010967
	Cor triatriatum (PT)	10010972
	Corneal dystrophy (PT)	10011005

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Corneal opacity congenital (PT)	10011037
	Corrected transposition of great vessels (PT)	10011120
	Coxsackie viral disease of the newborn (PT)	10011260
	Cranial nerve injury secondary to birth trauma (PT)	10011308
	Craniorachischisis (PT)	10011321
	Cri du Chat syndrome (PT)	10011385
	Crigler-Najjar syndrome (PT)	10011386
	Cryptophthalmos (PT)	10011497
	Cryptorchism (PT)	10011498
	Cyanosis neonatal (PT)	10011705
	Cystic eyeball, congenital (PT)	10011761
	Cystic fibrosis (PT)	10011762
	Cystic fibrosis lung (PT)	10011763
	Cystic fibrosis pancreatic (PT)	10011766

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Cystinosis (PT)	10011777
	Cystinuria (PT)	10011778
	Dacryostenosis congenital (PT)	10011850
	Deaf mutism (PT)	10011875
	Deafness congenital (PT)	10011882
	Death neonatal (PT)	10011912
	Delayed delivery (PT)	10012186
	Delta-beta thalassaemia (PT)	10012236
	Dentofacial anomaly (PT)	10012331
	Dermoid cyst (PT)	10012522
	Developmental glaucoma (PT)	10012565
	Dextrocardia (PT)	10012592
	Diabetes complicating pregnancy (PT)	10012596
	Diaphragmatic aplasia (PT)	10012711

Listing 16.2.7-1.2 (Page 73 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Diarrhoea neonatal (PT)	10012743
	Diarrhoea infectious neonatal (PT)	10012744
	Diastematomyelia (PT)	10012750
	Diencephalic syndrome of infancy (PT)	10012774
	Diethylstilboestrol syndrome (PT)	10012780
	DiGeorge's syndrome (PT)	10012979
	Dilatation intrahepatic duct congenital (PT)	10013003
	Disseminated intravascular coagulation in newborn (PT)	10013443
	Diverticulitis Meckel's (PT)	10013542
	Diverticulum of pharynx, congenital (PT)	10013568
	Double heterozygous sickling disorders (PT)	10013609
	Double outlet right ventricle (PT)	10013611
	Double ureter (PT)	10013613

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Drug dependence, antepartum (PT)	10013675
	Drug dependence, postpartum (PT)	10013676
	Drug withdrawal syndrome neonatal (PT)	10013756
	Duane's syndrome (PT)	10013799
	Dubin-Johnson syndrome (PT)	10013800
	Duchenne muscular dystrophy (PT)	10013801
	Ductus arteriosus stenosis foetal (PT)	10013808
	Duodenal atresia (PT)	10013812
	Dyskinesia neonatal (PT)	10013922
	Dysplastic naevus syndrome (PT)	10013960
	Ear malformation (PT)	10014016
	Ebstein's anomaly (PT)	10014075
	Ectopia cordis (PT)	10014144
	Ectopic pregnancy (PT)	10014166

Listing 16.2.7-1.2 (Page 75 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Ectopic pregnancy termination (PT)	10014168
	Ectopic ureter (PT)	10014172
	Eczema infantile (PT)	10014198
	Ehlers-Danlos syndrome (PT)	10014316
	Elderly primigravida (PT)	10014349
	Elliptocytosis hereditary (PT)	10014490
	Encephalocele (PT)	10014617
	Encephalopathy neonatal (PT)	10014633
	Endocardial cushion defect repair (PT)	10014657
	Endocardial fibroelastosis (PT)	10014663
	Endometritis decidual (PT)	10014792
	Entropion congenital (PT)	10014923
	Epidermal naevus (PT)	10014985
	Epidermolysis bullosa (PT)	10014989

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Epilepsy congenital (PT)	10015039
	Epispadias (PT)	10015088
	Erythroblastosis foetalis (PT)	10015251
	Essential fructosuria (PT)	10015487
	Evacuation of retained products of conception (PT)	10015550
	Exomphalos (PT)	10015677
	Extraocular retinoblastoma (PT)	10015831
	Eyelid ptosis congenital (PT)	10015996
	Fabry's disease (PT)	10016016
	Face presentation (PT)	10016035
	Facial nerve injury due to birth trauma (PT)	10016056
	Factor I deficiency (PT)	10016075
	Factor II deficiency (PT)	10016076
	Factor IX deficiency (PT)	10016077

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Factor VII deficiency (PT)	10016079
	Factor VIII deficiency (PT)	10016080
	Factor XI deficiency (PT)	10016082
	Factor XIII deficiency (PT)	10016083
	Failed forceps delivery (PT)	10016116
	Failed induction of labour (PT)	10016123
	Failed trial of labour (PT)	10016142
	Failure to thrive (PT)	10016165
	Fallot's tetralogy (PT)	10016193
	False labour (PT)	10016194
	Familial amyloidosis (PT)	10016202
	Familial mediterranean fever (PT)	10016207
	Familial periodic paralysis (PT)	10016208
	Familial polycythaemia (PT)	10016209

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Familial tremor (PT)	10016212
	Fanconi syndrome (PT)	10016219
	Fever neonatal (PT)	10016562
	Fibrous dysplasia of bone (PT)	10016664
	Fissure of tongue, congenital (PT)	10016715
	Foetal alcohol syndrome (PT)	10016845
	Foetal arm prolapse (PT)	10016846
	Foetal arrhythmia (PT)	10016847
	Foetal damage (PT)	10016852
	Foetal distress syndrome (PT)	10016855
	Foetal malnutrition (PT)	10016862
	Foetal malposition (PT)	10016863
	Foetal-maternal haemorrhage (PT)	10016871
	Fontanelle bulging (PT)	10016945

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Forceps delivery (PT)	10016991
	Fracture of clavicle due to birth trauma (PT)	10017107
	Fragile X syndrome (PT)	10017324
	Friedreich's ataxia (PT)	10017374
	Galactocele (PT)	10017590
	Galactosaemia (PT)	10017604
	Gangrene neonatal (PT)	10017717
	Gastrointestinal arteriovenous malformation (PT)	10017932
	Gastroschisis (PT)	10018046
	Gaucher's disease (PT)	10018048
	Generalised resistance to thyroid hormone (PT)	10018096
	Genitalia external ambiguous (PT)	10018183
	Gestational diabetes (PT)	10018209
	Gilbert's syndrome (PT)	10018267

Listing 16.2.7-1.2 (Page 80 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Glanzmann's disease (PT)	10018303
	Glucose tolerance impaired in pregnancy (PT)	10018430
	Glucose-6-phosphate dehydrogenase deficiency (PT)	10018444
	Glycogen storage disease type V (PT)	10018462
	Glycogen storage disease type I (PT)	10018464
	Glycosuria during pregnancy (PT)	10018475
	Goitre congenital (PT)	10018499
	Gonadal dysgenesis (PT)	10018504
	Granulocytopenia neonatal (PT)	10018688
	Grey syndrome neonatal (PT)	10018723
	Haemangioma congenital (PT)	10018818
	Haemangioma of retina (PT)	10018822
	Haemoglobin C disease (PT)	10018883
	Haemorrhage in pregnancy (PT)	10018981

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Haemorrhagic disease of newborn (PT)	10019008
	Hamartoma vascular (PT)	10019106
	Harlequin foetus (PT)	10019163
	Hartnup disease (PT)	10019165
	Heart block congenital (PT)	10019263
	Heart disease congenital (PT)	10019273
	Hemihypertrophy (PT)	10019463
	Hemivertebra (PT)	10019477
	Hepatic arteriovenous malformation (PT)	10019633
	Hepatitis neonatal (PT)	10019785
	Hepato-lenticular degeneration (PT)	10019819
	Hepatocellular damage neonatal (PT)	10019834
	Hepatosplenomegaly neonatal (PT)	10019848
	Hereditary angioedema (PT)	10019860

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Hereditary choroidal dystrophy (PT)	10019864
	Hereditary fructose intolerance (PT)	10019878
	Hereditary haemorrhagic telangiectasia (PT)	10019883
	Hereditary neuropathic amyloidosis (PT)	10019889
	Hereditary optic atrophy (PT)	10019895
	Hereditary retinal dystrophy (PT)	10019899
	Hereditary sideroblastic anaemia (PT)	10019902
	Hereditary spastic paraplegia (PT)	10019903
	Hereditary spherocytosis (PT)	10019904
	Hermaphroditism (PT)	10019906
	Hernia congenital (PT)	10019912
	Herpes gestationis (PT)	10019939
	Congenital herpes simplex infection (PT)	10019949
	Hexokinase deficiency anaemia (PT)	10020022

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	High arched palate (PT)	10020046
	High foetal head (PT)	10020065
	Homocystinuria (PT)	10020365
	Hydrocele (PT)	10020488
	Hydrops foetalis (PT)	10020529
	Hyperbilirubinaemia neonatal (PT)	10020580
	Hyperemesis gravidarum (PT)	10020614
	Hyperkinesia neonatal (PT)	10020652
	Hypertrophic cardiomyopathy (PT)	10020871
	Hypochondroplasia (PT)	10020967
	Hypoglycaemia neonatal (PT)	10020994
	Hypopituitarism foetal (PT)	10021068
	Hypoplastic left heart syndrome (PT)	10021076
	Hypospadias (PT)	10021093

Listing 16.2.7-1.2 (Page 84 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Hypotonia neonatal (PT)	10021119
	Hypoventilation neonatal (PT)	10021134
	Ichthyosis (PT)	10021198
	Ileal atresia (PT)	10021298
	Immature respiratory system (PT)	10021412
	Immunodeficiency congenital (PT)	10021450
	Imperforate hymen (PT)	10021529
	Imperforate oesophagus (PT)	10021530
	Impetigo herpetiformis (PT)	10021534
	Incoordinate uterine action (PT)	10021648
	Induced labour (PT)	10021718
	Infantile colic (PT)	10021746
	Infantile scurvy (PT)	10021749
	Iniencephaly (PT)	10022034

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Injury to brachial plexus due to birth trauma (PT)	10022158
	Injury to spinal cord secondary to birth trauma (PT)	10022343
	Interruption of aortic arch (PT)	10022599
	Intestinal transposition (PT)	10022712
	Intraventricular haemorrhage neonatal (PT)	10022841
	Isoimmune haemolytic disease (PT)	10023052
	Jaundice neonatal (PT)	10023138
	Keratosis follicular (PT)	10023369
	Kernicterus (PT)	10023376
	Kidney duplex (PT)	10023416
	Kidney malformation (PT)	10023430
	Klinefelter's syndrome (PT)	10023463
	Klippel-Feil syndrome (PT)	10023464
	Krabbe's disease (PT)	10023492

Listing 16.2.7-1.2 (Page 86 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Lacrimal punctum agenesis (PT)	10023636
	Lactation puerperal increased (PT)	10023671
	Large for dates baby (PT)	10023789
	Laryngeal web (PT)	10023871
	Laryngocele (PT)	10023885
	Late metabolic acidosis of newborn (PT)	10024004
	Lens abnormality, congenital (PT)	10024202
	Leukodystrophy (PT)	10024381
	Lichen spinulosus (PT)	10024436
	Limb malformation (PT)	10024500
	Limb reduction defect (PT)	10024503
	Lipidosis (PT)	10024585
	Locked twins (PT)	10024787
	Low set ears (PT)	10024929

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Lown-Ganong-Levine syndrome (PT)	10024984
	Lymphocytopenia neonatal (PT)	10025279
	Macrocheilia (PT)	10025378
	Macrodactyly (PT)	10025386
	Macrogenia (PT)	10025387
	Macroglossia (PT)	10025391
	Macrostomia (PT)	10025395
	Macrotia (PT)	10025396
	Macular dystrophy congenital (PT)	10025412
	Malformation biliary (PT)	10025523
	Malformation venous (PT)	10025532
	Malignant hydatidiform mole (PT)	10025598
	Malignant neoplasm of placenta (PT)	10026350
	Maple syrup disease (PT)	10026817

Listing 16.2.7-1.2 (Page 88 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Marfan's syndrome (PT)	10026829
	Mastitis (PT)	10026883
	Mastitis postpartum (PT)	10026889
	Maternal death affecting foetus (PT)	10026912
	Maternal drugs affecting foetus (PT)	10026923
	Maternal hypertension affecting foetus (PT)	10026924
	Meconium ileus (PT)	10027058
	Meconium increased (PT)	10027059
	Melkersson-Rosenthal syndrome (PT)	10027166
	Meningocele (PT)	10027266
	Meningomyelocele (PT)	10027287
	Menkes' syndrome (PT)	10027294
	Mesonephric duct cyst (PT)	10027405
	Metatarsus primus varus (PT)	10027489

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Microcephaly (PT)	10027534
	Microcheilia (PT)	10027535
	Microgenia (PT)	10027541
	Microglossia (PT)	10027542
	Micrognathia (PT)	10027543
	Microphthalmos (PT)	10027548
	Microstomia (PT)	10027553
	Microtia (PT)	10027555
	Mitochondrial myopathy (PT)	10027710
	Moebius II syndrome (PT)	10027802
	Morning glory syndrome (PT)	10027974
	Morning sickness (PT)	10027975
	Mucopolysaccharidosis (PT)	10028093
	Mucopolysaccharidosis IV (PT)	10028095

Listing 16.2.7-1.2 (Page 90 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Multigravida (PT)	10028160
	Multiparous (PT)	10028163
	Multiple carboxylase deficiency (PT)	10028176
	Multiple cardiac defects (PT)	10028178
	Multiple congenital abnormalities (PT)	10028182
	Multiple epiphyseal dysplasia (PT)	10028197
	Multiple gastrointestinal atresias (PT)	10028210
	Multiple pregnancy (PT)	10028243
	Muscular dystrophy (PT)	10028356
	Mutagenic effect (PT)	10028400
	Myasthenia gravis neonatal (PT)	10028419
	Mycoplasmal postabortal fever (PT)	10028479
	Myotonia congenita (PT)	10028655
	Neonatal alveolar aeration excessive (PT)	10028918

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Listing 16.2.7-1.2 (Page 91 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Neonatal anoxia (PT)	10028921
	Neonatal asphyxia (PT)	10028923
	Neonatal candida infection (PT)	10028924
	Neonatal diabetes mellitus (PT)	10028933
	Neonatal disorder (PT)	10028934
	Neonatal exchange blood transfusion (PT)	10028937
	Neonatal infective mastitis (PT)	10028950
	Neonatal intestinal obstruction (PT)	10028951
	Neonatal leukaemia (PT)	10028958
	Neonatal respiratory acidosis (PT)	10028966
	Neonatal respiratory alkalosis (PT)	10028967
	Neonatal respiratory arrest (PT)	10028968
	Neonatal respiratory depression (PT)	10028970
	Neonatal respiratory distress (PT)	10028973

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Neonatal respiratory distress syndrome (PT)	10028974
	Neonatal respiratory failure (PT)	10028975
	Neonatal thyrotoxicosis (PT)	10028976
	Neuroblastoma (PT)	10029260
	Neurofibromatosis (PT)	10029268
	Neutropenia neonatal (PT)	10029358
	Niemann-Pick disease (PT)	10029403
	Nipple infection (PT)	10029419
	Noonan syndrome (PT)	10029748
	Normal labour (PT)	10029767
	Normal newborn (PT)	10029769
	Nulliparous (PT)	10029827
	Obstetrical pulmonary embolism (PT)	10029925
	Obstructed labour (PT)	10029934

Listing 16.2.7-1.2 (Page 93 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Oesophageal atresia (PT)	10030146
	Oligohydramnios (PT)	10030289
	Omphalitis (PT)	10030306
	Ophthalmia neonatorum (PT)	10030861
	Osteogenesis imperfecta (PT)	10031243
	Osteopetrosis (PT)	10031280
	Osteopoikilosis (PT)	10031281
	Ovarian agenesis (PT)	10033120
	Parity (PT)	10033997
	Patent ductus arteriosus (PT)	10034130
	Patent ductus arteriosus repair (PT)	10034131
	Pectus carinatum (PT)	10034203
	Pectus excavatum (PT)	10034204
	Pelvic haematoma obstetric (PT)	10034248

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Pelvic kidney (PT)	10034259
	Perineal haematoma (PT)	10034520
	Perineal repair breakdown (PT)	10034528
	Persistent foetal circulation (PT)	10034708
	Peutz-Jeghers syndrome (PT)	10034764
	Phenylketonuria (PT)	10034872
	Phimosis (PT)	10034878
	Pituitary infarction (PT)	10035092
	Placenta praevia (PT)	10035119
	Placenta praevia haemorrhage (PT)	10035121
	Placental disorder (PT)	10035132
	Placental insufficiency (PT)	10035138
	Placental necrosis (PT)	10035139
	Placental polyp (PT)	10035142

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Placental transfusion syndrome (PT)	10035146
	Poland's syndrome (PT)	10036007
	Polydactyly (PT)	10036063
	Polyhydramnios (PT)	10036079
	Porencephaly (PT)	10036172
	Porokeratosis (PT)	10036175
	Porphyria (PT)	10036181
	Porphyria acute (PT)	10036182
	Porphyria non-acute (PT)	10036186
	Porphyrinuria (PT)	10036193
	Post abortion complication (PT)	10036244
	Post abortion haemorrhage (PT)	10036246
	Postpartum hypopituitarism (PT)	10036297
	Postpartum venous thrombosis (PT)	10036300

Listing 16.2.7-1.2 (Page 96 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Postauricular fistula (PT)	10036329
	Postmature baby (PT)	10036392
	Postpartum haemorrhage (PT)	10036417
	Postpartum neurosis (PT)	10036419
	Postpartum sepsis (PT)	10036422
	Postpartum uterine subinvolution (PT)	10036423
	Potter's syndrome (PT)	10036462
	Prader-Willi syndrome (PT)	10036476
	Pre-eclampsia (PT)	10036485
	Preauricular cyst (PT)	10036509
	Precipitate labour (PT)	10036519
	Pregnancy (PT)	10036556
	Pregnancy in habitual aborter (PT)	10036562
	Pregnancy on oral contraceptive (PT)	10036567

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Pregnancy test positive (PT)	10036575
	Pregnancy test urine positive (PT)	10036578
	Pregnancy with advanced maternal age (PT)	10036582
	Premature baby (PT)	10036590
	Premature delivery (PT)	10036595
	Premature labour (PT)	10036600
	Premature rupture of membranes (PT)	10036603
	Premature separation of placenta (PT)	10036608
	Previous caesarean section (PT)	10036656
	Primary cerebellar degeneration (PT)	10036686
	Primigravida (PT)	10036757
	Primiparous (PT)	10036758
	Progeria (PT)	10036794
	Progressive cerebellar degeneration (PT)	10036801

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Progressive external ophthalmoplegia (PT)	10036802
	Prolonged labour (PT)	10036872
	Prolonged pregnancy (PT)	10036877
	Pseudohermaphroditism (PT)	10037122
	Pseudohermaphroditism female (PT)	10037123
	Pseudohermaphroditism male (PT)	10037124
	Pseudohypoparathyroidism (PT)	10037126
	Pseudoxanthoma elasticum (PT)	10037150
	Puerperal pyrexia (PT)	10037294
	Pulmonary aplasia (PT)	10037322
	Pulmonary arteriovenous fistula (PT)	10037332
	Pulmonary artery atresia (PT)	10037337
	Pulmonary artery stenosis congenital (PT)	10037339
	Pulmonary hypoplasia (PT)	10037407

Listing 16.2.7-1.2 (Page 99 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Pulmonary malformation (PT)	10037419
	Pulmonary valve stenosis congenital (PT)	10037451
	Purpura neonatal (PT)	10037557
	Pyloric stenosis (PT)	10037621
	Pyloromyotomy (PT)	10037626
	Pyruvate kinase deficiency anaemia (PT)	10037682
	Rash neonatal (PT)	10037871
	Rectal atresia (PT)	10038031
	Refsum's disease (PT)	10038275
	Renal arteriovenous malformation (PT)	10038368
	Renal dysplasia (PT)	10038433
	Renal failure neonatal (PT)	10038447
	Renal vessel congenital anomaly (PT)	10038552
	Repair of imperforate rectum (PT)	10038570

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Respiratory tract haemorrhage neonatal (PT)	10038728
	Respiratory tract malformation (PT)	10038733
	Retained placenta or membranes (PT)	10038758
	Retained products of conception (PT)	10038773
	Retinal anomaly congenital (PT)	10038821
	Retinal arteriovenous malformation (PT)	10038824
	Retinitis pigmentosa (PT)	10038914
	Retinopathy of prematurity (PT)	10038933
	Retinoschisis congenital (PT)	10038938
	Retracted nipple (PT)	10038944
	Rhesus haemolytic disease of newborn (PT)	10039037
	Riley-Day syndrome (PT)	10039179
	Rotor's syndrome (PT)	10039234
	Rubella in pregnancy (PT)	10039264

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Rubinstein-Taybi syndrome (PT)	10039281
	Sebaceous naevus (PT)	10039785
	Sensory neuropathy hereditary (PT)	10040037
	Sepsis neonatal (PT)	10040049
	Shoulder dystocia (PT)	10040613
	Sickle cell anaemia (PT)	10040641
	Sickle cell disease (PT)	10040644
	Sickle cell trait (PT)	10040650
	Skin hypoplasia (PT)	10040869
	Skin malformation (PT)	10040888
	Small for dates baby (PT)	10041092
	Somnolence neonatal (PT)	10041350
	Special senses congenital anomaly (PT)	10041420
	Spherophakia (PT)	10041513

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Spina bifida (PT)	10041524
	Spina bifida occulta (PT)	10041525
	Spinal muscular atrophy (PT)	10041582
	Spinal vessel congenital anomaly (PT)	10041603
	Spine malformation (PT)	10041611
	Stillbirth (PT)	10042062
	Strabismus congenital (PT)	10042161
	Sturge-Weber syndrome (PT)	10042265
	Subarachnoid haemorrhage neonatal (PT)	10042317
	Subdural haemorrhage neonatal (PT)	10042365
	Sudden infant death syndrome (PT)	10042440
	Supernumerary nipple (PT)	10042571
	Suppressed lactation (PT)	10042576
	Syndactyly (PT)	10042778

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Synostosis (PT)	10042856
	Syringomyelia (PT)	10042928
	Tachycardia foetal (PT)	10043074
	Talipes (PT)	10043101
	Teratogenicity (PT)	10043275
	Tetanus neonatorum (PT)	10043378
	Thalassaemia (PT)	10043388
	Thalassaemia alpha (PT)	10043390
	Thalassaemia beta (PT)	10043391
	Thalassaemia minor (PT)	10043393
	Thalassaemia sickle cell (PT)	10043395
	Third stage postpartum haemorrhage (PT)	10043449
	Threatened labour (PT)	10043508
	Thrombocytopenia neonatal (PT)	10043557

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Thrombophlebitis neonatal (PT)	10043586
	Tooth discolouration congenital (PT)	10044033
	Tooth hypoplasia (PT)	10044041
	Tooth malformation hereditary (PT)	10044047
	Tourette's disorder (PT)	10044126
	Tracheo-oesophageal fistula (PT)	10044310
	Tracheobronchomegaly (PT)	10044316
	Transient hypogammaglobulinaemia of infancy (PT)	10044388
	Transient tachypnoea of the newborn (PT)	10044403
	Transposition of the great vessels (PT)	10044443
	Transverse presentation (PT)	10044456
	Traumatic delivery (PT)	10044520
	Trisomy 11 (PT)	10044685
	Trisomy 13 (PT)	10044686

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Trisomy 21 (PT)	10044688
	Trisomy 22 (PT)	10044689
	Truncus arteriosus persistent (PT)	10044703
	Turner's syndrome (PT)	10045181
	Twin pregnancy (PT)	10045188
	Type II hyperlipidaemia (PT)	10045254
	Type IIa hyperlipidaemia (PT)	10045261
	Type IIb hyperlipidaemia (PT)	10045263
	Ultrasound antenatal screen abnormal (PT)	10045400
	Ultrasound antenatal screen normal (PT)	10045401
	Umbilical artery hypoplasia (PT)	10045445
	Umbilical cord around neck (PT)	10045447
	Umbilical cord compression (PT)	10045451
	Umbilical cord prolapse (PT)	10045452

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Umbilical cord short (PT)	10045453
	Umbilical cord vascular disorder (PT)	10045454
	Umbilical malformation (PT)	10045469
	Umbilical sepsis (PT)	10045470
	Unintended pregnancy (PT)	10045542
	Univentricular heart (PT)	10045545
	Unstable foetal lie (PT)	10046255
	Unwanted pregnancy (PT)	10046267
	Urethral valves (PT)	10046479
	Urinary tract infection neonatal (PT)	10046573
	Urinary tract malformation (PT)	10046580
	Uterine atony (PT)	10046763
	Uterine hypertonus (PT)	10046790
	Uterine hypotonus (PT)	10046792

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Uterine inversion (PT)	10046796
	Uterine malposition (PT)	10046800
	Uterine rupture (PT)	10046820
	Vacuum extractor delivery (PT)	10046868
	Vaginal atresia (PT)	10046879
	Vasa praevia (PT)	10047036
	Ventricular hypoplasia (PT)	10047296
	Ventricular septal defect (PT)	10047298
	Ventricular septal defect repair (PT)	10047301
	Virilism foetal (PT)	10047487
	Vision abnormal neonatal (PT)	10047511
	Von Willebrand's disease (PT)	10047715
	Von Hippel-Lindau disease (PT)	10047716
	Weight decrease neonatal (PT)	10047894

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Wiskott-Aldrich syndrome (PT)	10047992
	Xeroderma pigmentosum (PT)	10048220
	XXXY syndrome (PT)	10048228
	XXYY syndrome (PT)	10048230
	Ruptured ectopic pregnancy (PT)	10048407
	Brain malformation (PT)	10048409
	Dandy-Walker syndrome (PT)	10048411
	Biopsy chorionic villous abnormal (PT)	10048537
	Limb hypoplasia congenital (PT)	10048575
	Kyphosis congenital (PT)	10048576
	Plagiocephaly (PT)	10048586
	Umbilical cord abnormality (PT)	10048596
	Wyburn Mason's syndrome (PT)	10048661
	Sjogren-Larsson syndrome (PT)	10048676

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Schimke immunoosseous dysplasia (PT)	10048699
	Homocystinaemia (PT)	10048707
	Infantile septic granulomatosis (PT)	10048708
	Congenital dermal sinus (PT)	10048728
	Phakomatosis (PT)	10048734
	Postpartum state (PT)	10048738
	Tocolysis (PT)	10048773
	Accessory kidney (PT)	10048781
	Congenital cerebellar agenesis (PT)	10048784
	Congenital choroid plexus cyst (PT)	10048785
	Keratitis-ichthyosis-deafness syndrome (PT)	10048786
	Congenital scrotal hypertrophy (PT)	10048800
	Congenital thymus absence (PT)	10048801
	Kearns-Sayre syndrome (PT)	10048804

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Polycystic liver disease (PT)	10048834
	Immature larynx (PT)	10048855
	Congenital kyphoscoliosis (PT)	10048890
	Rib hypoplasia (PT)	10048893
	Steatocystoma multiplex (PT)	10048905
	Pachygyria (PT)	10048910
	Lissencephaly (PT)	10048911
	Congenital cerebral haemangioma (PT)	10048924
	Factor V deficiency (PT)	10048930
	Uhl's anomaly (PT)	10048951
	Congenital hyperextension of spine (PT)	10048953
	Congenital hyperextension of knee (PT)	10048954
	Angelman's syndrome (PT)	10049004
	Congenital limb hyperextension (PT)	10049011

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Camptodactyly congenital (PT)	10049028
	Erythrokeratodermia variabilis (PT)	10049048
	Cholestasis of pregnancy (PT)	10049055
	Congenital adrenal gland hypoplasia (PT)	10049057
	HELLP syndrome (PT)	10049058
	Cohen syndrome (PT)	10049066
	Normal foetus (PT)	10049081
	Renal hypoplasia (PT)	10049102
	Red blood cell enzymes abnormal (PT)	10049191
	Adactyly (PT)	10049207
	Aorta hypoplasia (PT)	10049209
	Mitral valve hypoplasia (PT)	10049211
	Phalangeal hypoplasia (PT)	10049212
	Monopodia (PT)	10049214

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Neonatal hyponatraemia (PT)	10049222
	Neonatal hypotension (PT)	10049223
	Blepharophimosis congenital (PT)	10049241
	Ankyloglossia congenital (PT)	10049244
	Hypersplenism congenital (PT)	10049282
	Wolff-Parkinson-White syndrome congenital (PT)	10049291
	Scaphocephaly (PT)	10049426
	Werner's syndrome (PT)	10049429
	Peripartum cardiomyopathy (PT)	10049430
	Congenital facial nerve hypoplasia (PT)	10049449
	Herpes simplex virus conjunctivitis neonatal (PT)	10049458
	Gestational trophoblastic detachment (PT)	10049469
	Live birth (PT)	10049550
	Afterbirth pain (PT)	10049589

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Williams syndrome (PT)	10049644
	Metastases to placenta (PT)	10049725
	Congenital tricuspid valve atresia (PT)	10049767
	Neonatal tachycardia (PT)	10049775
	Renal impairment neonatal (PT)	10049776
	Melaena neonatal (PT)	10049777
	Neonatal anuria (PT)	10049778
	Peripheral oedema neonatal (PT)	10049779
	Neonatal cardiac failure (PT)	10049780
	Hypertension neonatal (PT)	10049781
	Accessory breast (PT)	10049786
	Neonatal neuroblastoma (PT)	10049793
	Single umbilical artery (PT)	10049807
	Thanatophoric dwarfism (PT)	10049808

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Achromotrichia congenital (PT)	10049864
	Craniosynostosis (PT)	10049889
	Hypophosphatasia (PT)	10049933
	Congenital pyelocaliectasis (PT)	10049938
	Uterine contractions during pregnancy (PT)	10049975
	Neonatal hepatomegaly (PT)	10049995
	Ductus arteriosus premature closure (PT)	10049996
	Intoxication by breast feeding (PT)	10049999
	Pseudotruncus arteriosus (PT)	10050053
	Hypothermia neonatal (PT)	10050080
	Neonatal hypoxia (PT)	10050081
	Lipomeningocele (PT)	10050084
	Poor weight gain neonatal (PT)	10050086
	Cardiomyopathy neonatal (PT)	10050111

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Cerebral haemorrhage foetal (PT)	10050157
	Macrocephaly (PT)	10050183
	Haemolysis neonatal (PT)	10050190
	Pregnancy of partner (PT)	10050192
	Carnitine palmitoyltransferase deficiency (PT)	10050215
	Hygroma colli (PT)	10050249
	Congenital labia pudendi adhesions (PT)	10050268
	Beckwith-Wiedemann syndrome (PT)	10050344
	Foetal acidosis (PT)	10050347
	Wolf-Hirschhorn syndrome (PT)	10050361
	Neonatal oversedation (PT)	10050395
	Neonatal multi-organ failure (PT)	10050401
	Paternal drugs affecting foetus (PT)	10050425
	Pulmonary oedema neonatal (PT)	10050459

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Holt-Oram syndrome (PT)	10050469
	Leukopenia neonatal (PT)	10050504
	Langer-Giedion syndrome (PT)	10050638
	Congenital scoliosis (PT)	10050694
	Exophthalmos congenital (PT)	10050696
	Congenital pulmonary hypertension (PT)	10050701
	Retinopathy congenital (PT)	10050706
	Congenital acrochordon (PT)	10050730
	Bartter's syndrome (PT)	10050839
	Naevus spider congenital (PT)	10050896
	Congenital hydronephrosis (PT)	10050975
	Floppy infant (PT)	10051004
	Eagle Barrett syndrome (PT)	10051025
	Hyper IgE syndrome (PT)	10051040

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Congenital eye naevus (PT)	10051050
	Angiotensin converting enzyme inhibitor foetopathy (PT)	10051098
	Congenital dysfibrinogenaemia (PT)	10051123
	Congenital hepatomegaly (PT)	10051130
	Meconium abnormal (PT)	10051132
	Meconium in amniotic fluid (PT)	10051133
	Foetal heart rate decreased (PT)	10051136
	Foetal heart rate increased (PT)	10051138
	Foetal heart rate abnormal (PT)	10051139
	Foetal heart rate normal (PT)	10051140
	Congenital hydrocele renalis (PT)	10051147
	Hypermethioniuria (PT)	10051231
	Hypermethioninaemia (PT)	10051245

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Adrenoleukodystrophy (PT)	10051260
	Protein S deficiency (PT)	10051292
	Protein C deficiency (PT)	10051298
	Congenital hypoparathyroidism (PT)	10051315
	Thyroglossal cyst (PT)	10051320
	Mitochondrial DNA deletion (PT)	10051403
	Amniotic infection syndrome of Blane (PT)	10051407
	Foetal warfarin syndrome (PT)	10051445
	Klippel-Trenaunay syndrome (PT)	10051452
	Mandibulofacial dysostosis (PT)	10051456
	Imminent abortion (PT)	10051459
	Amniorrhexis (PT)	10051641
	Congenital multiplex arthrogryposis (PT)	10051643
	Haemophilia carrier (PT)	10051658

Listing 16.2.7-1.2 (Page 119 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Lipid proteinosis (PT)	10051661
	Pachydermoperiostosis (PT)	10051686
	Oculocerebrorenal syndrome (PT)	10051707
	Ota's naevus (PT)	10051713
	Multiple endocrine neoplasia (PT)	10051747
	Factor XII deficiency (PT)	10051806
	Tangier disease (PT)	10051875
	Benign congenital hypotonia (PT)	10051900
	Cowden's disease (PT)	10051906
	Hereditary non-polyposis colorectal cancer syndrome (PT)	10051922
	Oculoauriculovertebral dysplasia (PT)	10051934
	Scimitar syndrome (PT)	10051951
	Trichorhinophalangeal syndrome (PT)	10051956

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Listing 16.2.7-1.2 (Page 120 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Pterygium colli (PT)	10051972
	Foetal cystic hygroma (PT)	10052011
	Congenital teratoma (PT)	10052012
	Albright's disease (PT)	10052032
	Neural tube defect (PT)	10052046
	Foetal cardiac disorder (PT)	10052088
	Oculopharyngeal dystrophy (PT)	10052181
	Infantile genetic agranulocytosis (PT)	10052210
	Cerebral atrophy congenital (PT)	10052236
	High-pitched crying (PT)	10052286
	Myocardial bridging (PT)	10052289
	Keratolysis exfoliativa congenital (PT)	10052290
	Kaufman-McKusick syndrome (PT)	10052312
	Liddle's syndrome (PT)	10052313

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	First trimester pregnancy (PT)	10052395
	Second trimester pregnancy (PT)	10052396
	Third trimester pregnancy (PT)	10052397
	Ornithine transcarbamoylase deficiency (PT)	10052450
	Osteoporosis-pseudoglioma syndrome (PT)	10052452
	Congenital poikiloderma (PT)	10052465
	Factor III deficiency (PT)	10052473
	Factor X deficiency (PT)	10052474
	Periventricular leukomalacia (PT)	10052594
	Dihydropyrimidine dehydrogenase deficiency (PT)	10052622
	Mitochondrial DNA duplication (PT)	10052640
	Mitochondrial DNA mutation (PT)	10052641
	Iris coloboma (PT)	10052642
	Retinal coloboma (PT)	10052643

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Congenital pulmonary valve atresia (PT)	10052644
	Thymus hypoplasia (PT)	10052645
	Cancer gene carrier (PT)	10052648
	Amyotrophic lateral sclerosis gene carrier (PT)	10052653
	Duchenne muscular dystrophy gene carrier (PT)	10052655
	Cystic fibrosis carrier (PT)	10052656
	Fragile X carrier (PT)	10052657
	Macrognathia (PT)	10052658
	Systemic-pulmonary artery shunt (PT)	10052717
	High risk pregnancy (PT)	10052744
	Accessory liver lobe (PT)	10052752
	Oroticaciduria congenital (PT)	10052773
	Induced abortion haemorrhage (PT)	10052844
	Induced abortion infection (PT)	10052845

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Abortion early (PT)	10052846
	Abortion late (PT)	10052847
	Brow presentation (PT)	10052848
	Oblique presentation (PT)	10052849
	Anaesthetic complication foetal (PT)	10052850
	Anaesthetic complication neonatal (PT)	10052851
	Labour stimulation (PT)	10052855
	Labour induction (PT)	10052856
	Prenatal care (PT)	10052859
	Congenital aplastic anaemia (PT)	10053138
	Olfacto genital dysplasia (PT)	10053142
	Hydroxyprolinaemia (PT)	10053148
	Congenital floppy infant (PT)	10053153
	Epidermolysis (PT)	10053177

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Glycogen storage disease type II (PT)	10053185
	Induced abortion failed (PT)	10053191
	Posterior segment of eye anomaly congenital (PT)	10053202
	Fontanelle depressed (PT)	10053214
	Haemoglobin E disease (PT)	10053215
	Glycogen storage disease type VI (PT)	10053240
	Glycogen storage disease type VII (PT)	10053241
	Glycogen storage disease type VIII (PT)	10053242
	Glycogen storage disease type IV (PT)	10053249
	Glycogen storage disease type III (PT)	10053250
	Pregnancy with injectable contraceptive (PT)	10053394
	Venous angioma of brain (PT)	10053485
	Uvula aplasia (PT)	10053506
	Cleft uvula (PT)	10053507

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Congenital generalised lipodystrophy (PT)	10053547
	Neonatal pneumonia (PT)	10053584
	Disseminated neonatal herpes simplex (PT)	10053585
	Meningoencephalitis herpes simplex neonatal (PT)	10053586
	Neonatal mucocutaneous herpes simplex (PT)	10053587
	Group B streptococcus neonatal sepsis (PT)	10053588
	Hereditary stomatocytosis (PT)	10053589
	Newborn persistent pulmonary hypertension (PT)	10053592
	Foetal cerebrovascular disorder (PT)	10053601
	Radiation injury affecting foetus (PT)	10053602
	Asplenia (PT)	10053622
	Cholangiectasis congenital (PT)	10053630
	Obstetric infection (PT)	10053636
	Brachycephaly (PT)	10053682

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Cerebrohepatorenal syndrome (PT)	10053684
	Foetal macrosomia (PT)	10053700
	Pulmonary dysmaturity syndrome (PT)	10053766
	Vaginal hypoplasia (PT)	10053843
	Alagille syndrome (PT)	10053870
	Trisomy 8 (PT)	10053871
	MELAS syndrome (PT)	10053872
	Congenital oculomotor apraxia (PT)	10053877
	Greig's syndrome (PT)	10053878
	Trisomy 18 (PT)	10053884
	Trisomy 17 (PT)	10053925
	Abortion induced incomplete (PT)	10053984
	Inclusion conjunctivitis neonatal (PT)	10053991
	Congenital syphilitic osteochondritis (PT)	10054002

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Delayed closure of cranial sutures (PT)	10054008
	Pilonidal cyst congenital (PT)	10054019
	Delayed fontanelle closure (PT)	10054034
	Congenital bowing of long bones (PT)	10054064
	Congenital aural fistula (PT)	10054215
	Lymphangiectasia intestinal congenital (PT)	10054722
	Retroplacental haematoma (PT)	10054798
	Placental dysplasia (PT)	10054810
	External auditory canal atresia (PT)	10054875
	Phalangeal agenesis (PT)	10054879
	Fibula agenesis (PT)	10054882
	Neonatal respiratory distress syndrome prophylaxis (PT)	10054933
	Aicardi's syndrome (PT)	10054935

Listing 16.2.7-1.2 (Page 128 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Cervix dystocia (PT)	10054939
	Congenital cerebral cyst (PT)	10054954
	Tracheal atresia (PT)	10054955
	Cervix cerclage procedure (PT)	10054992
	Hypodontia (PT)	10055001
	Cardiac lymphangioma (PT)	10055010
	Haemoglobin D disease (PT)	10055019
	Haemoglobin D trait (PT)	10055020
	Haemoglobin C trait (PT)	10055021
	Necrotising enterocolitis neonatal (PT)	10055667
	Foetal death (PT)	10055690
	Intrauterine infection (PT)	10056254
	Anorectal agenesis (PT)	10056271
	Erythema toxicum neonatorum (PT)	10056274

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Listing 16.2.7-1.2 (Page 129 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Androgen insensitivity syndrome (PT)	10056292
	Holoprosencephaly (PT)	10056304
	Caput succedaneum (PT)	10056311
	Blood incompatibility haemolytic anaemia of newborn (PT)	10056369
	Cerebrovascular arteriovenous malformation (PT)	10056371
	Maternal distress during labour (PT)	10056391
	Perinatal brain damage (PT)	10056392
	Postpartum stress disorder (PT)	10056394
	Congenital ureterocele (PT)	10056434
	Cerebral dysgenesis (PT)	10056467
	Bradycardia neonatal (PT)	10056471
	Haemophilia A with anti factor VIII (PT)	10056492
	Haemophilia A without inhibitors (PT)	10056493

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Haemophilia B with anti factor IX (PT)	10056494
	Haemophilia B without inhibitors (PT)	10056495
	Renal disorder in pregnancy (PT)	10056505
	Thyroid dysfunction in pregnancy (PT)	10056525
	Neonatal cholestasis (PT)	10056528
	Congenital epiblepharon (PT)	10056531
	Congenital hepatic fibrosis (PT)	10056533
	X-linked chromosomal disorder (PT)	10056554
	Y-linked chromosomal disorder (PT)	10056555
	Neonatal warming therapy (PT)	10056585
	Incubator therapy (PT)	10056613
	Bladder agenesis (PT)	10056655
	Sacral hypoplasia (PT)	10056659
	Laurence-Moon-Bardet-Biedl syndrome (PT)	10056715

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Placental chorioangioma (PT)	10056718
	Apgar score abnormal (PT)	10056850
	Dermatofibrosis lenticularis disseminata (PT)	10056878
	Mucopolysaccharidosis I (PT)	10056886
	Mucopolysaccharidosis II (PT)	10056889
	Mucopolysaccharidosis III (PT)	10056890
	Mucopolysaccharidosis V (PT)	10056891
	Mucopolysaccharidosis VI (PT)	10056892
	Mucopolysaccharidosis VII (PT)	10056893
	XYY syndrome (PT)	10056894
	Neonatal hypoparathyroidism (PT)	10056974
	Hereditary pancreatitis (PT)	10056976
	Adenomatous polyposis coli (PT)	10056981
	Congenital ectopic pancreas (PT)	10056987

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Cleft lip repair (PT)	10056999
	Meconium stain (PT)	10057028
	Neonatal tetany (PT)	10057037
	Congenital cutis laxa (PT)	10057042
	Meconium plug syndrome (PT)	10057075
	Platybasia (PT)	10057115
	Neonatal tachypnoea (PT)	10057183
	Acquired mitochondrial DNA deletion (PT)	10057251
	Acquired mitochondrial DNA mutation (PT)	10057252
	Foetal therapeutic procedure (PT)	10057294
	Choroidal coloboma (PT)	10057402
	Congenital iris anomaly (PT)	10057411
	Microcornea (PT)	10057414
	Bernard-Soulier syndrome (PT)	10057473

Listing 16.2.7-1.2 (Page 133 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Periodontal congenital anomaly (PT)	10057476
	Congenital calyceal diverticulum (PT)	10057510
	Interferon gamma receptor deficiency (PT)	10057605
	Central core disease (PT)	10057620
	Asphyxiating thoracic dystrophy (PT)	10057621
	Cyclopia (PT)	10057648
	Encephalocutaneous angiomatosis (PT)	10057653
	Maternal condition affecting foetus (PT)	10057673
	Hypotelorism of orbit (PT)	10057855
	Reproductive tract hypoplasia, male (PT)	10057858
	Hypertelorism (PT)	10057862
	Hereditary haemochromatosis (PT)	10057873
	Congenital choroidal anomaly (PT)	10057886
	Neonatal lupus erythematosus (PT)	10057887

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Long QT syndrome congenital (PT)	10057926
	Congenital mitochondrial cytopathy (PT)	10057954
	Foetal malpresentation (PT)	10058013
	Anomalous pulmonary venous connection (PT)	10058079
	Arrhythmogenic right ventricular dysplasia (PT)	10058093
	Meconium peritonitis (PT)	10058113
	Otocephaly (PT)	10058118
	Congenital aortic dilatation (PT)	10058150
	Branchiogenic syndrome (PT)	10058169
	Hyperexplexia (PT)	10058271
	Factor V Leiden mutation (PT)	10058279
	Carbamoyl phosphate synthetase deficiency (PT)	10058297
	Argininosuccinate synthetase deficiency (PT)	10058298
	Argininosuccinate lyase deficiency (PT)	10058299

Listing 16.2.7-1.2 (Page 135 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Lysinuric protein intolerance (PT)	10058300
	Maternal therapy to enhance foetal lung maturity (PT)	10058340
	Biopsy foetal abnormal (PT)	10058370
	Biopsy foetal normal (PT)	10058398
	Hyperprolinaemia (PT)	10058509
	Cranial sutures widening (PT)	10058604
	Poor sucking reflex (PT)	10058605
	Breast milk discolouration (PT)	10058665
	Clinodactyly (PT)	10058668
	Meningitis neonatal (PT)	10058780
	Mitochondrial encephalomyopathy (PT)	10058799
	Congenital thrombocyte disorder (PT)	10058896
	Neonatal intestinal dilatation (PT)	10058934

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Cystic lymphangioma (PT)	10058949
	Rathke's cleft cyst (PT)	10058969
	Neonatal aspiration (PT)	10059033
	Missed labour (PT)	10059107
	Diabetic foetopathy (PT)	10059116
	Becker's muscular dystrophy (PT)	10059117
	Congenital visual acuity reduced (PT)	10059157
	Congenital eye disorder (PT)	10059159
	Pulmonary sequestration (PT)	10059160
	Familial hypertriglyceridaemia (PT)	10059183
	Anterior chamber cleavage syndrome (PT)	10059199
	Labour pain (PT)	10059204
	Fallot's pentalogy (PT)	10059205
	Macrocornea (PT)	10059253

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Overfeeding of infant (PT)	10059260
	Testicular dysplasia (PT)	10059271
	Sarcosinaemia (PT)	10059299
	Caudal regression syndrome (PT)	10059387
	Mitochondrial DNA depletion (PT)	10059396
	Congenital genital malformation male (PT)	10059492
	Coma neonatal (PT)	10059497
	Methylmalonic aciduria (PT)	10059521
	Dubowitz syndrome (PT)	10059589
	Preduodenal portal vein (PT)	10059798
	Persistent urogenital sinus (PT)	10059800
	Head circumference abnormal (PT)	10060043
	Bruton's agammaglobulinaemia (PT)	10060360
	Polycythaemia neonatorum (PT)	10060476

Listing 16.2.7-1.2 (Page 138 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Galactostasis (PT)	10060710
	Congenital nephrotic syndrome (PT)	10060737
	Alpha 1 foetoprotein amniotic fluid decreased (PT)	10060746
	Congenital hypogammaglobulinaemia (PT)	10060747
	Type I hyperlipidaemia (PT)	10060749
	Type III hyperlipidaemia (PT)	10060751
	Type IV hyperlipidaemia (PT)	10060753
	Type V hyperlipidaemia (PT)	10060755
	Laryngomalacia (PT)	10060786
	Hollow visceral myopathy (PT)	10060811
	Benign familial haematuria (PT)	10060876
	Haemoglobinopathy (PT)	10060892
	Hereditary haemolytic anaemia (PT)	10060893
	Foetal malformation (PT)	10060919

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Abnormal product of conception (PT)	10060927
	Abortion induced complete (PT)	10060928
	Alloimmunisation (PT)	10060935
	Amniotic cavity disorder (PT)	10060936
	Amniotic cavity infection (PT)	10060937
	Anomaly of middle ear congenital (PT)	10060957
	Autosomal chromosome anomaly (PT)	10060975
	Carbohydrate metabolism disorder (PT)	10061023
	Labour complication (PT)	10061050
	Eye anterior chamber congenital anomaly (PT)	10061051
	Congenital aortic anomaly (PT)	10061052
	Congenital bladder anomaly (PT)	10061053
	Congenital cardiovascular anomaly (PT)	10061054
	Congenital corneal anomaly (PT)	10061059

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Congenital coronary artery malformation (PT)	10061060
	Congenital diaphragmatic anomaly (PT)	10061061
	Congenital fallopian tube anomaly (PT)	10061062
	Congenital gastric anomaly (PT)	10061063
	Congenital hair disorder (PT)	10061064
	Congenital hepatobiliary anomaly (PT)	10061065
	Congenital intestinal malformation (PT)	10061067
	Congenital knee deformity (PT)	10061068
	Congenital oesophageal anomaly (PT)	10061069
	Congenital oral malformation (PT)	10061070
	Congenital ovarian anomaly (PT)	10061071
	Congenital pancreatic anomaly (PT)	10061072
	Congenital pharyngeal anomaly (PT)	10061073
	Congenital pulmonary artery anomaly (PT)	10061074

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Congenital pulmonary valve disorder (PT)	10061075
	Congenital spinal cord anomaly (PT)	10061076
	Congenital tongue anomaly (PT)	10061077
	Congenital ureteric anomaly (PT)	10061078
	Congenital uterine anomaly (PT)	10061079
	Congenital great vessel anomaly (PT)	10061080
	Congenital vitreous anomaly (PT)	10061085
	Congenital white blood cell disorder (PT)	10061086
	Congenital eyelid malformation (PT)	10061146
	Foetal disorder (PT)	10061157
	Foetal heart rate disorder (PT)	10061158
	Gallbladder anomaly congenital (PT)	10061163
	Haemorrhage foetal (PT)	10061191
	Hamartoma (PT)	10061193

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Hereditary cerebral degeneration (PT)	10061204
	Hereditary disorder (PT)	10061205
	Lactation disorder (PT)	10061261
	Neonatal infection (PT)	10061308
	Obstetric procedure complication (PT)	10061315
	Oedema neonatal (PT)	10061317
	Placental neoplasm (PT)	10061349
	Porphyrin metabolism disorder (PT)	10061356
	Uterine contractions abnormal (PT)	10061400
	Complication of pregnancy (PT)	10061452
	Dermatoglyphic anomaly (PT)	10061455
	Post abortion infection (PT)	10061467
	Postpartum disorder (PT)	10061469
	Respiratory disorder neonatal (PT)	10061484

Listing 16.2.7-1.2 (Page 143 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Sex chromosome abnormality (PT)	10061513
	Congenital optic nerve anomaly (PT)	10061528
	Congenital scleral disorder (PT)	10061530
	Congenital pseudarthrosis (PT)	10061573
	Telangiectasia congenital (PT)	10061575
	Gastrointestinal malformation (PT)	10061596
	Abortion complete (PT)	10061614
	Abortion complicated (PT)	10061615
	Abortion spontaneous complete (PT)	10061616
	Abortion spontaneous incomplete (PT)	10061617
	Adrenogenital syndrome (PT)	10061630
	Assisted delivery (PT)	10061661
	Asymptomatic gene carrier (PT)	10061662
	Chromosomal deletion (PT)	10061764

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Chromosomal mutation (PT)	10061765
	Complication of delivery (PT)	10061781
	Neonatal complications of substance abuse (PT)	10061862
	Gastrointestinal disorder congenital (PT)	10061973
	Glycogen storage disorder (PT)	10061990
	Haemophilia (PT)	10061992
	Haemorrhage neonatal (PT)	10061993
	Hereditary ataxia (PT)	10062002
	Inborn error of bilirubin metabolism (PT)	10062017
	Inborn error of metabolism (PT)	10062018
	Intestinal atresia (PT)	10062022
	Thyroid malformation (PT)	10062125
	Congenital hyperthyroidism (PT)	10062264
	Septum pellucidum agenesis (PT)	10062267

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Silver-Russell syndrome (PT)	10062282
	Congenital arterial malformation (PT)	10062325
	Congenital cerebrovascular anomaly (PT)	10062327
	Congenital cyst (PT)	10062328
	Congenital endocrine anomaly (PT)	10062329
	Congenital epiglottal anomaly (PT)	10062330
	Congenital Eustachian tube anomaly (PT)	10062331
	Congenital foot malformation (PT)	10062332
	Congenital genital malformation (PT)	10062333
	Congenital genitourinary abnormality (PT)	10062334
	Congenital hand malformation (PT)	10062335
	Congenital jaw malformation (PT)	10062336
	Congenital joint malformation (PT)	10062337
	Congenital lacrimal passage anomaly (PT)	10062338

Listing 16.2.7-1.2 (Page 146 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Anomaly of external ear congenital (PT)	10062339
	Congenital anomaly of inner ear (PT)	10062340
	Congenital anomaly of adrenal gland (PT)	10062341
	Congenital gastrointestinal vessel anomaly (PT)	10062342
	Congenital infection (PT)	10062343
	Congenital musculoskeletal anomaly (PT)	10062344
	Congenital neurological disorder (PT)	10062345
	Congenital neuropathy (PT)	10062346
	Congenital nose malformation (PT)	10062347
	Skull malformation (PT)	10062348
	Congenital urethral anomaly (PT)	10062349
	Spleen malformation (PT)	10062350
	Congenital myopathy (PT)	10062547
	Lowry-Wood syndrome (PT)	10062600

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Thyroglossal fistula (PT)	10062601
	Accessory navicular syndrome (PT)	10062626
	Pseudocholinesterase deficiency (PT)	10062674
	Arginase deficiency (PT)	10062695
	Congenital carnitine deficiency (PT)	10062698
	Trisomy 15 (PT)	10062757
	Congenital dyskeratosis (PT)	10062759
	Stargardt's disease (PT)	10062766
	Basal cell naevus syndrome (PT)	10062804
	Multiple lentigines syndrome (PT)	10062901
	Gitelman's syndrome (PT)	10062906
	Netherton's syndrome (PT)	10062909
	Haemoglobin E-thalassaemia disease (PT)	10062917
	Spondyloepiphyseal dysplasia (PT)	10062920

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Habitual abortion (PT)	10062935
	Placenta accreta (PT)	10062936
	Mitochondrial hepatopathy (PT)	10062938
	Neuropathy, ataxia, retinitis pigmentosa syndrome (PT)	10062940
	Pearson's syndrome (PT)	10062941
	Optic nerve hypoplasia (PT)	10062942
	Laryngo-onycho-cutaneous syndrome (PT)	10062987
	Kinematic imbalances due to suboccipital strain (PT)	10062992
	Muir-Torre syndrome (PT)	10063042
	Ectopic kidney (PT)	10063044
	Trisomy 12 (PT)	10063092
	Uterine cervix hypoplasia (PT)	10063120
	Pregnancy with implant contraceptive (PT)	10063122

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Pregnancy with contraceptive device (PT)	10063130
	Uterine hypoplasia (PT)	10063146
	Infantile spitting up (PT)	10063338
	Amniotic fluid volume decreased (PT)	10063356
	Amniotic fluid volume increased (PT)	10063357
	Wagner's disease (PT)	10063383
	Usher's syndrome (PT)	10063396
	Stickler's syndrome (PT)	10063402
	Lumbarisation (PT)	10063410
	Gestational oedema (PT)	10063412
	Odontogenic cyst (PT)	10063413
	Aase syndrome (PT)	10063429
	Nail-patella syndrome (PT)	10063431
	Tyrosinaemia (PT)	10063443

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Hereditary areflexic dystasia (PT)	10063449
	Congenital vaginal cyst (PT)	10063457
	Congenital androgen deficiency (PT)	10063469
	False negative pregnancy test (PT)	10063476
	Schinzel-Giedion syndrome (PT)	10063540
	Congenital coagulopathy (PT)	10063563
	Biochemical pregnancy (PT)	10063639
	Testotoxicosis (PT)	10063654
	Pregnancy after post coital contraception (PT)	10063671
	Rhesus incompatibility (PT)	10063676
	Lymphocytic hypophysitis (PT)	10063685
	Young's syndrome (PT)	10063689
	Oculodentodigital dysplasia (PT)	10063691
	Congenital anomaly in offspring (PT)	10063726

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Bicuspid pulmonary valve (PT)	10063730
	Aorticopulmonary septal defect (PT)	10063732
	Haemoglobin E trait (PT)	10063740
	Atrioventricular septal defect (PT)	10063836
	Arachnodactyly (PT)	10063847
	Dolichocolon (PT)	10063917
	Kabuki make-up syndrome (PT)	10063935
	Phytosterolaemia (PT)	10063985
	Fallot's trilogy (PT)	10064011
	Cardiac septal defect (PT)	10064021
	Intestinal malrotation (PT)	10064024
	Foetal chromosome abnormality (PT)	10064041
	Nipple inflammation (PT)	10064043
	CHARGE syndrome (PT)	10064063

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Congenital heart valve disorder (PT)	10064086
	Facioscapulohumeral muscular dystrophy (PT)	10064087
	Amniotic band syndrome (PT)	10064100
	Foramen magnum stenosis (PT)	10064157
	Parachute mitral valve (PT)	10064192
	Persistent left superior vena cava (PT)	10064193
	Right ventricle outflow tract obstruction (PT)	10064195
	Balloon atrial septostomy (PT)	10064200
	Heterotopic pregnancy (PT)	10064228
	Omphalorrhexis (PT)	10064270
	Sotos' syndrome (PT)	10064387
	Funisitis (PT)	10064502
	Vaginal septum (PT)	10064513
	Femoral retroversion (PT)	10064514

Listing 16.2.7-1.2 (Page 153 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Tibial torsion (PT)	10064515
	Femoral anteversion (PT)	10064516
	Umbilical cord haemorrhage (PT)	10064534
	Chronic infantile neurological cutaneous and articular syndrome (PT)	10064568
	Muckle-Wells syndrome (PT)	10064569
	Familial cold autoinflammatory syndrome (PT)	10064570
	Gene mutation (PT)	10064571
	Marcus Gunn syndrome (PT)	10064583
	Bronchogenic cyst (PT)	10064585
	Haemorrhagic arteriovenous malformation (PT)	10064595
	Berdon's syndrome (PT)	10064596
	Venous thrombosis neonatal (PT)	10064602
	Placental infarction (PT)	10064620

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Symphysiotomy (PT)	10064625
	Renal aplasia (PT)	10064655
	Congenital lenticonus (PT)	10064660
	Amniotic fluid erythropoietin level increased (PT)	10064845
	Primary immunodeficiency syndrome (PT)	10064859
	Urethral atresia (PT)	10064895
	Anomalous arrangement of pancreaticobiliary duct (PT)	10064902
	Preternatural anus (PT)	10064917
	Sacralisation (PT)	10064932
	Penoscrotal fusion (PT)	10064951
	Hypoplastic right heart syndrome (PT)	10064962
	Weill-Marchesani syndrome (PT)	10064963
	Drug exposure before pregnancy (PT)	10064998

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Prophylaxis of abortion (PT)	10065000
	Factor II mutation (PT)	10065003
	Apparent life threatening event (PT)	10065044
	Membranous lipodystrophy (PT)	10065127
	Mayer-Rokitansky-Kuster-Hauser syndrome (PT)	10065148
	Maternal alcohol use (PT)	10065158
	Mastitis fungal (PT)	10065211
	Mastitis bacterial (PT)	10065212
	Mitochondrial neurogastrointestinal encephalopathy (PT)	10065271
	Prominent epicanthal folds (PT)	10065273
	Ocular albinism (PT)	10065276
	Craniotabes (PT)	10065419
	Coagulation factor mutation (PT)	10065442

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	CADASIL (PT)	10065555
	Thymus enlargement (PT)	10065588
	Mount-Reback syndrome (PT)	10065658
	Congenital fibrosarcoma (PT)	10065859
	Left ventricle outflow tract obstruction (PT)	10065930
	Molar abortion (PT)	10065942
	Varicose veins vaginal (PT)	10066002
	VACTERL syndrome (PT)	10066022
	Dysmorphism (PT)	10066054
	Congenital aqueductal stenosis (PT)	10066084
	Polymorphic eruption of pregnancy (PT)	10066100
	Lochial infection (PT)	10066103
	Urachal abnormality (PT)	10066125
	Distichiasis (PT)	10066128

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Arterial switch operation (PT)	10066129
	Hyper IgM syndrome (PT)	10066130
	Congenital central hypoventilation syndrome (PT)	10066131
	Metaphyseal dysplasia (PT)	10066147
	Vertical talus (PT)	10066242
	Abortion of ectopic pregnancy (PT)	10066266
	Uterine hyperstimulation (PT)	10066288
	Prophylaxis against Rh isoimmunisation (PT)	10066359
	Maternal death during childbirth (PT)	10066376
	Sucrase-isomaltase deficiency (PT)	10066387
	Glucose-galactose malabsorption (PT)	10066388
	Velo-cardio-facial syndrome (PT)	10066430
	Cordocentesis (PT)	10066447
	Anaemia of pregnancy (PT)	10066468

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Amniorrhoea (PT)	10066470
	Foetal anticonvulsant syndrome (PT)	10066485
	Li-Fraumeni syndrome (PT)	10066795
	Heterochromia iridis (PT)	10066799
	Mitral valve atresia (PT)	10066800
	Aortic valve atresia (PT)	10066801
	Shone complex (PT)	10066802
	Sertoli-cell-only syndrome (PT)	10066833
	Aorticopulmonary window repair (PT)	10066834
	Congenital renal disorder (PT)	10066875
	Vertebral artery hypoplasia (PT)	10066907
	Congenital condyloma (PT)	10066944
	Craniofacial dysostosis (PT)	10066946
	Vitello-intestinal duct remnant (PT)	10066969

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Anaphylactoid syndrome of pregnancy (PT)	10067010
	Tetralogy of Fallot repair (PT)	10067017
	Venous thrombosis in pregnancy (PT)	10067030
	Familial hemiplegic migraine (PT)	10067039
	Amniotic fluid index abnormal (PT)	10067079
	Pregnancy with contraceptive patch (PT)	10067082
	Buried penis syndrome (PT)	10067131
	Faciodigitogenital dysplasia (PT)	10067141
	Septo-optic dysplasia (PT)	10067159
	Congenital abdominal hernia (PT)	10067183
	Naevus flammeus (PT)	10067193
	Congenital naevus (PT)	10067248
	Heterotaxia (PT)	10067265
	Penoscrotal transposition (PT)	10067287

Listing 16.2.7-1.2 (Page 160 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Costello syndrome (PT)	10067380
	Right aortic arch (PT)	10067407
	Cloacal exstrophy (PT)	10067424
	Cytogenetic abnormality (PT)	10067477
	Selective abortion (PT)	10067499
	Low birth weight baby (PT)	10067508
	Tubal rupture (PT)	10067553
	Dysmyelination (PT)	10067601
	Canavan disease (PT)	10067608
	Metachromatic leukodystrophy (PT)	10067609
	Pelizaeus-Merzbacher disease (PT)	10067610
	Delivery (PT)	10067647
	Pregnancy on contraceptive (PT)	10067667
	Intrapartum haemorrhage (PT)	10067703

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Uterine aplasia (PT)	10067704
	Shortened cervix (PT)	10067726
	Beta ketothiolase deficiency (PT)	10067728
	Mitochondrial enzyme deficiency (PT)	10067729
	Umbilical granuloma (PT)	10067731
	Uterine cervix stenosis (PT)	10067732
	Birt-Hogg-Dube syndrome (PT)	10067736
	Congenital skin disorder (PT)	10067769
	Tumour necrosis factor receptor-associated periodic syndrome (PT)	10067774
	Pulmonary air leakage (PT)	10067826
	Arcuate foramen (PT)	10067850
	Nijmegen breakage syndrome (PT)	10067857
	Kidney malrotation (PT)	10067877

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Congenital tricuspid valve incompetence (PT)	10067887
	Shwachman-Diamond syndrome (PT)	10067940
	Hereditary papillary renal carcinoma (PT)	10067943
	Hereditary leiomyomatosis renal cell carcinoma (PT)	10067944
	PHACES syndrome (PT)	10068032
	Renal fusion anomaly (PT)	10068033
	Chimerism (PT)	10068051
	Mosaicism (PT)	10068052
	Accessory spleen (PT)	10068059
	Norwood procedure (PT)	10068098
	Congenital ureterovesical junction anomaly (PT)	10068133
	Aspartylglucosaminuria (PT)	10068220
	Trimethylaminuria (PT)	10068233
	Vesicoamniotic shunt (PT)	10068236

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Cystic fibrosis related diabetes (PT)	10068271
	Cystic fibrosis hepatic disease (PT)	10068289
	Congenital nephrogenic diabetes insipidus (PT)	10068304
	Microencephaly (PT)	10068320
	Congenital inguinal hernia (PT)	10068321
	Placental hypertrophy (PT)	10068326
	X-linked lymphoproliferative syndrome (PT)	10068348
	Femur-fibula-ulna complex (PT)	10068448
	Foetal hypokinesia (PT)	10068461
	Septate hymen (PT)	10068484
	Microvillous inclusion disease (PT)	10068494
	18q minus syndrome (PT)	10068533
	Congenital oxalosis (PT)	10068593
	Bulbospinal muscular atrophy congenital (PT)	10068597

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Platyspondylia (PT)	10068629
	Dowling-Degos disease (PT)	10068651
	Ductus venosus agenesis (PT)	10068665
	Familial hypocalciuric hypercalcaemia (PT)	10068698
	Fibrodysplasia ossificans progressiva (PT)	10068715
	Decidual cast (PT)	10068735
	Alstroem syndrome (PT)	10068783
	Sticky platelet syndrome (PT)	10068788
	Metabolic myopathy (PT)	10068836
	Cobb syndrome (PT)	10068841
	Olmsted syndrome (PT)	10068842
	Gnathoschisis (PT)	10068845
	Cryopyrin associated periodic syndrome (PT)	10068850
	Myotonic dystrophy (PT)	10068871

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Mirror syndrome (PT)	10068875
	Atrial switch operation (PT)	10068964
	Lactation inhibition therapy (PT)	10069058
	Omenn syndrome (PT)	10069097
	Cutaneovisceral angiomatosis with thrombocytopenia (PT)	10069098
	Laryngeal cleft (PT)	10069115
	Tetrahydrobiopterin deficiency (PT)	10069116
	Discordant twin (PT)	10069150
	Prenatal screening test abnormal (PT)	10069151
	Congenital myopia (PT)	10069153
	Gasping syndrome (PT)	10069162
	Dent's disease (PT)	10069199
	Waardenburg syndrome (PT)	10069203

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Naevus anaemicus (PT)	10069365
	Hereditary neuropathy with liability to pressure palsies (PT)	10069382
	Chiari network (PT)	10069393
	Wildervanck syndrome (PT)	10069402
	Rippling muscle disease (PT)	10069417
	Pancreas divisum (PT)	10069419
	Persistent cloaca (PT)	10069442
	Acrokeratosis verruciformis (PT)	10069445
	Azygos lobe (PT)	10069490
	Ectopic thyroid (PT)	10069503
	Congenital monorchidism (PT)	10069505
	Subgaleal haematoma (PT)	10069510
	Autoimmune lymphoproliferative syndrome (PT)	10069521

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Cartilage-hair hypoplasia (PT)	10069596
	Pregnancy with young maternal age (PT)	10069615
	Methylenetetrahydrofolate reductase polymorphism (PT)	10069666
	Nasopharyngeal atresia (PT)	10069701
	Primary ciliary dyskinesia (PT)	10069713
	Acquired gene mutation (PT)	10069754
	K-ras gene mutation (PT)	10069755
	Norrie's disease (PT)	10069760
	Congenital cranial nerve paralysis (PT)	10069774
	Os trigonum (PT)	10069805
	Denys-Drash syndrome (PT)	10070179
	Penile torsion (PT)	10070235
	Inherited cardiac conduction disorder (PT)	10070294

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Listing 16.2.7-1.2 (Page 168 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Uterine dehiscence (PT)	10070301
	Methylenetetrahydrofolate reductase deficiency (PT)	10070309
	Congenital intrinsic factor deficiency (PT)	10070440
	Sclerotylosis (PT)	10070504
	Foetal growth restriction (PT)	10070531
	Fibrous dysplasia of jaw (PT)	10070535
	Gestational hypertension (PT)	10070538
	Disorder of sex development (PT)	10070597
	Meier-Gorlin syndrome (PT)	10070612
	External cephalic version (PT)	10070636
	Mesoblastic nephroma (PT)	10070665
	Cortical dysplasia (PT)	10070666
	Leber's congenital amaurosis (PT)	10070667
	Huntington's disease (PT)	10070668

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Persistent pupillary membrane (PT)	10070872
	Inborn error in primary bile acid synthesis (PT)	10070882
	Familial haemophagocytic lymphohistiocytosis (PT)	10070904
	Inferior vena cava syndrome (PT)	10070911
	Congenital hypercoagulation (PT)	10070954
	Subchorionic haemorrhage (PT)	10071010
	Spina bifida cystica (PT)	10071011
	Laevocardia (PT)	10071015
	Platelet glycoprotein gene mutation (PT)	10071024
	Plasminogen activator inhibitor polymorphism (PT)	10071045
	Perinatal HIV infection (PT)	10071049
	Primary insulin like growth factor-1 deficiency (PT)	10071079
	N-acetylglutamate synthase deficiency (PT)	10071092
	Cystathionine beta-synthase deficiency (PT)	10071093

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Growth failure (PT)	10071095
	Branchio-oto-renal syndrome (PT)	10071135
	Foetal methotrexate syndrome (PT)	10071183
	Vulvovaginal injury (PT)	10071212
	Protuberant ear (PT)	10071232
	Constricted ear deformity (PT)	10071233
	Thalidomide embryopathy (PT)	10071249
	Gorham's disease (PT)	10071283
	Hereditary motor neurone disease (PT)	10071328
	Human chorionic gonadotropin increased (PT)	10071332
	Human chorionic gonadotropin positive (PT)	10071335
	Congenital hemiparesis (PT)	10071359
	Vanishing twin syndrome (PT)	10071398
	Exposure via father (PT)	10071403

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Foetal exposure during pregnancy (PT)	10071404
	Foetal exposure timing unspecified (PT)	10071405
	Maternal exposure before pregnancy (PT)	10071406
	Maternal exposure during delivery (PT)	10071407
	Maternal exposure during pregnancy (PT)	10071408
	Foetal exposure during delivery (PT)	10071409
	Maternal exposure timing unspecified (PT)	10071415
	Acetylcholinesterase deficiency (PT)	10071435
	Dyschondrosteosis (PT)	10071437
	Foetal monitoring abnormal (PT)	10071507
	Foetal non-stress test abnormal (PT)	10071516
	Trisomy 9 (PT)	10071547
	NAT2 polymorphism (PT)	10071600
	CYP2D6 polymorphism (PT)	10071601

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Genetic polymorphism (PT)	10071602
	CYP2C19 polymorphism (PT)	10071603
	Anterior displaced anus (PT)	10071651
	Umbilical cord thrombosis (PT)	10071652
	Micropenis (PT)	10071706
	Thrombocytopenia-absent radius syndrome (PT)	10071719
	Cerebral cavernous malformation (PT)	10071747
	Blau syndrome (PT)	10071755
	Annular pancreas (PT)	10071757
	Trisomy 14 (PT)	10071762
	Hermansky-Pudlak syndrome (PT)	10071775
	H-ras gene mutation (PT)	10071971
	N-ras gene mutation (PT)	10071972
	C-kit gene mutation (PT)	10071973

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	C-kit gene overexpression (PT)	10071974
	EGFR gene mutation (PT)	10071975
	HERG gene mutation (PT)	10071976
	Anaplastic lymphoma kinase gene mutation (PT)	10071977
	Anaplastic lymphoma kinase gene and nucleophosmin gene fusion overexpression (PT)	10071978
	Androgen receptor gene overexpression (PT)	10071979
	BRCA1 gene mutation (PT)	10071980
	BRCA2 gene mutation (PT)	10071981
	Carbonic anhydrase gene mutation (PT)	10071982
	Oestrogen receptor gene overexpression (PT)	10071983
	Platelet-derived growth factor receptor overexpression (PT)	10071984
	Progesterone receptor gene overexpression (PT)	10071985
	PTEN gene mutation (PT)	10071986

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	RET gene mutation (PT)	10071987
	UGT1A1 gene mutation (PT)	10071988
	Vascular endothelial growth factor overexpression (PT)	10071989
	Tyrosine kinase mutation (PT)	10071990
	Transmembrane receptor tyrosine kinase overexpression (PT)	10071991
	EGFR gene overexpression (PT)	10071992
	Frenulum breve (PT)	10072007
	Hyper IgD syndrome (PT)	10072010
	Renal malposition (PT)	10072019
	Congenital melanocytic naevus (PT)	10072036
	Small size placenta (PT)	10072038
	Fatal familial insomnia (PT)	10072077
	Congenital haematological disorder (PT)	10072107

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Craniolacunia (PT)	10072116
	Hooded prepuce (PT)	10072135
	Breast milk substitute intolerance (PT)	10072187
	Neonatal insufficient breast milk syndrome (PT)	10072188
	Auditory neuropathy spectrum disorder (PT)	10072198
	Endothelial protein C receptor polymorphism (PT)	10072205
	Janus kinase 2 mutation (PT)	10072206
	Mevalonic aciduria (PT)	10072219
	Mevalonate kinase deficiency (PT)	10072221
	Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome (PT)	10072222
	Majeed's syndrome (PT)	10072223
	Deficiency of the interleukin-1 receptor antagonist (PT)	10072224
	Familial scaphocephaly syndrome (PT)	10072229

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Foetal placental thrombosis (PT)	10072240
	Chronic villitis of unknown etiology (PT)	10072271
	Inborn error of lipid metabolism (PT)	10072272
	3-hydroxyacetyl-coenzyme A dehydrogenase deficiency (PT)	10072273
	Intracranial lipoma (PT)	10072288
	Hand-foot-genital syndrome (PT)	10072361
	Delivery outside health facility (PT)	10072446
	Sirenomelia (PT)	10072457
	Gestational age test abnormal (PT)	10072479
	Hereditary palmoplantar keratoderma (PT)	10072537
	Kleihauer-Betke test positive (PT)	10072577
	Platonychia (PT)	10072590
	Umbilical discharge (PT)	10072595

Listing 16.2.7-1.2 (Page 177 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Subchorionic haematoma (PT)	10072596
	Neonatal behavioural syndrome (PT)	10072605
	Adenine phosphoribosyl transferase deficiency (PT)	10072609
	Skeletal dysplasia (PT)	10072610
	Puerperal infection (PT)	10072652
	Long-chain acyl-coenzyme A dehydrogenase deficiency (PT)	10072653
	Medium-chain acyl-coenzyme A dehydrogenase deficiency (PT)	10072654
	Short-chain acyl-coenzyme A dehydrogenase deficiency (PT)	10072655
	Very long-chain acyl-coenzyme A dehydrogenase deficiency (PT)	10072656
	Transient neonatal pustular melanosis (PT)	10072688
	Peripartum haemorrhage (PT)	10072693
	Extrarenal pelvis (PT)	10072727

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Pregnancy of unknown location (PT)	10072811
	Brachydactyly (PT)	10072883
	Mucolipidosis type I (PT)	10072927
	Mucolipidosis type II (PT)	10072928
	Mucolipidosis type III (PT)	10072929
	Mucolipidosis type IV (PT)	10072930
	Mucolipidosis (PT)	10072939
	Olfactory nerve agenesis (PT)	10072941
	Cerebellar dysplasia (PT)	10072942
	Term birth (PT)	10072953
	Neuroendocrine cell hyperplasia of infancy (PT)	10072968
	Congenital skin dimples (PT)	10072978
	Congenital central diabetes insipidus (PT)	10073008
	Preterm premature rupture of membranes (PT)	10073024

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Prolonged rupture of membranes (PT)	10073027
	Bloom syndrome (PT)	10073032
	Multiple endocrine neoplasia Type 2A (PT)	10073148
	Multiple endocrine neoplasia Type 2 (PT)	10073149
	Multiple endocrine neoplasia Type 1 (PT)	10073150
	Multiple endocrine neoplasia Type 2B (PT)	10073151
	Familial medullary thyroid cancer (PT)	10073153
	Induction of cervix ripening (PT)	10073175
	Postponement of preterm delivery (PT)	10073177
	Infantile cortical hyperostosis (PT)	10073206
	Congenital intestinal obstruction (PT)	10073207
	Haemochromatosis trait (PT)	10073217
	Kenny-Caffey syndrome (PT)	10073228
	Reversible cerebral vasoconstriction syndrome (PT)	10073240

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Perineal injury (PT)	10073329
	Twin reversed arterial perfusion sequence malformation (PT)	10073455
	Microcolon (PT)	10073456
	Congenital retinoblastoma (PT)	10073470
	Hydranencephaly (PT)	10073472
	Lipodermoid tumour (PT)	10073484
	Congenital malignant neoplasm (PT)	10073492
	Congenital benign neoplasm (PT)	10073493
	Exposure during pregnancy (PT)	10073513
	Triple A syndrome (PT)	10073592
	Congenital trichomegaly (PT)	10073654
	Freeman-Sheldon syndrome (PT)	10073655
	Intestinal neuronal dysplasia (PT)	10073659

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Foetal megacystis (PT)	10073660
	Pulmonary lymphangiectasia (PT)	10073661
	Hypocalvaria (PT)	10073670
	Familial renal glycosuria (PT)	10073689
	Foetal retinoid syndrome (PT)	10073720
	Ectopic pregnancy under hormonal contraception (PT)	10073727
	Developmental hip dysplasia (PT)	10073767
	Lenticulostriatal vasculopathy (PT)	10073774
	Osteopathia striata (PT)	10073776
	Larsen syndrome (PT)	10073856
	CYP2B6 polymorphism (PT)	10073943
	Perinatal stroke (PT)	10073945
	CANDLE syndrome (PT)	10073960
	Choanal stenosis (PT)	10074053

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Proteus syndrome (PT)	10074067
	Disturbance of thermoregulation of newborn (PT)	10074158
	Neonatal gastrointestinal haemorrhage (PT)	10074159
	Neonatal intestinal perforation (PT)	10074160
	Dry lung syndrome (PT)	10074163
	Craniofacial deformity (PT)	10074180
	Meconium cyst (PT)	10074182
	Congenital high airway obstruction syndrome (PT)	10074187
	Fixed bowel loop (PT)	10074216
	Ectopic ovary (PT)	10074217
	Transitional vertebrae (PT)	10074306
	Mobile caecum syndrome (PT)	10074307
	Uterine adhesions (PT)	10074333
	Dysgnathia (PT)	10074336

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Paranasal sinus aplasia (PT)	10074401
	Congenital varicocele (PT)	10074459
	Ectopic pregnancy with contraceptive device (PT)	10074497
	Uterine scar (PT)	10074527
	Congenital Horner's syndrome (PT)	10074554
	Viral mastitis (PT)	10074560
	Neuronal ceroid lipofuscinosis (PT)	10074607
	Biliary hamartoma (PT)	10074610
	Foetal heart rate deceleration abnormality (PT)	10074636
	Baseline foetal heart rate variability disorder (PT)	10074638
	Junctional ectopic tachycardia (PT)	10074640
	Nonreassuring foetal heart rate pattern (PT)	10074641
	Foetal heart rate acceleration abnormality (PT)	10074642
	Sinusoidal foetal heart rate pattern (PT)	10074643

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Methylenetetrahydrofolate reductase gene mutation (PT)	10074753
	Myeloperoxidase deficiency (PT)	10074767
	Endometritis bacterial (PT)	10074861
	Hyperreactio luteinalis (PT)	10074866
	Johanson-Blizzard syndrome (PT)	10074947
	Hypoplastic nasal cartilage (PT)	10074970
	Vascular malformation (PT)	10074979
	Congenital astigmatism (PT)	10074992
	Foeticide (PT)	10075033
	Neonatal alloimmune thrombocytopenia (PT)	10075149
	Fryns syndrome (PT)	10075223
	Perinatal HBV infection (PT)	10075233
	Barakat syndrome (PT)	10075281

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Dentatorubral-pallidoluysian atrophy (PT)	10075298
	Hypomelanosis of Ito (PT)	10075301
	Infantile vomiting (PT)	10075315
	Poor feeding infant (PT)	10075316
	Infantile haemangioma (PT)	10075378
	Neonatal testicular torsion (PT)	10075380
	Laron syndrome (PT)	10075492
	Complement deficiency disease (PT)	10075551
	Parkes-Weber syndrome (PT)	10075554
	HER2 protein overexpression (PT)	10075638
	LDLR mutation (PT)	10075640
	Thiopurine methyltransferase polymorphism (PT)	10075641
	BLyS polymorphism (PT)	10075642
	Interleukin 28B polymorphism (PT)	10075643

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	CYP2C9 polymorphism (PT)	10075647
	BRAF gene mutation (PT)	10075648
	CYP1A2 polymorphism (PT)	10075651
	Factor V Leiden carrier (PT)	10075652
	HER2 gene amplification (PT)	10075653
	Platelet-derived growth factor receptor gene mutation (PT)	10075655
	Gaucher's disease type I (PT)	10075697
	Gaucher's disease type II (PT)	10075698
	Gaucher's disease type III (PT)	10075699
	UGT1A1 gene polymorphism (PT)	10075771
	NAT1 polymorphism (PT)	10075772
	Hypoxanthine-guanine phosphoribosyl transferase deficiency (PT)	10075774
	VKORC1 gene polymorphism (PT)	10075776

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Maxillonasal dysplasia (PT)	10075843
	Amniotic fluid index decreased (PT)	10075866
	Amniotic fluid index increased (PT)	10075867
	Congenital disorder of glycosylation (PT)	10075892
	Transient hypothyroxinaemia of prematurity (PT)	10075901
	Lamin A/C gene mutation (PT)	10075979
	Cleidocranial dysostosis (PT)	10075994
	Mittendorf dot (PT)	10076031
	Progressive familial intrahepatic cholestasis (PT)	10076033
	Baraitser Rodeck Garner syndrome (PT)	10076038
	Feeding intolerance (PT)	10076042
	Planning to become pregnant (PT)	10076056
	Ash leaf macule (PT)	10076367
	Neonatal gastrointestinal disorder (PT)	10076388

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Kimmerle's anomaly (PT)	10076416
	Ellis-van Creveld syndrome (PT)	10076418
	Meconium aspiration syndrome (PT)	10076496
	Splenic hamartoma (PT)	10076586
	Carney complex (PT)	10076601
	Congenital thyroid disorder (PT)	10076602
	Right-to-left cardiac shunt (PT)	10076605
	Uterine scar diverticulum (PT)	10076608
	Portal venous system anomaly (PT)	10076609
	Rib synostosis (PT)	10076624
	Primary familial hypomagnesaemia (PT)	10076626
	Enteric duplication (PT)	10076653
	Early onset primary dystonia (PT)	10076668
	Neuronal migration disorder (PT)	10076677

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Premature baby death (PT)	10076700
	Periventricular haemorrhage neonatal (PT)	10076706
	Umbilical cord occlusion (PT)	10076714
	Amegakaryocytic thrombocytopenia (PT)	10076744
	Labial tie (PT)	10076772
	XXX syndrome (PT)	10076910
	Caesarean delivery on maternal request (PT)	10076983
	Postpartum thrombosis (PT)	10077022
	Alveolar capillary dysplasia (PT)	10077023
	Familial amyotrophic lateral sclerosis (PT)	10077024
	Lysosomal acid lipase deficiency (PT)	10077267
	Infantile back arching (PT)	10077276
	Intracranial arterial fenestration (PT)	10077285
	Hereditary motor and sensory neuropathy (PT)	10077306

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Infantile apnoea (PT)	10077321
	Congenital spinal stenosis (PT)	10077379
	Epileptic encephalopathy (PT)	10077380
	Familial infantile bilateral striatal necrosis (PT)	10077450
	Sporadic infantile bilateral striatal necrosis (PT)	10077451
	Tracheloplasty (PT)	10077464
	Ectopic posterior pituitary gland (PT)	10077557
	Foetal tachyarrhythmia (PT)	10077575
	Foetal movement disorder (PT)	10077576
	Foetal anaemia (PT)	10077577
	Ultrasound foetal abnormal (PT)	10077578
	Foetal gastrointestinal tract imaging abnormal (PT)	10077579
	Foetal musculoskeletal imaging abnormal (PT)	10077580
	Foetal renal imaging abnormal (PT)	10077581

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Foetal growth abnormality (PT)	10077582
	Congenital heart valve incompetence (PT)	10077594
	Thyroid hemiagenesis (PT)	10077609
	Bloch-Sulzberger syndrome (PT)	10077624
	Foetal compartment fluid collection (PT)	10077628
	Cornelia de Lange syndrome (PT)	10077707
	Rett syndrome (PT)	10077709
	Congenital thrombocytopenia (PT)	10077833
	Left-to-right cardiac shunt (PT)	10077834
	Multiple cutaneous and uterine leiomyomatosis (PT)	10077859
	Mismatch repair cancer syndrome (PT)	10077888
	Vein of Galen aneurysmal malformation (PT)	10077889
	Atrioventricular node dispersion (PT)	10077893
	Lecithin-cholesterol acyltransferase deficiency (PT)	10077917

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Supernumerary vertebra (PT)	10077919
	Tracheal web (PT)	10077940
	Hereditary hypophosphataemic rickets (PT)	10077943
	Pyruvate carboxylase deficiency (PT)	10077944
	GNE myopathy (PT)	10077945
	Adult polyglucosan body disease (PT)	10077946
	Citrate transporter deficiency (PT)	10077947
	Alternating hemiplegia of childhood (PT)	10077948
	Trifunctional protein deficiency (PT)	10077949
	Fatty acid oxidation disorder (PT)	10077951
	Epidermal naevus syndrome (PT)	10077952
	Primary hypercholesterolaemia (PT)	10077965
	Newborn head moulding (PT)	10077984
	Early onset familial Alzheimer's disease (PT)	10078036

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Welander distal myopathy (PT)	10078052
	Foetal biophysical profile score equivocal (PT)	10078123
	Foetal biophysical profile score abnormal (PT)	10078124
	Duplex appendix (PT)	10078212
	Hypothalamic hamartoma (PT)	10078217
	Retained placenta operation (PT)	10078243
	Activated PI3 kinase delta syndrome (PT)	10078281
	NUT gene mutation (PT)	10078296
	Camptomelia (PT)	10078297
	Wolfram syndrome (PT)	10078338
	Risk of future pregnancy miscarriage (PT)	10078342
	Ureteric atresia (PT)	10078351
	Neonatal haemochromatosis (PT)	10078355
	Oral-facial-digital syndrome type II (PT)	10078419

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Proximal focal femoral deficiency (PT)	10078473
	Tornwaldt cyst (PT)	10078492
	Barth syndrome (PT)	10078537
	Acral peeling skin syndrome (PT)	10078538
	Congenital neoplasm (PT)	10078557
	Smith-Lemli-Opitz syndrome (PT)	10078573
	Joubert syndrome (PT)	10078574
	Birth weight normal (PT)	10078661
	DNA mismatch repair protein gene mutation (PT)	10078672
	Carnitine-acylcarnitine translocase deficiency (PT)	10078729
	Uterine compression sutures (PT)	10078738
	Congenital chylothorax (PT)	10078770
	MLASA syndrome (PT)	10078801
	Allan-Herndon-Dudley syndrome (PT)	10078821

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Primary familial brain calcification (PT)	10078822
	Amniotic membrane rupture test positive (PT)	10078834
	Winchester syndrome (PT)	10078901
	Juvenile Paget's disease (PT)	10078977
	Blood type incompatibility (PT)	10078985
	Neonatal toxicity (PT)	10078986
	Foetal renal impairment (PT)	10078987
	Silent thyroiditis (PT)	10079012
	Left ventricular false tendon (PT)	10079017
	Gallbladder agenesis (PT)	10079018
	Hereditary multiple osteochondromas (PT)	10079019
	Oesophageal cyst (PT)	10079063
	Familial high density lipoprotein deficiency (PT)	10079119
	Umbilical cord cyst (PT)	10079122

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Emanuel syndrome (PT)	10079203
	Timothy syndrome (PT)	10079205
	Perry syndrome (PT)	10079207
	Uterine irritability (PT)	10079224
	Non-compaction cardiomyopathy (PT)	10079253
	Short interpregnancy interval (PT)	10079272
	Cervical dilatation (PT)	10079273
	Neonatal hypocalcaemia (PT)	10079306
	Morton's syndrome (PT)	10079320
	Glutathione synthetase deficiency (PT)	10079364
	Kleefstra syndrome (PT)	10079365
	Tilted disc syndrome (PT)	10079368
	Adams-Oliver syndrome (PT)	10079369
	Cystic angiomatosis (PT)	10079371

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Drug use disorder, antepartum (PT)	10079382
	Drug use disorder, postpartum (PT)	10079383
	Cystic fibrosis gastrointestinal disease (PT)	10079428
	Opitz-G/BBB syndrome (PT)	10079435
	MYH9-related disease (PT)	10079437
	Deficiency of the interleukin-36 receptor antagonist (PT)	10079451
	Ovarian hypoplasia (PT)	10079495
	Hepatic hamartoma (PT)	10079685
	Congenital midline defect (PT)	10079687
	Congenital amputation (PT)	10079701
	Tibial agenesis (PT)	10079730
	Gollop-Wolfgang complex (PT)	10079731
	Nail aplasia (PT)	10079732

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Angiotensin II receptor type 1 antibody positive (PT)	10079737
	Delayed foetal renal development (PT)	10079753
	Lactation stimulation therapy (PT)	10079806
	Labour augmentation (PT)	10079807
	Anembryonic gestation (PT)	10079814
	Ectrodactyly (PT)	10079827
	Acrodysostosis (PT)	10079856
	Currarino syndrome (PT)	10079857
	Posthaemorrhagic hydrocephalus (PT)	10079859
	Congenital anosmia (PT)	10079876
	Maternal cancer in pregnancy (PT)	10079877
	Venolymphatic malformation (PT)	10079880
	Foetal heart rate indeterminate (PT)	10079882

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Popliteal pterygium syndrome (PT)	10079892
	Floating-Harbor syndrome (PT)	10079943
	Optic disc pit (PT)	10079967
	Urea cycle disorder (PT)	10080020
	Uterine tachysystole (PT)	10080022
	Dopa-responsive dystonia (PT)	10080034
	Trisomy 4p (PT)	10080079
	Pachyonychia congenita (PT)	10080088
	Paternal exposure during pregnancy (PT)	10080091
	Paternal exposure timing unspecified (PT)	10080092
	Paternal exposure before pregnancy (PT)	10080093
	Right ventricular false tendon (PT)	10080132
	Double outlet left ventricle (PT)	10080133
	Fraser syndrome (PT)	10080219

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Apparent mineralocorticoid excess (PT)	10080229
	Arterial tortuosity syndrome (PT)	10080250
	Pallister-Killian syndrome (PT)	10080297
	Dyke-Davidoff-Masson syndrome (PT)	10080312
	Frasier syndrome (PT)	10080313
	Bannayan-Riley-Ruvalcaba syndrome (PT)	10080314
	Shawl scrotum (PT)	10080319
	Breast milk odour abnormal (PT)	10080335
	Congenital nipple inversion (PT)	10080355
	Congenital nipple anomaly (PT)	10080356
	Chorioamniotic separation (PT)	10080381
	Hereditary renal microhaematuria (PT)	10080385
	Pendred syndrome (PT)	10080398
	Threatened uterine rupture (PT)	10080427

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Familial acromegaly (PT)	10080509
	Foetal surgery (PT)	10080563
	Pseudohypoaldosteronism (PT)	10080593
	IPEX syndrome (PT)	10080631
	Microorchidism (PT)	10080650
	Term baby (PT)	10080681
	Vestibulocerebellar syndrome (PT)	10080748
	Exposure via breast milk (PT)	10080751
	Maternal exposure during breast feeding (PT)	10080752
	Familial isolated hyperparathyroidism (PT)	10080773
	Dyschromatosis (PT)	10080785
	Oxycephaly (PT)	10080833
	DOOR syndrome (PT)	10080835
	Von Willebrand's disease gene carrier (PT)	10080844

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Isocitrate dehydrogenase gene mutation (PT)	10080848
	Congenital hypoplasia of depressor angularis oris muscle (PT)	10080879
	Hyperglycinaemia (PT)	10080883
	Neonatal deafness (PT)	10080897
	Subgaleal haemorrhage (PT)	10080900
	Neonatal hypoacusis (PT)	10080902
	Bimanual uterine compression (PT)	10080950
	Hereditary angioedema with normal C1 esterase inhibitor (PT)	10080953
	Hereditary angioedema with C1 esterase inhibitor deficiency (PT)	10080955
	Congenital Zika syndrome (PT)	10081044
	Zika virus associated ocular birth defect (PT)	10081045
	Zika virus associated birth defect (PT)	10081047

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Zika virus associated microencephaly (PT)	10081048
	Bronchial atresia (PT)	10081164
	Zhu-Tokita-Takenouchi-Kim syndrome (PT)	10081208
	Gatad2b associated neurodevelopmental disorder (PT)	10081209
	Birth defect correction (PT)	10081218
	Familial gigantiform cementoma (PT)	10081225
	Diastrophic dysplasia (PT)	10081228
	PIK3CA-activated mutation (PT)	10081234
	Familial multiple lipomatosis (PT)	10081235
	PIK3CA related overgrowth spectrum (PT)	10081236
	BPES syndrome (PT)	10081258
	Monolid eyes (PT)	10081275
	Kommerell's diverticulum (PT)	10081282
	Loeys-Dietz syndrome (PT)	10081284

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Brachymetatarsia (PT)	10081308
	Benjamin syndrome (PT)	10081309
	Carpenter syndrome (PT)	10081310
	Hyperlysinaemia (PT)	10081311
	Kosaki overgrowth syndrome (PT)	10081313
	CARASIL syndrome (PT)	10081315
	Asymmetric thigh fold (PT)	10081340
	Persistent Muellerian duct syndrome (PT)	10081352
	Hypermutation (PT)	10081364
	Brunner syndrome (PT)	10081371
	Duplication of inferior vena cava (PT)	10081399
	Enlarged foetal cisterna magna (PT)	10081422
	Bergmeister's papilla (PT)	10081443
	Congenital dyserythropoietic anaemia (PT)	10081457

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Chorea-acanthocytosis (PT)	10081505
	Neuroacanthocytosis (PT)	10081506
	McLeod neuroacanthocytosis syndrome (PT)	10081507
	Truncus arteriosus repair (PT)	10081508
	Fructose-1,6-bisphosphatase deficiency (PT)	10081516
	Griscelli syndrome (PT)	10081517
	ACAD9 deficiency (PT)	10081518
	CTLA4 deficiency (PT)	10081533
	Iris hamartoma (PT)	10081541
	Polyorchidism (PT)	10081542
	Emery-Dreifuss muscular dystrophy (PT)	10081544
	Morgagni-Stewart-Morel syndrome (PT)	10081545
	Unicuspid aortic valve (PT)	10081548
	Infantile fibromatosis (PT)	10081654

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Mucopolysaccharidosis IX (PT)	10081679
	Smith-Magenis syndrome (PT)	10081680
	Adenylosuccinate lyase deficiency (PT)	10081681
	Isodicentric chromosome 15 syndrome (PT)	10081682
	GRACILE syndrome (PT)	10081684
	Kniest dysplasia (PT)	10081685
	Mazabraud's syndrome (PT)	10081724
	Placental lake (PT)	10081737
	NTRK gene fusion overexpression (PT)	10081769
	3M syndrome (PT)	10081775
	Coffin-Lowry syndrome (PT)	10081806
	TRPV4 gene mutation (PT)	10081831
	Brachyolmia (PT)	10081832
	PAPSS2 gene mutation (PT)	10081833

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Paroxysmal extreme pain disorder (PT)	10081856
	Laband syndrome (PT)	10081859
	Autosomal recessive megaloblastic anaemia (PT)	10081878
	Ring chromosome (PT)	10081894
	Donohue syndrome (PT)	10081896
	Tympanomeningeal fissure (PT)	10081914
	Checkpoint kinase 2 gene mutation (PT)	10081927
	Trisomy 16 (PT)	10081933
	Confined placental mosaicism (PT)	10081934
	PSTPIP1-associated myeloid-related proteinaemia inflammatory syndrome (PT)	10081947
	CHILD syndrome (PT)	10081963
	Placental calcification (PT)	10082008
	CYP3A4 polymorphism (PT)	10082012

Listing 16.2.7-1.2 (Page 208 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Uterine hypokinesia (PT)	10082029
	Neonatal bradyarrhythmia (PT)	10082054
	Neonatal tachyarrhythmia (PT)	10082055
	Neonatal pneumothorax (PT)	10082056
	Short stature homeobox gene mutation (PT)	10082164
	Placenta duplex (PT)	10082173
	Infant sedation (PT)	10082187
	Neonatal sinus bradycardia (PT)	10082188
	Infant irritability (PT)	10082189
	Constipation neonatal (PT)	10082190
	Neonatal sinus tachycardia (PT)	10082191
	Administration site reaction neonatal (PT)	10082193
	Pulmonary haemorrhage neonatal (PT)	10082194
	Gap junction protein beta 2 gene mutation (PT)	10082218

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Congenital nasal septum deviation (PT)	10082221
	Infant dyschezia (PT)	10082228
	Postpartum anxiety (PT)	10082233
	Shprintzen-Goldberg syndrome (PT)	10082234
	Pfeiffer syndrome (PT)	10082289
	Alpha-thalassaemia-intellectual deficit syndrome (PT)	10082291
	Small fontanelle (PT)	10082319
	Congenital supraventricular tachycardia (PT)	10082343
	Ogden syndrome (PT)	10082376
	X-linked intellectual disability, Siderius type (PT)	10082377
	Schwartz Jampel syndrome (PT)	10082378
	Woodhouse-Sakati syndrome (PT)	10082379
	Aberrant aortic arch (PT)	10082380

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	SADDAN syndrome (PT)	10082381
	Penta X syndrome (PT)	10082382
	Hyperpipecolic acidaemia (PT)	10082383
	Phelan-McDermid syndrome (PT)	10082417
	Neutrophil Fc gamma RIIIb deficiency (PT)	10082479
	Neonatal deformity (PT)	10082494
	Congenital arterial occlusion (PT)	10082546
	Plasminogen activator inhibitor type 1 deficiency (PT)	10082567
	Familial glucocorticoid deficiency (PT)	10082603
	Connective tissue dysplasia (PT)	10082604
	Uterine cervix canal atresia (PT)	10082605
	Asynclitic presentation (PT)	10082614
	Neurodegeneration with brain iron accumulation disorder (PT)	10082633

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Apolipoprotein E e4 gene carrier (PT)	10082637
	Double inlet left ventricle (PT)	10082665
	ROS1 gene rearrangement (PT)	10082790
	Anorectal malformation (PT)	10082798
	Cardiofaciocutaneous syndrome (PT)	10082805
	Papillon-Lefevre syndrome (PT)	10082856
	CFTR gene mutation (PT)	10082864
	RPE65 gene mutation (PT)	10082888
	Paranasal sinus hypoplasia (PT)	10082941
	Congenital LUMBAR syndrome (PT)	10082949
	TORCH infection (PT)	10082952
	Metatropic dysplasia (PT)	10082970
	Pycnodysostosis (PT)	10082973
	Lithopedion (PT)	10082976

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Congenital ureteropelvic junction obstruction (PT)	10083021
	Glycogen storage disease type IX (PT)	10083034
	Alexander disease (PT)	10083059
	Hypotonia-cystinuria syndrome (PT)	10083099
	Infantile acropustulosis (PT)	10083179
	Aicardi-Goutieres syndrome (PT)	10083189
	Mannose-binding lectin deficiency (PT)	10083190
	Dacryocystocoele (PT)	10083192
	Placental cyst (PT)	10083196
	Systemic right ventricle (PT)	10083204
	Single atrium (PT)	10083205
	Fibromatosis colli of infancy (PT)	10083212
	Straddling tricuspid valve (PT)	10083223
	Bosch-Boonstra-Schaaf optic atrophy syndrome (PT)	10083269

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	SATB2-associated syndrome (PT)	10083270
	Weaver syndrome (PT)	10083271
	Vacuum aspiration (PT)	10083276
	Stahl's ear (PT)	10083305
	Galactosialidosis (PT)	10083306
	Saposin C deficiency (PT)	10083307
	Pelvic girdle pain (PT)	10083336
	Severe primary insulin like growth factor-1 deficiency (PT)	10083342
	Accessory renal artery (PT)	10083349
	OHVIRA syndrome (PT)	10083351
	Acquired chromosomal abnormality (PT)	10083362
	CYP3A5 polymorphism (PT)	10083372
	Transgenerational epigenetic inheritance (PT)	10083374

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Congenital dengue disease (PT)	10083386
	Odontoma (PT)	10083400
	Desmin myopathy (PT)	10083445
	Nievergelt-Pearlman syndrome (PT)	10083492
	Camptodactyly-arthropathy-coxa vara-pericarditis syndrome (PT)	10083494
	Congenital hyperinsulinaemic hypoglycaemia (PT)	10083495
	Congenital rubella syndrome (PT)	10083496
	Postnatal growth restriction (PT)	10083523
	Foetal dystocia (PT)	10083545
	Rapid-onset dystonia-parkinsonism (PT)	10083658
	Congenital Ebola virus infection (PT)	10083704
	Abetalipoproteinaemia (PT)	10083851
	Isovaleric acidaemia (PT)	10083852

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Achard Thiers syndrome (PT)	10083853
	Acromicric dysplasia (PT)	10083854
	Alpha-mannosidosis (PT)	10083855
	ADNP syndrome (PT)	10083856
	Aniridia-cerebellar ataxia-mental deficiency (PT)	10083858
	Andersen-Tawil syndrome (PT)	10083859
	Ablepharon macrostomia syndrome (PT)	10083860
	ADCY5-related dyskinesia (PT)	10083861
	Antley-Bixler syndrome (PT)	10083864
	Acrocallosal syndrome (PT)	10083865
	Acromesomelic dysplasia (PT)	10083866
	AIDS dysmorphic syndrome (PT)	10083867
	Alpha-1 antitrypsin deficiency (PT)	10083869

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Listing 16.2.7-1.2 (Page 216 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency (PT)	10083910
	Congenital hypotransferrinaemia (PT)	10083911
	Sarcoglycanopathy (PT)	10083931
	Congenital hypogonadotropic hypogonadism (PT)	10083932
	Congenital growth hormone deficiency (PT)	10083935
	Leukocyte adhesion deficiency type I (PT)	10083936
	Pro-opiomelanocortin deficiency (PT)	10083937
	Cone dystrophy (PT)	10083940
	Coffin Siris syndrome (PT)	10083941
	Congenital myasthenic syndrome (PT)	10083942
	Filippi syndrome (PT)	10083943
	Femoral facial syndrome (PT)	10083944
	Fountain syndrome (PT)	10083946

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	De Barsy syndrome (PT)	10083947
	COPA syndrome (PT)	10083948
	Catel Manzke syndrome (PT)	10083949
	Schmid Fraccaro syndrome (PT)	10083957
	CARD9 deficiency (PT)	10083959
	ASAH1 related disorder (PT)	10083960
	Campomelic syndrome (PT)	10083962
	Baller-Gerold syndrome (PT)	10083963
	Opitz trigonocephaly syndrome (PT)	10083975
	Conradi-Huenermann syndrome (PT)	10084050
	Elbow synostosis (PT)	10084070
	Senior-Loken syndrome (PT)	10084074
	Transcobalamin deficiency (PT)	10084086
	Brown-Vialetto-Van Laere syndrome (PT)	10084089

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Creatine deficiency syndrome (PT)	10084104
	Leptin receptor deficiency (PT)	10084105
	Hyperphenylalaninaemia (PT)	10084106
	Primary coenzyme Q10 deficiency (PT)	10084107
	Inborn error of amino acid metabolism (PT)	10084108
	Pyruvate dehydrogenase complex deficiency (PT)	10084109
	Aromatic L-amino acid decarboxylase deficiency (PT)	10084110
	Primary hyperoxaluria (PT)	10084111
	Supernumerary rib (PT)	10084170
	Platelet storage pool deficiency (PT)	10084190
	ADSL gene mutation (PT)	10084193
	Hyperornithinaemia-hyperammonaemia-homocitrullinuria syndrome (PT)	10084220
	Pallister W syndrome (PT)	10084236

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Neonatal Crohn's disease (PT)	10084237
	Neonatal dyspnoea (PT)	10084238
	Cryptotia (PT)	10084250
	Congenital viral hepatitis (PT)	10084251
	Congenital hepatitis C infection (PT)	10084252
	Asymmetric crying facies (PT)	10084253
	Haemoglobin Lepore trait (PT)	10084259
	Piebaldism (PT)	10084262
	Foetal cardiac arrest (PT)	10084280
	Autoinflammation with infantile enterocolitis (PT)	10084306
	Congenital lymphatic dysplasia (PT)	10084317
	Midline head position (PT)	10084324
	Robinow syndrome (PT)	10084325
	Roberts syndrome (PT)	10084326

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Swyer syndrome (PT)	10084327
	22q11.2 deletion syndrome (PT)	10084363
	Mitochondrial cardiomyopathy (PT)	10084364
	Split hand nystagmus syndrome (PT)	10084376
	Otospondylomegaepiphyseal dysplasia (PT)	10084407
	Otopalatodigital spectrum disorder (PT)	10084408
	Schinzel syndrome (PT)	10084409
	Nager syndrome (PT)	10084410
	KBG syndrome (PT)	10084411
	Riedel lobe (PT)	10084530
	Block vertebra (PT)	10084531
	DDX3X syndrome (PT)	10084534
	Myoclonic dystonia (PT)	10084572
	Melanocortin 4 receptor deficiency (PT)	10084582

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	CBL gene mutation (PT)	10084604
	KMT2A gene mutation (PT)	10084605
	CALR gene mutation (PT)	10084606
	PRPF8 gene mutation (PT)	10084607
	SRSF2 gene mutation (PT)	10084608
	TP53 gene mutation (PT)	10084609
	ZRSR2 gene mutation (PT)	10084610
	ASXL1 gene mutation (PT)	10084611
	DNMT3A gene mutation (PT)	10084612
	EZH2 gene mutation (PT)	10084613
	MPL gene mutation (PT)	10084614
	NPM1 gene mutation (PT)	10084615
	STAG2 gene mutation (PT)	10084616
	U2AF1 gene mutation (PT)	10084617

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	FLT3 gene mutation (PT)	10084619
	RUNX1 gene mutation (PT)	10084620
	SF3B1 gene mutation (PT)	10084621
	TET2 gene mutation (PT)	10084622
	WT1 gene mutation (PT)	10084623
	PTPN11 gene mutation (PT)	10084624
	BCOR gene mutation (PT)	10084625
	CEBPA gene mutation (PT)	10084626
	Umbilical artery vascular resistance increased (PT)	10084637
	Labrune syndrome (PT)	10084766
	Zeichi-Ceide syndrome (PT)	10084780
	NR5A1 gene mutation (PT)	10084823
	Superimposed pre-eclampsia (PT)	10084825
	Abnormal DNA methylation (PT)	10084827

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Abnormal cord insertion (PT)	10084854
	Uterine diverticulum (PT)	10084900
	Maternal exposure via partner during pregnancy (PT)	10084938
	Bifid ureter (PT)	10085056
	Loose anagen syndrome (PT)	10085066
	Congenital COVID-19 (PT)	10085080
	Stiff skin syndrome (PT)	10085085
	Dolichocephaly (PT)	10085104
	JAG1 gene mutation (PT)	10085239
	Heritable pulmonary arterial hypertension (PT)	10085244
	Lacrimo-auriculo-dento-digital syndrome (PT)	10085252
	Inherited otosclerosis (PT)	10085362
	Cervix scarring (PT)	10085368
	Cayler cardiofacial syndrome (PT)	10085379

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Finnegan score increased (PT)	10085520
	Cone-rod dystrophy (PT)	10085521
	Congenital, familial and genetic disorders (SMQ) (broad)	20000077
	Pregnancy and neonatal topics (SMQ) (broad)	20000185
	Pregnancy, labour and delivery complications and risk factors (excl abortions and stillbirth) (SMQ) (broad)	20000186
	Lactation related topics (incl neonatal exposure through breast milk) (SMQ) (broad)	20000187
	Functional lactation disorders (SMQ) (broad)	20000188
	Neonatal exposures via breast milk (SMQ) (broad)	20000189
	Foetal disorders (SMQ) (broad)	20000190
	Neonatal disorders (SMQ) (broad)	20000191
	Termination of pregnancy and risk of abortion (SMQ) (broad)	20000192

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.

Listing 16.2.7-1.2 (Page 225 of 225)
Case retrieval sheet

Safety topic	MedDRA term for selection from adverse events Sublevel 1 Sublevel 2 Sublevel 3 Sublevel 4	MedDRA code
Teratogenicity	Normal pregnancy conditions and outcomes (SMQ) (broad)	20000193

MedDRA version 24.0, Case Retrieval Strategy version released 12OCT2021.